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Abstract 
 
Background: One-third of men may experience biochemical failure by 8 years 
following radical radiotherapy for prostate cancer. Focal salvage therapy 
(FST) may offer further curative treatment. Before FST, distant disease must 
be ruled-out and intra-prostatic disease must be accurately detected and 
characterised. 
 
Aim: The aim of this thesis was to evaluate novel diagnostic and staging 
techniques and outcomes of focal salvage treatments for radiorecurrent 
prostate cancer.  
 
Methods: Both retrospective and prospective data will be presented. A 
retrospective analysis was conducted to compare a) Bone scan with Choline 
PET/CT in the detection of distant metastases b) Accuracy of MRI-Targeted 
Biopsy (MRI-TB) with whole-gland template mapping biopsy (TPM) c) the 
outcomes of focal salvage HIFU (FS-HIFU). These retrospective analyses 
provided important inputs into the design and conduct of the prospective trial 
FORECAST - Focal RECurrent Assessment and Salvage Treatment. Key trial 
outcomes were a) detection rate of distant metastatic disease of Whole Body 
MRI compared to other staging scans b) detection rate of MRI for clinically 
significant prostate cancer and c) Short-term outcomes of focal salvage 
therapies.   
 
Outcomes: Within the retrospective analyses, there was poor concordance 
with bone scan and Choline PET/CT in the detection of metastatic disease 
(kappa value 0.024). MRI-TB had lower detection rates of clinically significant 
cancer compared with TPM biopsy; 77.9% vs. 85.7% (p=0.146). The b-DFS 
rate post FS-HIFU was 48% (95% CI 39–59) and composite end free survival 
was 40% (95% CI 31–50). In the prospective analyses, there was moderate 
agreement between WB-MRI and Choline PET/CT for bony metastatic 
disease (Kappa=0.411 (p<0.0001)). MRI (PIRADS 4) had a high sensitivity, 
specificity, PPV and NPV for the detection of clinically significant cancer 90%, 
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81.3%, 85.7% and 86.7%. b-DFS rates post FS-HIFU and FS-cryotherapy 
was 73% (95% CI  51-100) and 67% (95% CI  30-100) at 12 months (p=0.95).  
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Impact Statement 
 
In 2015 in the UK approximately 47,151 men were diagnosed with prostate 
cancer. Up to 30% of these men went on to have radiotherapy and up to half 
of these men will have biochemical relapse (rise in PSA) within ten years of 
primary radiation treatment. For these 7000 men who are suspected to have 
radiorecurrent disease, hormones are the main form of treatment offered. 
Hormones however only control disease (for up to three years) and do not 
provide a cure; this can have significant impact on patients’ well being.  
 
Further localised prostate treatments (salvage therapy) may be an option for 
these men, but it is important to accurately characterise radiorecurrent 
disease. It is felt that men who fail radiotherapy and are found to have 
widespread metastatic disease, will not benefit from further localised prostate 
treatment. Thus, it is important to diagnose intra and extra prostatic disease 
accurately.  
 
The aims of this thesis were to find better techniques at diagnosing metastatic 
and localised radiorecurrent prostate cancer and reducing morbidity of 
salvage treatment by providing focal salvage treatment, where only the area 
of radiorecurrent disease was targeted and treated. Several potential benefits 
were found. 
 
Firstly, there could be a further drive to advance diagnostic scans for 
radiorecurrent prostate cancer. Currently patients suspected of having 
recurrence post radiotherapy must undergo two staging scans – Choline 
PET/CT and bone scan – both involving exposure to radiation and having 
poor accuracy at low PSA levels (PSA <20 ng/ml). This means that 
recurrence may not be identified until the cancer has metastasized which then 
limits patients to systemic hormonal treatment. It is therefore imperative that 
new imaging is capable of scanning the whole body and able to identify any 
recurrence at low levels of PSA. Our prospective study compared Whole 
Body-MRI to Choline PET and Bone scan and found a moderate agreement 
between WB-MRI and Choline PET/CT (Kappa score 0.548 (p=0.00032)) in 
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the detection of NX-0 nodal disease and for bony metastatic disease 
(Kappa=0.411 (p<0.0001)) which was significant. There was fair agreement 
for bony metastatic disease detected by WB-MRI and BS (kappa score 0.333 
p=0.157) and also for Choline PET/CT and BS (Kappa = 0.333 (p=0.46)) 
however significance was not achieved. 
 
Secondly there may be further development in the minimally invasive and 
focal treatments for radio-recurrent disease. Issues following radiotherapy are 
often that there is significant fibrosis and scarring which can lead to significant 
side effects such as recto-urethral fistula. Developing or refining current 
treatment that targets recurrent cancer within the prostate, allowing for these 
structural changes and minimising further damage is also important. Our 
retrospective study examined FS-HIFU with tolerable side effect outcomes; 
UTI in 11.3% of patients, epididymitis in 1.3%, bladder neck strictures in 8%, 
rectourethral fistula after first HIFU in 2%and osteitis pubis in 0.7%. 
Our prospective study has shown the potential of focal salvage HIFU and 
cryotherapy as a salvage treatment post radiotherapy. b-DFS rates post FS-
HIFU was 93% (95% CI  80-100) at 6 months, and 73% (95% CI  51-100) at 
12 months (p=0.95). For focal salvage cryotherapy this was 100% and 67% 
(95% CI  30-100) respectively (p=0.95). Only one patient developed Clavien 
3b complication – urethral stricture requiring dilation - and there are no 
prostate cancer related deaths at present.  
 
Thirdly, follow up of these patients for minimum of ten years is necessary. 
This means that prospective databases should be kept up to date. This allows 
future researchers, to formulate algorithms determining the outcomes of each 
treatment. A new risk classification can be created which could be based 
upon baseline risk prior to radiotherapy, re-staging information and treatment 
outcomes, to determine those who may benefit from salvage treatment or 
systemic therapy. The research conducted within this study is the first to 
produce a composite failure rate after salvage therapy. This consisted of a 
patient failing by any of the following parameters; BCF and/or positive 
localized or distant imaging and/or positive biopsy and/or systemic therapy 
and/or metastases and/or prostate cancer-specific death. Within this research, 
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following focal salvage HIFU, univariable analyses showed that primary 
Gleason score 8–10, T stage 3 before salvage HIFU, and PSA-nadir post-
salvage achieved statistical significance for the composite endpoint. A risk 
model can therefore be calculated as a point scoring system, similar to 
D’Amico risk score, that takes into account primary and salvage baseline 
characteristics to determine those suitable for focal salvage therapy. The 
outcomes from the FORECAST study will aid in the prediction model.   
 
Lastly the impact on public policy for patients post primary treatment 
(radiotherapy) in this instance could be changed dramatically. There will be a 
focus on a systematic flow of patients from time of biochemical failure to 
accurate re-staging and tailored treatment.  
 
Having a single re-staging scan, in this case Whole-body MRI (PSMA Choline 
PET/CT which is gaining popularity in the diagnosis of metastatic prostate 
cancer was not initially available at time of trial set up and therefore could not 
be incorporated) as opposed to three scans is obviously less burden on the 
patient in terms of time spent at hospital but also exposure to radiation. Fewer 
scans and need for radioactive tracers could save costs. In the United 
Kingdom, sample costs for MRI may vary from up to £899 this is compared to 
CT (up to £665) and bone scan (£473) which have a total cost of up to £1138.  
 
Following re-staging, patients would then be classified into risk – low, 
intermediate and high risk, according to PSA, site of recurrence, number of 
distant metastases and could incorporate age and other co-morbidities.  
This is important as post radio-recurrence and re-diagnosis, patients may be 
significantly older than at the time of their initial radiotherapy. Risk of general 
anaesthetic and invasiveness of treatment therefore, must be considered.  
 
The key is to then have a number of treatment options available– focused, 
whole gland or systemic – from which patients classified into a risk category at 
re-staging will have treatments most likely to benefit them.
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Chapter 1 Introduction 
 
In this chapter, the background of radiorecurrent prostate cancer, 
methods of re-staging, local (intra-prostatic) diagnosis and current salvage 
treatment options will be discussed.  
 
1.1 Background of radiorecurrent prostate cancer 
 
Prostate cancer is the most common cancer amongst men aged over 70 
years (1,2). External beam radiotherapy (EBRT) is a common treatment for 
prostate cancer, however up to 50% of patients can develop biochemical 
recurrence within ten years of primary radiation treatment (3-8). Failure 
following EBRT is typically detected by rising PSA and is defined as a rise by 
2 ng/ml or more above the nadir PSA post treatment – Phoenix definition (9).  
 
The difficulty with PSA progression following primary therapy is whether this is 
due to recurrent local, regional or metastatic disease (10,11). It is widely 
reported however, that men who fail primary EBRT are commonly started on 
systemic adjuvant hormonal therapy (12,13). Indeed, one study found that 
63% of patients treated with EBRT developed recurrent disease and 93% of 
these received Androgen Deprivation Therapy (ADT) as the salvage treatment 
(14). Significant side effects such as weight gain, breast enlargement and 
tenderness, hot flashes, lethargy, osteoporosis and fracture risk, increased 
cardiovascular comorbidity and metabolic syndrome (15-17). Hormones are 
expensive and once started can lead to castrate resistance within 2 years with 
subsequent costly therapies. Thus, it is important to determine the site of 
recurrent disease as this determines the suitability of further local or systemic 
treatment (18,19).  
 
1.2 Current re-staging techniques 
 
Currently bone scan and Choline PET/CT are used in the re-staging of 
individuals suspected to have prostate cancer recurrence following 
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radiotherapy.  
 
1.2.1 Bone Scan 
 
After primary treatment of prostate cancer, bone is the first site of relapse in 
more than 80% of cases (20). Plain film and bone scans (BS) form the 
mainstay of detection. BS can detect metastases up to 18 months before plain 
film. There only needs to be a 10% change in bone mineral turnover to be 
detected by BS, whereas the bone must demineralise by 50% before a lesion 
is detected by plain film (21). BS and plain film have been shown to 
underestimate the true incidence of metastatic disease. Bubendorf et al. (22) 
performed autopsies on 1,589 men with prostate cancer (47 % were 
unsuspected), and the incidence of metastatic bone disease was 90%. BS are 
also well known for its high rate of false positives resulting from degenerative 
change, inflammation, Paget’s disease and trauma.  
 
Detection rates of bone scan are dependent upon PSA level, clinical stage 
and Gleason score (1). In patients with PSA level 10-20ng/ml detection rates 
are at 33% vs. 38.5% in men with PSA level of 20-50 ng/ mL (1). A high 
tumour stage >T3 appears to have the highest rate of bone scan positivity, up 
to 90.7% (1). Due to the poor specificity of bone scan, further correlation is 
often required with X-Rays exposing patients to further radiation (23). 
 
1.2.2 Choline PET/CT Scan 
 
There are now several radiotracers able to visualise different tumour 
metabolisms are currently available, including 18F- fluorodeoxyglucose for 
glucose metabolism (18F-FDG), carbon 11(11C)/fluorine 18 (18F)-labelled 
choline (11C/18F Choline) and 11C-acetate for lipid metabolism, 11C-
methionine for amino acid metabolism and deoxy-18F-fluorothymidine for 
imaging cell proliferation (24). 
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In tumour cells, there is an increased expression of cellular membrane 
glucose transporters and enhanced hexokinase II enzymatic activity in 
tumours resulting in a higher rate of glucose metabolism, which can be 
identified by 18F-FDG PET (11). However, 18F-FDG cannot distinguish 
between post-therapy changes and recurrent tumour cells or prostatitis. Also, 
high levels of 18F-FDG are excreted in the urinary bladder which can mask 
any lesions in the vicinity (11). 18F- or 11C-Acetate tracers are taken up by 
tumour cells within the prostate due to increased fatty acid synthesis (11,25). 
11C-Acetate has the advantage of not accumulating within the bladder unlike 
18F-FDG. 18F- or 11C-Choline radiotracers have been examined due to the 
upregulation of choline kinase in prostate cancer tumour, which leads to the 
incorporation and trapping of choline within the cell membrane. 11C-choline 
also has the advantage of minimal urinary excretion (11). Currently, of these 
radiotracers 18F-FDG is of limited value and whilst the other tracers hold 
promise there is still no recommended gold standard PET/CT tracer (1). 
 
Among the different PET tracers evaluated for prostate cancer imaging, 
11C/18F choline has been particularly investigated. Choline is an essential 
component of phospholipids of the cell membrane. Cell proliferation and 
upregulation of choline kinase are two mechanisms suggested for the 
increased uptake of this tracer in prostate cancer (26). The presence of 
choline transporters also seems to be involved in the process of its uptake in 
cancer cells (27). 18F-choline has been shown to have a greater sensitivity 
and accuracy than 18F-FDG PET/CT to detect prostate malignancy: 
sensitivity 73% versus 31% and accuracy 67% versus 53%, respectively (28). 
A high Gleason score and rising PSA level have been shown to increase rates 
of detection of 18F-Choline PET/CT. One study found 18F-Choline PET/CT 
detected prostate cancer recurrence in 97% of patients with Gleason Score 
>7, 82% of patients with Gleason Score = 7 and 63% of patients with Gleason 
Score < 7. A total of 43% of patients in this study had recurrence in the 
prostatic bed, and 57% patients had local metastasis (29). Currently, it is not 
recommended to perform a Choline PET/CT with a PSA value <1 ng/ml (24). 
Also, Choline PET/CT has a low spatial resolution and is limited in the 
identification of small lymph node deposits. 
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1.2.3 Whole-body MRI  
 
Recent advances in MRI have made it possible to image the whole body 
(Whole body-MRI (WB-MRI)) within a reasonable time of 50-60 minutes. 
Dynamic contrast enhanced (DCE) and diffusion weighted imaging (DWI) 
complement conventional anatomical MRI techniques and provide a 
combined approach assessing cancer anatomy, microstructure and function. 
This enables the study of extra-skeletal involvement, including lymph nodes 
and other soft tissue metastases (30,31). Also, WB-MRI is conducted without 
irradiation and so patients are not exposed to the cumulative radiation 
exposure of bone scan, plain films and CT which is more than several years 
of natural background radiation (23,32).  
 
1.3 Biopsy of radiorecurrent cancer  
 
Positive biopsies are currently the only way to confirm local relapse. However, 
it is well known that false-positive results can be observed due to difficulties in 
distinguishing radiation-induced atypia of benign glands from malignancy (33-
35). Tumour resolution after radiotherapy has no identifiable glandular 
morphology, and these remnants can be given a high Gleason score (33). 
Post radiotherapy prostate biopsies should be evaluated by a pathologist who 
is familiar with these findings (35-37). The time after radiotherapy at which to 
perform prostate biopsy has been discussed previously. Crook et al. (33) 
showed that 34% of positive biopsies that are obtained 12 months after 
radiotherapy convert to negative status by 24-30 months, whilst about 20% of 
the patients who have a negative post treatment biopsy will later experience 
positive re-biopsy. Scardino (38) also demonstrated a similar rate of 32% of 
men with a positive 12-month biopsy result transitioning to negative by 24 
months. False negatives have been put down to sampling error whereas 
false-positives and indeterminate biopsies also frequently occur due to 
delayed tumour regression (33). These ‘false-positive’ biopsies might be one 
of the reasons for over-diagnosing radiorecurrent prostate cancer (34). 
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Overall, these studies indicate biopsies should take place at least 24-36 
months after radiotherapy. 
 
1.3.1 Transrectal Ultrasound biopsy  
 
Whilst transrectal ultrasound (TRUS) systematic 10-12 core biopsies are 
standard care, they have inherent inaccuracies as a diagnostic strategy. In the 
setting of radiorecurrent disease, these errors can equally lead to 
inappropriate therapeutic decisions. First, TRUS biopsies miss clinically 
significant disease that is present. Second, they miss-classify significant 
disease as insignificant. These two errors may lead a man being 
recommended to effectively undergo palliative care with expectant 
management and hormones rather than potentially curative local therapy. 
Third, TRUS biopsies detect small volume clinically insignificant disease 
which may inappropriately be attributed as the cause of biochemical failure 
(BF) when in fact micro-metastases are present. This could lead to 
unnecessary local salvage therapy which carry variable rates of complications 
and side effects.  
 
1.3.2 Transperineal biopsies  
 
Transperineal template prostate mapping (TPM) biopsies have been shown to 
be more accurate in detecting both primary and radiorecurrent disease. TPM 
biopsies involve using a 5mm brachytherapy grid applied to the perineum and 
a transrectal ultrasound probe to visualise the prostate. Biopsy cores are 
taken every 5-10 mm with two biopsy cores taken in the same grid co-ordinate 
to cover mid-gland to base if the full length of the gland is not covered by one 
biopsy core. In a treatment-naive prostate gland, 5mm TPM has been shown 
to be a more accurate diagnostic method when compared with current 
standard TRUS biopsy (39,40).  
 
Multi-parametric MRI (mpMRI) using various combinations of T2-weighted 
(T2W), DCE-MRI, DWI has become more prominent in the (pre-biopsy) 
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diagnosis of prostate cancer. Indeed, mpMRI has been shown to accurately 
detect lesions in the prostate (41,42). After radiotherapy, prostatic tissue 
demonstrates diffuse low signal intensity on T2W MRI, with indistinct zonal 
anatomy and diffuse low T2 signal, which hinder tumour detection. DCE-MRI 
has been shown to have significantly better sensitivity (72 vs. 38%), positive 
predictive value (46 vs. 24%) and negative predictive value (95 vs. 88%) than 
T2W MRI (43). 
 
MRI-targeted biopsies (MRI-TB) as well as whole-gland TPM biopsies have 
shown promising accuracy rates in identifying radiorecurrent disease (44,45). 
MRI-TB have been shown to have similar detection rates to TPM for clinically 
significant cancer detection in radiorecurrent setting: 84% vs 92%, 
respectively (45).  
 
1.4 Whole-gland salvage therapy 
 
Current whole-gland salvage treatments for radiorecurrent prostate cancer 
include radical prostatectomy (RP), brachytherapy, cryotherapy and High 
Intensity Focused Ultrasound (HIFU).  
 
1.4.1 Salvage radical prostatectomy 
Salvage radical prostatectomy (S-RP) has satisfactory oncological control with 
biochemical disease-free survival (b-DFS) of 31-69% at 5 years and at 30-
43% at 10 years (46,47). However, this salvage method is not often 
performed due to the high risks of morbidity. Complications such as 
incontinence (10-80%), anastomotic stricture (17-32%) and rectal injuries 
(3.3-50%), stem from the fibrosis, merging of tissue planes used for dissection 
and poor wound healing caused by radiotherapy (36,48). Studies reporting 
these outcomes have all emphasised the importance of an experienced 
surgeon due to the high technical demand.  
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1.4.2 Whole-gland salvage brachytherapy  
 
Several studies have shown good b-DFS  rates with salvage brachytherapy 
for radiorecurrent disease. Grado et al. (48) examined salvage Brachytherapy 
in 49 patients and reported b-DFS at 3 and 5 years was 48% (95% CI 32-63) 
and 34% (95% CI 17-51), respectively. Disease specific survival was reported 
as 89% (95% CI 73-96), and 79% (95% CI 58-91), at 3 and 5 years 
respectively. Aaronson et al. (49) showed rates of 89.5% b-DFS  at 3 years. 
Common complications include lower urinary tract symptoms, hesitancy, 
nocturia, rectal bleeding and frequent bowel movements. A serious 
complication is a prostatic-rectal fistula which in one study occurred in 12% of 
patients. These complications were found to be higher than those of salvage 
cryotherapy (50,51). Brachytherapy appears to be a potentially useful salvage 
therapy that needs further evaluation. 
 
1.4.3 Whole-gland salvage cryotherapy  
 
Salvage cryotherapy has shown good 5 year b-DFS (40-58 %), which can be 
up to 73% in patients who had low-risk disease prior to radiotherapy. It must 
be noted that these studies vary on their definition of BF (PSA >0.5 ng/ ml vs. 
ASTRO vs. Phoenix definition) (50-53). With improvements in technique and 
development of cryo-technology such as thermocouples that monitor the 
temperature at important sites within the prostate, and a urethral warming 
device used to prevent tissue sloughing, complication rates have improved 
although can still be high: incontinence 4-73%, recto-urethral fistula 0-3.4%, 
perineal pain 5.6-39.5% and urinary retention 0-67 % (50,51,54). Sloughing 
and urethral stricture rates have been reduced from 10 to 15% to as low as 
zero (52,55). Erectile dysfunction has not improved (72-86%).  
 
1.4.4 Whole-gland salvage HIFU  
 
Many studies have examined HIFU as a potential salvage therapy for 
radiotherapy failure cases. Murat et al. (56) treated 167 patients who had 
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radiorecurrent disease with salvage HIFU. Patients were separated into low, 
intermediate and high-risk groups based on pre-radiotherapy disease risk. 
The progression-free survival rate at 3-years was reported as 53%, 42% and 
25%, respectively. Ahmed et al. (57) reported 1 and 2 year b-DFS rates of 62 
and 48%, respectively, in patients who achieved a PSA nadir of <0.5 ng/ml. 
Overall, common complications include incontinence (10-50%), bladder neck 
stenosis (17%), retention due to urethral stricture (17%), erectile dysfunction 
66.2-100% and recto-urethral fistula (3-16%) (58-60).  
 
In summary, despite good oncological control, S-RP is not widely performed 
due to high morbidity. Brachytherapy, cryotherapy and HIFU are also used as 
salvage therapies, but their long-term oncological outcome is still unknown 
and the morbidity is still high. In primary therapy, these latter treatments are 
currently undergoing evaluation as part of tissue- preserving focal therapy 
strategies in which they target cancerous lesions in the prostate. Some early 
data suggest that a similar strategy could be adopted for radiorecurrent 
disease. The goal of these ablative therapies is the same: maximum 
destruction of cancerous tissue with minimal damage to critical surrounding 
structures such as the urethra, the urinary sphincter, bladder neck and the 
rectum (61). However, potential problems of focal therapy in radiorecurrent 
disease include accurately localising recurrent disease within the prostate, the 
margins of safe treatment which preserve oncological efficacy whilst 
minimising harms and strategies of follow-up. These problems are common to 
the focal therapy story in treatment naıve disease (62).  
 
1.5 Location of radiorecurrent prostate cancer 
 
There has been some debate on the multi-focality and location of 
radiorecurrent disease. Two studies conducted by Leibovici et al. (63) and 
Haung et al. (61) examined RP specimens in radiorecurrent disease. They 
showed that radiorecurrent disease is often bulky, high volume, bilateral 
(74%) and close to (67-74%) or involving the urethra (7%). They felt that as 
biopsies were not able to accurately detect radiorecurrent disease, focal 
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therapies may miss important areas of cancers that could lead to progression 
and metastatic spread.  
 
Haung et al. (61) found that in 46 RP specimens, 90% of cases had cancer 
foci at the apex. A further 28% of specimens in this study also had multi-focal 
disease. However, other studies have shown that recurrence occurs at the 
initial cancer index lesion site (64,65). Cellini et al. (65) found that in 118 
patients, areas not initially affected by tumour had no evidence of disease 
recurrence at a median of 45 months follow-up. There is a possibility that, if 
only one focus is treated, and multi-focal disease is present, these areas can 
develop and metastasise; however, it may be probable that the index lesion 
hypothesis may also be relevant in this setting (66,67). We have previously 
discussed the role of TPM biopsies and mpMRI in detection of localised 
recurrence—these modalities would in theory have the ability to provide three-
dimensional data to drive the focal delivery of ablative modalities.  
 
1.6 Focal Salvage Therapy 
 
This would involve delivering treatment to a localised area of the prostate 
sparing treatment to the rest of the gland thereby minimising further nerve 
damage and potentially reducing risk of bowel related injury. 
 
1.6.1 Focal Salvage brachytherapy 
 
There are limited studies on focal salvage brachytherapy, however one study 
performed by Peters et al. (68) examined 20 patients who underwent focal 
salvage brachytherapy post primary EBRT. Inclusion criteria for this study 
encompassed that patients had to have biochemical failure > 2 years after 
initial radiation treatment, with TRUS biopsy proven unilateral recurrence that 
was in concordance with MRI findings, no lymph node or metastatic disease 
and no ADT treatment at time of salvage therapy.  Median follow up was 36 
months where toxicity and PSA follow up was evaluated. Biochemical failure 
was defined according to the Phoenix definition (PSA nadir + 2.0 ng/ml). 30% 
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of patients were reported to have not responded to treatment either due to 
biochemical failure (n=3) or progression of metastatic disease (n=3). 3-year b-
DFS  estimates were 60% and 71% including and excluding non–responders. 
Incontinence occurred in four patients, urethral stricture in one patient and 
radiation cystitis in another. Only rectal pain was reported though it is unclear 
how many patients suffered this. No rectal fistula was reported and of five 
patients’ potent pre-op, four patients maintained their potency and one patient 
reported a slight decrease, but did not require any further therapy.  
 
1.6.2 Focal salvage cryotherapy  
 
Eisenberg et al. (69) performed a retrospective study on 19 patients. These 
patients were selected on the basis that they fulfilled Phoenix definition for BF 
and had TRUS biopsy confirmed recurrence: the recurrence was unilateral 
and their glands were only partially treated with cryotherapy. Fifteen men had 
6 months’ follow-up which included 3 monthly PSA and TRUS biopsy. The 
complication rates in this study were low with one patient developing mild 
stress urinary incontinence, one developed a urethral stricture that required 
dilation and one developed a prostatic urethral ulcer managed with supra-
pubic catheter drainage with resolution after 6 months; whether this 
represented a fistula was difficult to determine from the study report. Only 5 
patients had available potency data with 2 men maintaining potency and 3 
were impotent after treatment. Using the Phoenix definition of failure, 89%, 
79% and 79% of men were free of biochemical recurrence at 1, 2 and 3 years, 
respectively. Although 19 men were included, only 10 men were re-biopsied 
with 90% having no recurrence at 1 year biopsy. Overall, this was a small 
study with limited and poor follow-up. Although b-DFS rates appear to be 
high, not all patients were followed up and only half of these men had a 
biopsy post-salvage treatment.  
 
 
 
  
 
26 
1.6.3 Focal salvage HIFU  
 
Ahmed et al. (70) performed focal salvage HIFU in 39 patients. Disease 
recurrence was confirmed by mpMRI and either TPM (20 men) or TRUS 
biopsies targeted to the area of recurrence (19 men). Focal HIFU was either 
hemi-ablation (ablation of the lobe up to urethra) or quadrant ablation 
(ablation of one half of the lobe anterior or posterior). Those patients with 
recurrence confirmed by TRUS biopsies underwent hemi-ablation. If there 
was multi-focal cancer, then the patient underwent index lesion ablation if the 
untreated areas had 1 core or less with 3 mm or less of maximum 3 + 3 
disease (on TPM) and/or no lesion on mpMRI. Median follow-up was 17 
months. A total of 44% achieved a PSA nadir of <0.5 ng/ml, and the 1, 2 and 
3-year b-DFS rates for this group were 86%, 75% and 63%, respectively, 
using Phoenix criteria. However, when biopsy post salvage was positive and 
requirement for ADT was included in the definition of failure, these rates 
decreased to 79%, 67% and 45%, respectively. For men who did not achieve 
PSA nadir less than 0.5 ng/ml (56%), the 1, 2 and 3 year b-DFS rates were 
much lower at 55%, 24% and 0%, respectively (70). Pad-free, leak-free 
continence status after treatment was 64%, and the pad-free rate was 87% as 
measured at last follow-up. Erectile function worsened with IIEF-5 scores 
decreasing from a median of 18-13 at 6 months. One patient developed a 
recto-urethral fistula and this resolved spontaneously after 6 months of supra-
pubic catheter drainage and colostomy, as confirmed on repeat serial MRI 
studies, urethrograms and clinical symptoms.  
 
1.7 Cost effectiveness of salvage therapies 
 
There are several salvage therapies available and one important 
consideration is the impact on healthcare costs. As discussed earlier, the 
majority of patients who develop biochemical failure post radiotherapy, are 
placed on long term hormonal therapy (12-14). ADT has been shown to be 
more costly in both primary and salvage setting. Indeed, a longitudinal 
analysis performed by Wilson et al. (71) examined 171 patients who had been 
diagnosed with prostate cancer and had a primary treatment recorded. 
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Patients were classified according to D’Amico risk. ADT was found to have 
the highest cumulative cost over a 5.5-year period (71) compared with other 
prostate cancer therapies; ADT ($69,244 (£49,348)) vs. watchful waiting 
($32,135(£22,902)), brachytherapy ($35,143 (£25,046)) and EBRT ($59,455 
(£42,372)). This may be because higher D’Amico risk patients are treated with 
more costly therapies than those with lower risk disease who can be managed 
with watchful waiting. Despite this by the end of follow up, ADT and EBRT are 
the most costly therapies. 
 
Boyd et al. (72) created a model to compare salvage cryotherapy with 
immediate ADT and compared with 20% deferred ADT – i.e. patients not 
immediately started on ADT. All patients had biopsy proven radiorecurrent 
disease with no evidence of metastases. The study found that salvage 
cryotherapy was markedly cheaper over patients’ lifetime by £29 719 (€37 
619) compared with 20% deferred ADT with a mean Quality-Adjusted life 
years (QALY) gain of 0.68 (95% CI 0.4 to 1.04) versus 0.56 (95% CI 0.28 to 
0.87), respectively. There was an even greater average cost of starting ADT 
immediately compared with salvage cryotherapy of £100 914 versus £62 150.  
 
1.8 Conclusion 
 
With up to one-third of men undergoing curative radiation therapy for localised 
prostate cancer demonstrating biochemical failure within 5-8 years, there is a 
clinical need to find local curative salvage therapies. Salvage treatment is 
compromised by the irradiated pelvis, resulting in increased treatment toxicity. 
Although radical prostatectomy has good oncological outcome, it is not often 
performed due to the high technical skill required to avoid significant 
complications. Whole-gland salvage ablative therapies have improved 
resulting in decreased complication rates; however, their long-term 
oncological outcome is still not available and substantial side effects can still 
occur.  
 
Through improved methods of detection, including frequent PSA 
measurements, mpMRI and targeted image-guided prostate biopsy, as well 
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as novel imaging which may detect micro-metastatic cancer, those with radio-
recurrent disease could be better identified. As recurrent disease is better 
localised focal salvage ablative treatments may have a role. Studies 
examining these types of treatment show early signs that toxicity may be less 
compared to whole-gland salvage approaches. There is an urgent need for 
large, prospective studies involving focal salvage ablative treatments to 
evaluate benefits and risks and provide medium and long-term cancer survival 
outcomes. 
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Chapter 2 Hypotheses 
 
In this chapter, the hypotheses of the research study will be set out with the 
objectives. The methodology of the trial will then be discussed.  
 
As discussed above, there is a need for accurate re-staging of radiorecurrent 
prostate cancer, precise intra-prostatic recurrent disease localisation and 
feasibility of focal salvage treatments. 
 
The hypotheses are therefore: 
 
1) Whole body MRI has a greater sensitivity for the detection of 
metastases in patients with radio-recurrent prostate cancer compared 
to Choline PET/CT and bone scan. 
 
2) Abnormalities seen with multi-parametric MRI are associated with 
clinically significant prostate cancer in the radio-recurrent prostate 
cancer setting.  
 
3) The conduct of focal salvage therapy in men with radiorecurrent 
prostate cancer is both feasible and acceptable.  
 
 
In order to answer the above hypotheses, the FORECAST – FOCal 
RECurrent Assessment and Salvage Treatment - Study was set up. (Please 
see attached protocol in Appendix 10.1) 
 
FORECAST is a prospective, multi-centre, diagnostic and therapeutic, 
investigator-led study. It is a prospective cohort validating study conforming to 
level I evidence for diagnostic test evaluation and conforming to Idea, 
Development, Exploration, Assessment, Long-term Follow-up, Improving the 
Quality of Research in Surgery (IDEAL) guidelines stage 2b evaluation study 
for assessment of focal salvage therapy (73). Monitoring of subject safety and 
study compliance is being managed by Data Monitoring and Trial Steering 
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Committees, comprising an impartial (medically qualified) chairperson, the co-
chief investigators, study coordinator, principal investigators from each study 
site, study statistician, and two patient representatives. The trial is registered 
with ClinicalTrials.gov identifier NCT01883128. The study has also been 
awarded National Cancer Research Network (NCRN) approval.  
 
2.1 Study Objectives 
 
2.1.1 Primary Objectives 
1. To evaluate the accuracy of whole-body MRI to detect and rule-out regional 
lymph node and distant metastatic prostate cancer in men with biochemical 
recurrence following radiotherapy. 
 
2. To evaluate the accuracy of multi-parametric MRI targeted prostate 
biopsies in identifying areas of radiorecurrent prostate cancer compared to 
transperineal template prostate mapping biopsies.  
 
3. Presence of urinary incontinence (any pad usage plus any leakage of urine) 
as determined by the UCLA Expanded Prostate Cancer Index Composite 
(UCLA-EPIC) urinary continence questionnaire, at 12 months, in those men 
with no urinary incontinence at baseline.  
 
2.1.2 Secondary objectives  
 
1. To determine the complications and side-effect profile of focal salvage 
therapy to treat localised radiorecurrent prostate cancer.  
 
2. To provide preliminary data on short term disease control outcomes after 
focal salvage therapy (PSA kinetics, imaging evidence of localised 
recurrence, rate of ADT and metastases/death).  
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2.2 Study population  
 
Eligibility criteria for the trial primarily include men who have had previous 
external beam radiotherapy or brachytherapy with or without neo-
adjuvant/adjuvant hormone therapy. Biochemical failure as defined by the 
Phoenix criteria (PSA nadir + 2 ng/ml).  
 
See Appendix 10.1 for trial protocol with full inclusion and exclusion criteria.  
 
2.3 Imaging  
 
If the patient consents to the trial they will have a series of imaging tests 
(Choline PET/CT-CT, radio-isotope bone-scan if not already carried out in the 
last 6 months), mpMRI Pelvis/prostate and whole-body MRI (See below 
Flowchart 1 – FORECAST Study).  
 
Table 1 compares the standard care and index tests for localised and distant 
disease. Importantly, for each comparative analysis (WB-MRI versus standard 
staging tests; MRI-targeted biopsies versus TPM-biopsies) all men who are 
considered likely to benefit from having these tests will have both the index 
test and reference test relevant for each comparison; this will minimise the 
selection bias in a manner that reflects the clinical imperative. In other words, 
if initial tests show evidence of metastatic disease these men will not be 
included for further tests as it is considered that men with metastatic disease 
experience more harm from further invasive tests such as TPM-biopsies. This 
exclusion reflects the clinical standard and thus selection bias is minimised. 
To minimise any expectation bias clinicians reporting WB-MRI and 
pelvic/prostate mpMRI will be blinded to the result of the other. They will 
however have equal access to previous patient details such as PSA, previous 
biopsy results at initial diagnosis prior to radiotherapy, previous radiotherapy 
details and use of neo-adjuvant/adjuvant hormones, in order to pragmatically 
reflect standard practice. A bone biopsy will be performed if WB-MRI was 
positive and Choline PET/CT and bone-scan were negative. This decision 
would be by discussion at a multidisciplinary team meeting. This would ensure 
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that patients who are found to have a negative bone biopsy and presumed 
negative for metastatic disease can continue to have focal salvage treatment 
provided they have local positive disease on prostate targeted or TPM biopsy. 
Also, a repeat whole-body MRI at 12 months will be performed in all men as 
part of a further study LOCATE — Localising Occult prostate Cancer 
metastasis with Advanced imaging Techniques ClinicalTrials.gov Identifier: 
NCT02935816. This will be able to determine whether temporal changes (in 
response to surveillance or to therapy) allow lesions on WB-MRI which are 
not spotted on standard BS and Choline PET/CT to be concluded as 
malignant. If shown to have a better sensitivity and specificity compared to 
current diagnostic tools used in recurrent prostate cancer, this gives rise to 
the potential of introduction of WB-MRI as a single test or complementary to 
one or both of Choline PET/CT and bone-scan. This may allow patients to be 
accurately identified for further treatment appropriately without having the 
burden of several scans and without exposure to further irradiation. Patients 
will remain blinded to the results of the index tests under evaluation until after 
the appropriate reference test has been conducted. Patients will be excluded 
from analysis if they are withdrawn from the study or unable to undergo the 
reference test after one of the index test, or are unable to have focal salvage 
therapy. 
 
2.4 Transperineal template prostate mapping biopsy  
 
This will be carried out under general regional anaesthetic or local anaesthetic 
with sedation. The patient will undergo 12 zone sampling using a modified 
version of that described by Barzell et al. (74) (See Figure 1– Transperineal 
Prostate Mapping Modified Barzell Zones below). MRI cognitive targeted 
sampling will also be taken. This is performed by comparing the pre-
intervention mpMRI to the live intra-operative prostate ultrasound on two 
different screens (cognitive or visually targeted).  
 
Patients who have the following will not be eligible to have focal salvage 
therapy and thus will be withdrawn from the study and returned to standard 
care:  
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- Men in whom the TPM-biopsies were inadequate for analysis due to lack of 
complete gland sampling 
-Men unfit to undergo focal salvage therapy subsequent to TPM-biopsies.   
- Men unwilling to undergo focal salvage therapy 
- Bulky bilateral disease that would require whole gland treatment.  
 
2.5 Treatment  
 
The decision between focal cryotherapy or HIFU salvage ablative methods 
will be based on the location of recurrent disease. Patients are more likely to 
undergo HIFU if the tumour is posterior and/or apical and men will be advised 
to have cryotherapy if the tumour is predominantly anterior. This is to ensure 
optimum energy delivery as HIFU can often not deliver energy in the upper 
parts of the prostate whilst the cryoprobes can be placed directly into the area 
of the tumour. The decision in those which are basal-middle and posterior will 
be pragmatically chosen by physician and patient as would happen in 
standard care.  
 
2.6 Focal salvage treatment  
 
The treatment will cover the side of the gland in which the clinically significant 
lesion(s) have been identified by a combination of MRI and biopsy as follows.  
 
The following broad rules will be followed in order to standardise the therapy 
(See Figure 2- Types of focal therapy):  
 
- Tissue will be ablated in the entire affected quadrant of the prostate provided 
that less than one half of the lobe is affected.  
 
- Treatment will reach the urethra and may cross the midline by up to 5-10 
mm if the disease is close to the midline (minimum 5 mm margin over midline) 
or crosses over (minimum 10 mm margin over midline) (anterior or posterior 
‘dog-leg’), provided that the treatment does not cross the para-sagittal plane 
on that side (usually 10 mm from midline).  
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- At least one neurovascular bundle must be avoided by ensuring a minimum 
distance of ablation zone to contralateral neurovascular bundle of 10 mm. 
This would usually require preservation of the contralateral lobe but the 10mm 
rule ensures that in patients in whom the dog-leg is used the contralateral 
neurovascular bundle avoids damage.  
 
- When cancer is seen at the overlapping or going into the apical sphincter on 
mpMRI the patient should be excluded.  
 
- In men in whom both lobes meet criteria for clinically insignificant cancer (≤3 
mm and absence of Gleason pattern 4), the lobe with the dominant disease 
burden will be treated. This will be evaluated primarily on biopsy results. If 
these show identical bilateral disease burden, the side with the highest score 
for probability of malignancy on mpMRI will be treated. If this is also 
equivalent, a second re-view of the biopsies will be requested by the trial 
pathologist and the dominant side treated. Only those patients with exactly 
equivalent disease bilaterally following these three reviews will be excluded 
from the trial.  
 
2.7 Follow-up  
 
This will take place at 4 weeks, 3 months, 6 months, 9 months and 12 months’ 
post-treatment. At each follow-up appointment, the patient will have either a 
telephone consultation or clinic visit to discuss their results and review any 
adverse events using National Cancer Institute Common Terminology Criteria 
(NCI CTC) classification system. They will be asked to fill patient reported 
validated questionnaires International Prostate Symptom Score 
 (IPSS), IPSS Quality of Life (QoL), UCLA-EPIC Bowel Questionnaire, erectile 
dysfunction, the International Index of Erectile Function (IIEF)-15 
questionnaire to assess any change in urinary, bowel or sexual function and a 
PSA blood test. At 12 months, the patient will have mpMRI to see if there is 
any evidence of residual disease. If post treatment, there is a PSA doubling 
time of less than 3 months or fails by PHOENIX/ASTRO Definition (PSA nadir 
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+ 2 ng/ml). The patient will undergo repeat prostate mpMRI and if warranted 
repeat mpMRI targeted biopsy+/staging scans (Choline PET/CT/Bone Scan).  
 
Table 1 - Study diagnostic procedures  
 
Standard care Index Tests under evaluation 
Distant Disease Distant Disease 
Bone Scan 
Choline PET/CT 
+/- pelvic lymphadenectomy 
+/- bone or tissue biopsy 
    
Whole-body MRI    
  
Local Disease Local Disease 
TPM Biopsies  Multi-parametric MRI-targeted biopsies 
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2.8 Flow Chart 1 – FORECAST Study 
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Figure 1 – Transperineal Prostate Mapping Modified Barzell Zones 
 
 
 
 
 
Modified Barzell Zones
1  Left Parasagital Anterior Apex
2  Left Parasagital Anterior Base
3  Right Parasagital Anterior Apex
4  Right Parasagital Anterior Base
5  Midline Apex
6  Midline Base
7  Left Medial Anterior Apex
8  Left Medial Anterior Base
9  Right Medial Anterior Apex
10 Right Medial Anterior Base
12 11
Template Mapping Biopsies
Name: 
Hospital Number:
Date of Birth:
Date:
11 Left Lateral
12 Right Lateral
13 Left Parasagital Posterior Apex
14 Left Parasagital Posterior Base
15 Right Parasagital Posterior Apex
16 Right Parasagital Posterior Base
17 Left Medial Posterior Apex
18 Left Medial Posterior Base
19 Right Medial Posterior Apex
20 Right Medial Posterior Base
61620
14 18
410 2 8
15 5 171319
9 3 71
Apex
Base
HGPIN / atypical acini       
Clinically insignificant 
disease (G3+3 up to 3mm)
Gleason = 3+4 AND/OR 
Max Cancer length 4-5mm
Gleason >/= 4+3 AND/OR
Max cancer length >/=6mm
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Figure 2 - Methods of focal ablation (A) Posterior quadrant salvage ablation to 
a single lesion with focal salvage high-intensity focused ultrasound (HIFU). (B) 
Hemi-ablation of index lesion to two index lesions with focal salvage HIFU 
whilst leaving low-risk cancer untreated. 
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Chapter 3 Imaging techniques for diagnosing radiorecurrent prostate 
cancer 
 
This chapter includes two analyses examining diagnosis of distant metastases 
in suspected radio-recurrent prostate cancer. The first is a retrospective 
registry analysis comparing Bone Scan to Choline PET/CT. The second is a 
prospective analysis of WB-MRI vs. bone scan and Choline PET/CT from the 
initial results of the FORECAST Trial. 
 
3.1 Choline PET/CT VS. Bone Scan in detection of radio-recurrent prostate 
Cancer  
 
3.1.1 Introduction 
 
Radiation therapy for prostate cancer is a common treatment. However up to 
50% of patients can develop biochemical recurrence within ten years of 
primary radiation treatment (3-8). For men to be appropriately selected for 
further salvage treatment, metastatic disease should be ruled out and 
localised radiorecurrent disease should be identified accurately. Common 
sites of distant prostate cancer metastases are bone, lymph nodes, liver and 
lung (22). Current methods of detection of distant metastases are bone 
scintigraphy (BS) and Choline PET/CT.  
 
3.1.1.1 Bone Scan 
 
Bone is the first site of relapse in more than 80% of cases (20) following 
primary treatment of prostate cancer. BS however is known to have high rate 
of false positives resulting from trauma, degenerative change and 
inflammation. Bone scan is also limited by its ability to detect metastases at a 
low level of PSA. Previous European Association of Urology (EAU) guidance 
has advised that bone scan has no additional diagnostic value unless PSA 
serum levels are >20 ng/ml or the PSA velocity is >2 ng/ml per year (75). 
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3.1.1.2 Choline PET/CT Scan 
 
As discussed above in Section 1.2.2, there are several different radiotracers 
used in the detection of recurrent and metastatic prostate cancer. Studies 
have found varying rates of detection between different radio tracers. Fricke et 
al. (76) compared 11C-acetate with 18F-FDG tracer and found that 11C-
acetate had a higher detection rate of primary and recurrent prostate tumours 
than 18F-FDG (75% vs. 43%). However, it had a lower rate of detection of 
distant metastatic disease (50% vs. 75%) (76). Choline PET/CT also has a 
low spatial resolution and is limited in the accurate delineation of intra-
prostatic recurrence. Currently, it is not recommended to perform a 
Choline/PET with a PSA value <1 ng/ml (24).  
 
3.1.2 Aim 
Our aim was to assess the concordance between Choline PET/CT and bone 
scan for metastatic radiorecurrent prostate cancer. 
 
3.1.3 Methods and Materials 
A retrospective registry analysis identified 97 men who underwent bone scan 
and Choline PET/CT scan (January 2010 to December 2014). Inclusion 
criteria consisted of men that had undergone previous radiotherapy or 
brachytherapy who underwent both bone scan and Choline PET/CT. Men 
were excluded from analysis if they were on hormones at the time of imaging.  
 
Imaging protocol 
 
Choline PET/CT  
Patients were injected with either 18F-FECH/18F-FDG tracer. Whole-body 
PET/CT images were acquired 60 min after tracer injection. At approximately 
90 min, a limited (one bed position, PET/CT) pelvic view was obtained with 
the prostate in the field of view. The CT acquisition parameters include: scout 
120 kVp, 10 mA; CT 140 kVp, 80 mA, 0.8 s, pitch 1.75; CT slices 5 mm (70-
cm FOV PET AC), 2.5 mm (50-cm FOV Std), 2.5 mm (50-cm FOV Lung). PET 
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acquisition parameters were 3D attenuation-corrected and non- attenuation-
corrected images, 20 subsets with iterative reconstructions. CT images were 
then used to produce attenuation correction values for PET emission 
reconstruction and fused PET/CT presentation.  
 
Bone-scan +/- plain radiography  
 
Bone scans were performed using Technetium-99m labelled diphosphonates 
administered through intravenous injection. These diphosphonates chemically 
bond on the surface of hydroxyapatite crystals on the surface of bone such 
that the images represent local osteoblastic activity. Whole body imaging was 
performed with anterior and posterior views, 256 x 1024 matrix and energy 
window(s) of 140 KeV. Effective dose (ED) is 3mSv (or 5mSv for cancer 
patients) and Diagnostic Reference Level (DRL) is 600 MBq (0r 800 for 
cancer patients).  
 
Statistical Analysis 
 
Statistical analysis was performed using SPSS version 23.0 (SPSS, IBM 
Corporation, New York) and the R language environment (R Core Team 
2015, version 3.2.1). SPSS was used for descriptive statistics and the rms 
package in R for the modelling process.  
 
Using univariable and multivariable logistic regression, odds radios (ORs) with 
95% confidence intervals (95% CIs) were obtained to assess the influence of 
clinical characteristics on the outcome of Choline PET/CT positivity. A two-
tailed p <0.05 was considered statistically significant. Factors with p<0.05 
were retained in the final model. 
 
Cohen’s Kappa Score is useful for either interrater or intrarater reliability 
testing. The score can range from −1 to +1, 1 represents perfect agreement 
between the raters and 0 represents the amount of agreement that can be 
expected from random chance (77). Typically, it is accepted that values ≤ 0 
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indicate no agreement and 0.01–0.20 as none to slight, 0.21–0.40 as fair, 
0.41– 0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1.00 as almost 
perfect agreement (77). 
 
3.1.4 Results 
 
Mean age at time of imaging was 69.4 years (SD 6.1). Patients were 
classified as low 6% (5/97), intermediate 30.9% (30/97) and high-risk disease 
49.5% (48/97) (n=14 missing) according to D’Amico classification at baseline 
prior to external beam radiotherapy (EBRT). 91.8% (89/97) had external beam 
radiotherapy, 5.7% (6/97) had brachytherapy, 2.1% (2/97) had external beam 
radiotherapy with HDR brachytherapy boost. Radiation doses of 74 Grays in 
37 fractions were the most common (n=11). Time from radiotherapy to 
biochemical failure was an average (±SD) of 66 months (±35). Median PSA 
nadir post radiotherapy was 0.30ng/ml (IQR 0.1-0.8) and median PSA pre-
imaging was 4.80 ng/ml (IQR 2.7-7.3). (See Table 2) 
 
Table 2 – Baseline Demographics 
Baseline Demographics  
Age at time of referral years (Mean 
±SD) 
69.4 (±6.1) 
Risk Catergory pre original Tx 
High-risk: PSA >20, G >8, T2c-3a (N 
%) 
48 (49.5) 
Intermediate risk: PSA 10 - 20, G7, 
or T2b (N %) 
30 (30.9) 
Low risk: PSA <10, G <6, T1-2a (N 
%) 
5 (5.2) 
PSA Nadir (Median) 0.3 (0.1-0.8) 
PSA at time of scan (Median IQR) 4.8 (2.7-7.3) 
Time between BS and BF months 
(Mean ±SD) 
9.2 (±13.2) 
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Table 3 - Rates of Bone Scan Detection 
 
Bone Scan Result Frequency (%) 
 
Negative 79 (81.4) 
Positive 3 (3.1) 
Equivocal 15 (15.5) 
Total 97 (100.0) 
 
Bone scan was positive in 3.1% (3/97), equivocal in 15.5% (15/97) and 
negative in 81.4% (79/97). (See Table 3) Sites of bone metastases (according 
to bone scan) included the pelvis 22.2% (4/18), spine 33.3% (6/18), lower limb 
11.1% (2/18) and ribs 27.8% (5/18) One equivocal bone scan did not have 
site recorded (5.6% 1/18). 
 
Table 4 - Rates of Choline PET/CT Scan Detection 
 
 Choline 
PET/CT 
Positive 
Choline 
PET/CT 
Positive 
Local 
Choline 
PET/CT 
Positive 
Nodes 
Choline 
PET/CT 
positive 
metastatic 
disease 
 Frequency 
(%) 
Frequency 
(%) 
Frequency 
(%) 
Frequency 
(%) 
No 26 (26.8) 37 (38.1) 79 (81.4) 89 (88.7) 
Yes 71 (73.2) 60 (61.9) 18 (18.6) 5 (5.2) 
Equivocal    3 (3.1) 
Time between BF and CPET months  
(Mean ±SD) 
9.3 (±13.2) 
Time between BS and CPET days 
(Mean ±SD) 
17.2 (±19.6) 
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Total 97 (100.0) 97 (100.0) 97 (100.0) 97 (100.0) 
 
Table 5 - Site of Choline PET/CT Metastases 
 
Site of Choline PET/CT Metastases  Frequency (%) 
 
Bone (5 positive 1 equivocal) 6 (75) 
Tissue (both equivocal) 2 (25) 
Total 8 (100) 
 
Choline PET/CT was positive in 73.2% (71/97) and negative in 26.8% (26/97).  
Choline PET/CT scan was positive for local disease only in 48.5% (47/97), 
nodal disease only in 9.3% (9/97), and metastatic disease only in 2.1% (2/97). 
Choline PET/CT was positive in both local and nodal disease in 7.2% (7/97), 
in local and metastatic cases 1.0% (1/97) and in local, nodal and metastatic 
disease in 2.1% (2/97). Choline PET/CT was positive for local and equivocal 
for metastatic disease in 3.1% (3/97). Choline PET/CT was negative in 26.8% 
(26/97). Cumulatively, Choline PET/CT scan was positive for local disease in 
61.9% (60/97), for nodal disease in 18.6% (18/97) and metastatic disease in 
5.2% (5/97). Choline PET/CT was equivocal for metastatic disease in 3.1% 
(3/97). (See Tables 4&5) 
 
In patients where bone scan was positive (3/97), 66.7% (2/3) were classified 
as high risk according to D’Amico at baseline, in the third patient, there was 
not enough baseline data to classify according to D’Amico risk. In patients 
with an equivocal score (15/97), 40% (6/15) patients classified as high risk 
and 53.3% (8/15) patients were classified as intermediate risk according to 
D’Amico at baseline. In one case baseline risk information was not available. 
In patients with positive bone scan, median PSA at time of imaging was 
4.53ng/ml (range 2.35-6.70ng/ml). Median PSA in patients with equivocal 
bone scan was 4.95ng/ml (range 1.70 - 9.10ng/ml).  
 
Of patients with positive local disease on Choline PET/CT scan (60/97) 55.8% 
(29/60), 40.4% (21/60) and 3.8% (2/60) were classified as high, intermediate 
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and low risk at baseline according to D’Amico score (baseline information 
missing in 8 patients). Of patients with positive nodal disease on Choline 
PET/CT scan (18/97), 61.1% (11/18) were high risk and 22.2% (4/18) were 
intermediate risk at baseline according to D’Amico score (baseline information 
missing in 3 patients). For patients with positive metastatic disease on Choline 
PET/CT, 60% (3/5) and 20% (1/5) were classified as high risk and low risk at 
baseline respectively according to D’Amico classification (baseline information 
missing in 1 patient). Two of three patients who scored equivocal for 
metastatic disease, were intermediate risk at baseline (baseline information 
missing in one patient). Median PSA in patients who had positive local, nodal 
and metastatic disease on Choline PET/CT scan was 4.1ng/ml (range 0.89-
21.59), 4.65ng/ml (range 2.35-9.10ng/ml) and 2.36 (range 2.35-10.15ng/ml) 
respectively. It should be noted that there were only 5 patients with likely 
positive metastatic disease. In patients with equivocal metastatic disease on 
Choline PET/CT, median PSA was 6.15ng/ml (range 5.90-6.40ng/ml). 
 
Table 6 – Concordance between Choline PET/CT and bone scan for 
metastatic disease  
 
 Choline PET/CT positive for metastatic disease 
 
Bone Scan 
positive for 
metastatic 
disease 
 No Yes Equivocal Total 
No 74 3 2 79 
Yes 2 1 0 3 
Equivocal 13 1 1 15 
Total 89 5 3 97 
 
Concordance between bone scan and Choline PET/CT occurred in only 3 
cases, (kappa value 0.024). In three cases where bone scan was positive for 
metastatic disease, concordance with Choline PET/CT was present in only 
one case. Bone scan was equivocal in 15 cases, concordance was reached in 
one case, was positive in a further case and negative on Choline PET/CT for 
13 cases (kappa value 0.14). Choline PET/CT was positive for metastatic 
bony disease in 5 cases. In one case, Choline PET/CT and bone scan was 
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concordant, in one case bone scan was equivocal and in three cases, bone 
scan was negative (kappa value 0.14). (See Table 6) 
 
Table 7 – Concordance between Choline positive metastatic disease and 
bone scan positive and equivocal results combined 
 
 Choline PET/CT positive mets 
 
Bone Scan 
positive 
 No Yes Equivocal Total 
No 74 3 2 79 
Yes and 
Equivocal 
15 2 1 18 
Total 89 5 3 97 
 
When bone scan positive and equivocal results were combined (n=18) and 
compared with Choline PET/CT, only 2 cases were concordant (positive) with 
one case being equivocal and 15 cases being negative for metastatic disease 
(kappa vaule 0.13). (See Table 7) 
 
Table 8 - Univariable and Multivariable analysis for Choline-PET positive 
 
Determinant (missing) Univariable OR (95% 
CI); p-value 
Multivariable OR 
(95% CI); p-value 
Age at referral (0) 1.07 (0.99-1.16); 0.10 NS 
Time between RT and BF 
(15) 
1.00 (0.98-1.01); 0.57 NS 
PSA at RT (14) 0.99 (0.97-1.01); 0.44 NS 
Overall Gleason score pre-
RT (5) 
1.30 (0.72-2.35); 0.39 NS 
D’Amico risk score pre-RT 
(14) 
Intermediate vs low risk 
High risk vs low risk 
 
1.22 (0.42-3.52); 0.71 
0.56 (0.08-3.72); 0.55 
 
NS 
NS 
PSA-nadir post-RT (57) 1.62 (0.36-7.30); 0.53 NS 
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PSA at scan (32) 0.95 (0.83-1.10); 0.50 NS 
Time between BS and BF 
(12) 
0.98 (0.94-1.01); 0.18 NS 
Time between BF and CP 
(13) 
1.01 (0.98-1.03); 0.67 NS 
Type of Choline (18F vs 
18FDG) (0) 
4.06 (1.32-12.48); 
0.14 
NS 
 
In both univariable and multivariable analyses, no factors (PSA at EBRT, 
baseline D’Amico, PSA at imaging) had a significant outcome in predicting 
Choline PET/CT positivity. (See Table 8) 
 
3.1.5 Discussion 
 
3.1.5.1 Summary of results 
 
There is poor concordance with bone scan and Choline PET/CT in the 
detection of metastatic disease following radiotherapy for prostate cancer.  
 
Concordance between bone scan and Choline PET/CT occurred in only 3 
cases, (kappa value 0.024). In three cases where bone scan was positive for 
metastatic disease, concordance with Choline PET/CT was present in only 
one case. Choline PET/CT was positive for metastatic bony disease in 5 
cases. In one case, Choline PET/CT and bone scan was concordant, in one 
case bone scan was equivocal and in three cases bone scan was negative 
(kappa value 0.14) (See Table 5). As discussed above, the kappa score 
indicates the level of agreement between two reporters. Throughout this 
study, the kappa value was 0.01–0.20 indicating the agreement was none to 
slight (77). 
 
3.1.5.2 Methodological Limitations 
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Limitations of our study include its retrospective nature and lack of 
histopathological confirmation of suspected metastases, and lack of a 
reference standard so no diagnostic accuracies can be performed, this is 
similar to other studies. PSA doubling time and velocity data was not collected 
which could have aided the univariable and multivariable analysis in predicting 
likelihood of positive Choline PET/CT.  The median PSA at time of scans in 
our cohort was also low at 4.80 ng/ml (IQR 2.7-7.3) which could mean that 
true metastatic disease had not yet declared itself resulting in low detection 
rates.  Also, further follow up PSA and repeat scans post treatment 
(systemic/local) data was not collected. This could have given further 
information on equivocal scan results.  
 
 
 
 
3.1.5.3 Comparison with Existing Studies  
 
There are few studies that perform a direct comparison of bone scan to 
Choline PET/CT for the detection of distant disease. A study performed by 
Picchio et al. (78) compared 11C-Choline PET/CT with BS in detecting bone 
metastases (BM) of 78 patients with biochemical progression after radical 
treatment for prostate cancer. Suspicious lesions were confirmed during either 
conventional follow up with computed tomography (CT), MRI and X-rays 
within 20 days (median 10 days; range 1–84 days) of BS or Choline PET/CT, 
or instrumental follow up with imaging performed to monitor patients’ disease. 
Concordant findings were examined on both a patient and lesion based 
analysis.  
 
Concordance occurred in 71% (55/78) patients. 33% (18/55) were True 
Positive (TP) and 67% (37/55) were true negative (TN). In the remaining 23 
cases, findings were discordant. 21 were equivocal on BS that were TP on 
11C-Choline PET/CT in 29% (6/21) patients, TN in 63% (13/21) and FN in 9% 
(2/21).  
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On a lesion based analysis, 56 lesions were reported. Concordance occurred 
in 50% (28/56) lesions and in particular: 75% (21/28) were TP lesions, 4% 
(1/28) were equivocal lesions, and 21% (6/28) were FN lesions. As for 
discordant findings, 11C-Choline PET/CT reported TN in 24 of BS equivocal 
findings and in 5 of BS false positive (FP) findings. 11C-Choline PET/CT was 
TP in 6 of 36 BS equivocal lesions and in 1 FN BS lesion. BS was TP in 17 
FN bone metastases reported on11C-Choline PET/CT and TN in a single FP 
case of 11C- Choline PET/CT rib lesion. 
 
 As there were a high number of equivocal lesions in the study, this resulted in 
the analysis being performed twice to allow for equivocal to be reported as 
positive and negative resulting in ranges of sensitivity, specificity, positive 
predictive value (PPV), negative predictive value (NPV) and accuracy for 11C- 
Choline PET/CT  89–89%, 98–100%, 96–100%, 94–96% and 95–96%, 
versus BS 100–70%, 75–100%, 68-–100%, 100–86% and 83–90%, 
respectively. These high rates of detection could be due to an insufficient 
histopathological reference standard. In this study the mean free serum PSA 
level was 21.1 ng/ml (range 0.2- 500.0 ng/ml) compared to the current study 
where PSA was 4.80 ng/ml (IQR 2.7-7.3). This could be a reason for higher 
rates of metastatic disease within this Picchio’s study. 
 
Choline PET/CT also has the limitation of higher detection rates with a higher 
PSA level. Chondrogiannis et al. (7) examined the use of 18F-choline in 
detection of radiorecurrent disease and reported a detection rate of 54.5 % in 
patients with PSA levels between 1.0 and 2.0 ng/ml, 81 % with PSA level 
between 2.0 and 4.0 ng/ml, 89 % with PSA between 4 and 6 ng/ml and 100 % 
with PSA >6.0 ng/ml. Ceci et al. (4) reported on the performance of 11C – 
Choline in radiorecurrent disease and found a significant correlation between 
PSA kinetics and site of recurrence. In the detection of bony metastasis, PSA 
doubling time (PSAdt) and PSA Velocity (PSAvel) had an odds ratio (OR) of 
0.968 (95% CI 0.906 - 1.034, p =0.032) and 1.043, (95% CI 1.01 - 1.07, p =0.01) 
respectively. For positive lymph nodes, this was 0.876 (95% CI 0.793 - 0.968, 
p =0.009) for  PSAdt and 1.022 (95% CI 0.99 - 1.03, p =0.033) for PSAvel. Also 
within this study, patients with at least one site of Choline uptake, PSA was 
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9.08 ng/mL (median 5.1 ng/mL, range 2 – 60 ng/mL) compared to patients with 
negative results whose mean PSA level was 5.54 ng/mL (median 3.4 ng/mL, 
range 2 – 12 ng/mL, p < 0.05). Another study compared 11C-acetate with 
18FDG tracer and found that 11C-acetate had a higher detection rate of primary 
and recurrent prostate tumours than 18FDG (75% vs. 43%). However, it had a 
lower rate of detection of distant metastatic disease (50% vs. 75%) (76). 
 
Overall common problems with these studies are the lack of histopathological 
confirmation of distant metastases and low PSA values (typically less than 
20ng/ml) when the scans are performed. The latter meaning PSA rise is likely 
due to the presence of micro-metastatic disease. Furthermore, these studies 
are retrospective in nature and typically examine a combination of patients 
following primary treatment of either radical prostatectomy or EBRT. 
 
3.1.5.4 Clinical Implications 
 
Our study has shown that concordance between Choline PET/CT and BS for 
the detection of radiorecurrent disease is low. BS has poor detection rates of 
metastatic disease at low PSA levels (median PSA at time of BS - 4.53ng/ml 
(range 2.35-6.70ng/ml).) Ultimately if Choline PET/CT can identify local, nodal 
and bone metastases at a lower PSA level, with lower rates of false positives 
it poses the question as to whether BS has a role in the detection of 
radiorecurrent prostate cancer. Especially as this further exposes a patient to 
unnecessary radiation.  
 
3.1.5.5 Future Research 
 
Further prospective studies should be performed to determine the clinical 
utility of BS and Choline PET/CT in diagnosis of radiorecurrent prostate 
cancer and whether any novel imaging can outperform these current standard 
of care tests. These imaging tests need to detect recurrent prostate cancer at 
low PSA levels <20ng/ml before metastatic disease is established.  
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3.1.6 Conclusion 
 
There is poor concordance with BS and Choline PET/CT in the detection of 
metastatic disease following radiotherapy for prostate cancer. Further 
prospective trials examining emerging imaging techniques may be able to 
better characterize metastatic disease allowing men to be treated with the 
most appropriate salvage treatment.  
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3.2 Whole body - MRI vs. Choline PET/CT and Bone Scan in detection of 
radio-recurrent prostate Cancer 
 
3.2.1 Introduction 
 
Choline PET/CT and bone scan are common investigations used to 
investigate recurrent prostate cancer. Whilst BS is readily available, at low 
cost, it is anatomically imprecise and can have poor sensitivity and specificity 
for detection of metastatic disease in patients that have PSA <20ng/ml 
(75,79). Choline PET/CT has similar limitations and there is a wide use of 
radiotracers with differing detection rates as discussed above and no current 
recommended standard (24,80,81). 
 
Whole-body MRI is a novel technique that may have a higher diagnostic 
accuracy than these current standards. It is now possible to perform  
whole body- MRI (WB-MRI) within a reasonable time of 50-60 minutes. 
Diffusion weighted imaging (DWI) and Dynamic contrast enhanced (DCE-
MRI) complement conventional anatomical MRI techniques and provide a 
combined approach assessing cancer anatomy, function and microstructure. 
This allows for the examination of lymph node, soft tissue and bone 
metastases (30,31) without requiring ionizing radiation.  
Indeed, the cumulative irradiation of CT, bone-scan and plain film radiography 
is more than several years of natural background irradiation (23). One of the 
drawbacks of bone scan is its inability to detect bone marrow metastases. 
Bone metastases are preceded by bone marrow metastases. Prostate cancer 
cells ﬁrst seed into the normal haematopoietic marrow and its fat cells. This is 
followed by the activation of osteoblastic and osteoclastic cell lines, and the 
action of the former in particular, can be seen by bone scan (82). 18F-choline 
PET CT can detect bone marrow metastases due to the elevated uptake in 
cell proliferation. WB-MRI may detect prostate cancer cell masses in the 
normal haematopoietic marrow, before the bone marrow metastases are 
visible on bone scan (83). 
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3.2.2 Aim 
Our aim was to assess the concordance between WB-MRI and Choline 
PET/CT and BS for the detection of metastases in radiorecurrent prostate 
cancer. 
 
3.2.3 Methods and Materials 
A prospective analysis from FORECAST study identified 50 men who 
underwent WB-MRI, BS and Choline PET/CT scan (April 2014 to September 
2015).  
 
Imaging protocol 
 
Whole- Body MRI 
 
3 Tesla scanner and a pelvic phased array receiver, with a pelvic coil. A full 
protocol of T1 and T2 weighted turbo-spin echo images, diffusion weighted 
images and a dynamic post gadolinium volume acquisition was used.  
 
Choline PET/CT  
 
As described above, Whole-body PET/CT images were acquired 60 min after 
tracer injection of either 18F-FECH/18-FDG tracer. At approximately 90 min, a 
limited (one bed position, PET/CT) pelvic view was obtained with the prostate 
in the field of view. The CT acquisition and PET acquisition were as above 
and these were then reconstructed and fused to form PET/CT presentation.  
 
Bone-scan +/- plain radiography  
 
Technetium-99m labelled diphosphonates was administered through 
intravenous injection. Whole body imaging was performed with anterior and 
posterior views, 256 x 1024 matrix and energy window(s) of 140 KeV. 
Effective dose (ED) is 3mSv (or 5mSv for cancer patients) and Diagnostic 
Reference Level (DRL) is 600 MBq (0r 800 for cancer patients).  
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Statistical Analysis 
 
Statistical analysis was performed using SPSS version 23.0 (SPSS, IBM 
Corporation, New York) and the R language environment (R Core Team 
2015, version 3.2.1). SPSS was used for descriptive statistics and the rms 
package in R for the modelling process.  
 
Using univariable and multivariable logistic regression, odds radios (ORs) with 
95% confidence intervals (95% CIs) were obtained to assess the influence of 
clinical characteristics on the outcome of Choline PET/CT positivity. A two-
tailed p <0.05 was considered statistically significant. Factors with p<0.05 
were retained in the final model. 
 
As above in Section 3.14 Cohen’s Kappa Score is useful for either interrater 
or intrarater reliability testing.  
 
3.2.4 Results 
The mean age was 69.5 years (range 54-85; standard deviation 6.91). The 
median prostate-specific antigen (PSA) at the time of external beam 
radiotherapy (EBRT) was 14.7 ng/ml (interquartile range 7.78 - 36). Patients 
were classified as low 6% (5/48), intermediate 30.9% (30/48) and high-risk 
disease 49.5% (48/48) according to D’Amico classification at baseline prior to 
external beam radiotherapy (EBRT) (Missing baseline data in 2 cases). The 
most frequent EBRT dose given was 74 Gy over 37 fractions. 
Neoadjuvant/adjuvant hormonal therapy use was reported in 44 patients. The 
time from EBRT to biochemical recurrence was a median of 73 months 
(interquartile range 49.00-91.00). The time from EBRT to re-imaging was 78.9 
(IQR 48.5-93.8). The median PSA at the time of imaging was 3.29 ng/ml 
(interquartile range 2.40-5.30) (See Table 11).  
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Table 11 – Baseline Demographics 
 
 
WB-MRI identified local tumour in 52% (26/50) of cases. T3a disease was 
reported in only 1 case, with nodal disease being positive or equivocal in 6% 
(3/50) and 26% (13/50) of cases respectively.  The commonest sites of nodal 
disease were external iliac (18%) and internal iliac nodes (8%). WB-MRI did 
not report any positive tissue sites for metastatic disease, rather, 4% (2/50) 
was equivocal and 72% (36/50) was negative, there was no report, for 24% 
(12/50) cases. WB-MRI was positive in 4% (2/50), equivocal 10% (5/50) and 
negative in 62% (31/50) for bone metastases.  
 
Choline PET/CT was positive for local disease in 66% (33/50) of cases, and 
negative in 28% (14/50). T3a disease was reported in only 1 case. The 
commonest sites of nodal disease were external iliac 12% (6/50) and inguinal 
nodes 12% (6/50). Choline PET/CT reported two sites positive for tissue 
Baseline Demographics  
Age at time of referral years (Mean 
±SD) 
69.5 ± 6.9  
PSA at time of EBRT  median (IQR)  14.7 ng/ml (interquartile range 7.78 - 
36) 
Risk Catergory pre original Tx 
High-risk: PSA >20, G >8, T2c-3a (N 
%) 
36 (72) 
Intermediate risk: PSA 10 - 20, G7, 
or T2b (N %) 
8 (16) 
Low risk: PSA <10, G <6, T1-2a (N 
%) 
4 (8) 
PSA Nadir Median (IQR) 0.3 (0.1-0.6)  
PSA at time of scan Median (IQR) 3.29 (2.4-5.3) 
Time between BF and restaging 
imaging months (Mean ±SD) 
78.9 (±37)  
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metastases. Choline PET/CT was positive in 6% (3/50), equivocal 2% (1/50) 
and negative in 83% (43/50) for bone metastases. No report was given for 3 
patients as to whether there was any positive/equivocal or negative for nodal 
disease. 
 
Bone scan was positive and equivocal in 4% of cases (2/50) respectively.  
 
Of 35 patients reported to have local tumour, concordance between WB-MRI 
and Choline PET/CT occurred in 20 cases Kappa score 0.311 (p=0.056).  
There were 7 cases that Choline PET/CT reported positive for local tumour 
when WB-MRI was negative and 3 cases where WB-MRI was positive for 
local tumour where Choline PET/CT was negative. (See Table 12) 
 
Table 12 Concordance local tumour WB-MRI and CPET 
 
 
CPET Local Tumour 
Present 
Total No Yes 
WB-MRI Local 
Tumour Present 
No 5 7 12 
Yes 3 20 23 
Total 8 27 35 
 
Of 19 patients where nodal status was reported. Concordance between WB-
MRI and Choline PET/CT for NX-0 disease occurred in 14 cases Kappa score 
0.548 (p=0.00032).  There was one case reported as N1 disease on WB-MRI 
that was reported as N2 on Choline PET/CT. WB-MRI and Choline PET/CT 
were concordant in 4 cases for the same nodal site (external iliac node) kappa 
= 0.333 (p=0.121).  However, in 4 other cases, sites reported by WB-MRI as 
positive for nodal disease, were not concordant with the same site on Choline 
PET/CT. (See Table 13 & 14) 
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Table 13 Concordance nodal disease WB-MRI and Choline PET/CT 
 
 
Choline PET/CT N Stage 
Total N0 N1 N2 
WB-MRI  
N-Stage 
0 1 0 0 1 
NX 1 0 0 1 
N0 12 1 0 13 
N1 0 2 1 3 
N2 0 0 1 1 
Total 14 3 2 19 
 
 
Table 14 Site of Nodal disease WB-MRI vs. Choline PET/CT 
 
 
WB-MRI Nodal Site 1 
Total 
External 
Iliac 
Internal  
Iliac 
Common 
Iliac Para-aortic 
Choline PET/CT 
Nodal 
Site 1 
External 
Iliac 
4 0 0 1 5 
Internal Iliac 1 1 1 0 3 
Total 5 1 1 1 8 
 
Of 35 patients where bony metastatic disease outcome was reported, 
concordance between WB-MRI and Choline PET/CT was achieved 30 cases. 
Of these 28 were negative on both WB-MRI and Choline PET/CT and positive 
in 2 cases. These were also positive for same site (thoracic and lumbar spine 
disease).  5 patients were reported as having equivocal disease on WB-MRI 
that was negative on Choline PET/CT (kappa score 0.411 p<0.0001) (See 
Table 15) 
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Table 15 Concordance of bony disease WB-MRI and CPET 
 
 
Choline PET/CT Bone 
Sites Outcome 
Total Negative Positive 
WB-MRI Bone Sites 
Outcome 
Negative 28 0 28 
Equivocal 5 0 5 
Positive 0 2 2 
Total 33 2 35 
 
Concordance was achieved in only one case for bone metastatic disease 
between WB-MRI and Bone scan (kappa score 0.333 p=0.157). This was 
positive in same location (thoracic spine and left rib) (See Table 16).  
 
Table 16 Concordance of bony disease WB-MRI and Bone Scan 
 
 
BS Bone Sites 
Outcome 
Total Equivocal Positive 
WB-MRI Bone Sites 
Outcome 
Negative 1 0 1 
Positive 0 1 1 
Total 1 1 2 
    
 
Concordance was achieved in 2 cases where bony metastatic disease was 
detected on Choline PET/CT and bone scan (See Table 17). Of these cases, 
one was concordant in same area – thoracic spine, however in the latter case, 
the location was not reported on Choline PET/CT.  However, there were two 
cases that were negative on Choline PET/CT and equivocal in Bone scan 
(Kappa = 0.333 (p=0.46)).  
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Table 17 Concordance of bony disease Choline PET/CT and Bone Scan 
 
 
BS Bone Sites 
Outcome 
Total Equivocal Positive 
Choline PET/CT 
Bone Sites Outcome 
Negative 2 0 2 
Positive 0 2 2 
Total 2 2 4 
 
3.2.5 Discussion 
 
3.2.5.1 Summary of results 
 
Concordance between WB-MRI and Choline PET/CT for local disease 
occurred in 20/35 cases Kappa score 0.311 (p=0.056). Concordance between 
WB-MRI and Choline PET/CT for NX-0 disease occurred in 14/19 cases 
Kappa score 0.548 (p=0.00032). WB-MRI and Choline PET/CT were 
concordant in 4 cases for the same nodal site (external iliac node) kappa = 
0.333 (p=0.121).  However, in 4 other cases these tests were not concordant 
for sites of nodal disease (See Table 3 & 4). WB-MRI and Choline PET/CT 
was achieved 30/35 cases for bony metastatic disease (Kappa=0.411 
(p<0.0001)). (See Table 5) 
 
Concordance was achieved in only one case for bone metastatic disease 
between WB-MRI and Bone scan (kappa score 0.333 p=0.157). (See Table 
6).  
 
Concordance between Choline PET/CT and bone scan was achieved in 2 
cases for bony metastatic disease (See Table 7). However, there was 
discordance in two cases that were negative on Choline PET/CT and 
equivocal in Bone scan (Kappa = 0.333 (p=0.46)).  
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Overall our study has shown that there is moderate agreement between WB-
MRI and Choline PET/CT (Kappa score 0.548 (p=0.00032)) in the detection of 
NX-0 nodal disease and for bony metastatic disease (Kappa=0.411 
(p<0.0001)) which was significant. There was fair agreement for bony 
metastatic disease detected by WB-MRI and BS (kappa score 0.333 p=0.157) 
and also for Choline PET/CT and BS (Kappa = 0.333 (p=0.46)) however 
significance was not achieved. 
 
3.2.5.2 Methodological Limitations 
 
Limitations include low PSA at time of imaging. The median PSA at the time 
of imaging was 3.29 ng/ml whilst this is important in the detection of early 
radiorecurrent disease to offer salvage treatments, determination of accuracy 
of WB-MRI was not possible as there were only 2 cases of metastatic 
disease. The other significant limitation was reporting of bone scan. Whilst 
bone scan reports as positive or equivocal when present, all other reports did 
not have definitive negative report thereby limiting analyses. If bone scans 
were recorded as negative, concordance between WB-MRI and Bone scan 
occurred in 18 cases – 17 negative, 1 positive (Kappa = 0.172 (p=0.186). WB-
MRI reported 4 cases as equivocal and 1 case as positive that was negative 
on Bone scan. There was one equivocal result on bone scan that was 
negative on WB-MRI. Similarly, concordance between Choline PET/CT and 
bone scan occurred in 24 cases – 22 negative and 2 positive. One case 
reported as equivocal and one case reported as positive on Choline PET/CT 
were both negative on Bone scan.  Two cases equivocal on bone scan were 
negative for bony disease on Choline PET/CT (Kappa = 0.440 (p=0.003). 
 
3.2.5.3 Comparison with Existing Studies  
Overall, we have shown that there was moderate agreement between WB-
MRI and Choline PET/CT in the of detection of bony disease. There was also 
fair agreement between Choline PET/CT and bone scan for metastatic 
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disease. However these results must be interpreted with caution as there 
were limited cases of metastatic disease.  
 
Other studies have also examined the concordance between WB-MRI and 
Bone scan. A study performed by An et al. (84) examined WB-MRI- Diffusion 
weighted imaging (WB-MRI-DWI), BS and PSA as predictors for bone 
metastases in prostate cancer – both primary and post ADT/EBRT (n=38). 
WB-MRI-DWI appeared to detect more spinal lesions than BS (24 vs. 19). 
Overall, however more metastatic lesions were detected by BS than WB-MRI-
DWI (53 vs. 49).  
 
A study performed by Barchetti et al. examined WB-MRI for the detection of 
metastases (85) in men wither treated with radical prostatectomy (n=82) or 
post EBRT (n=70) without hormonal treatment. WB-MRI had a sensitivity, 
specificity, PPV, NPV and Area Under Curve (AUC) of 99%, 98%, 98%, 96% 
and 0.971 respectively, for detection of bone metastases. For lymph node 
metastases, this was 98%, 99%, 97%, 98%, and 0.960 respectively. In this 
study 18FCholine-PET/CT was the comparative imaging technique and so 
detection differences between the two imaging investigations were not 
reported.  
 
Conde-Moreno et al. (86) performed a similar study in 35 patients post 
primary treatment who were considering for salvage treatment. In this study 
however WB-MRI- DWI had a lower sensitivity, PPV, and NPV compared with 
Choline-PET/CT 44.93%, 86.11%, and 19.15%, vs. 97.10%, 93.06% and 
77.78%, respectively. Specificity of WB-MRI-DWI was higher than Choline 
PET/CT 64.29% vs. 58.33%. The scans were concordant in seven patients 
and in three cases, a lesion was observed using WB-DW-MRI that was not 
detected with Choline-PET/CT. Choline-PET/CT detected lesions in 16 
patients that were not observable using WB-MRI-DWI. However, a low kappa 
index score did not find consistency between the scans for bone (K index of 
0.292 (p = 0.003)) or lymph node metastases (K index of 0.252 (p = 0.001)). 
34.3% (12/35) patients remained the same staging. A change in metastatic 
staging occurred in 45.7% (16/35) patients went from being non-metastatic to 
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metastatic, 14.2% (5/35) being oligometastatic (<5 metastases) to be 
polymetastatic, 5.7% (2/35) went from being considered metastatic to M0. As 
a result of the outcomes of the WB-MRI-DWI and choline-PET/CT 65.7% 
(23/35) of patients, a different therapeutic approach was adopted. 
 
A few studies have reported good sensitivity and specificity of WB-MRI 
compared with current imaging tools. LeCouvet compared DWI-WBMRI with 
BS/plain films and CT in 100 patients; 68 were felt to have metastases. The 
sensitivity of BS/plain films and WB-MRI for detecting bone metastases was 
86 % and 98-100 %, respectively (p <0.04), and specificity was 98 % and 98-
100 %, respectively. The sensitivity of CT and WB-MRI for detecting enlarged 
lymph nodes was similar, at 77-82 % for both; specificity was 95-96 % and 96-
98 %, respectively. The sensitivity of the combination of BS/plain films plus 
CT and WB-MRI for detecting bone metastases and/or enlarged lymph nodes 
was 84 % and 91-94 %, respectively (p = 0.03-0.10); specificities were 94-97 
% and 91-96 %, respectively (23). Another study compared the detection rate 
of metastatic disease by WB-MRI to BS in 39 patients diagnosed with local 
prostate cancer. Interestingly, the sensitivity for detection of skeletal 
metastases for both BS and WB-MRI was 70 % (95 % CI 0.42-0.98), the 
specificity 100 % and the positive predictive value 100 %. WB-MRI and BS 
differed in the areas of detection. For instance, seven patients had bone 
metastases on BS and seven had skeletal metastases by WB-MRI, with 
concordant findings in only four. BS detected more rib metastases, whilst MRI 
identified more metastatic lesions in the spine (83). This study showed that 
WBMRI and BS have similar specificity and sensitivity, but may have to be 
used as complementary investigations to detect skeletal metastases from 
prostate cancer, rather than as alternatives.  
 
Disadvantages however, include the cost of MRI and inability to be used in 
patients with metallic implants such as pacemakers or hip replacements.  In 
the United Kingdom, sample costs for MRI may vary from up to £899 this is 
compared to CT up to £665 or bone scan up to £473. 
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The recognised limitations of these studies are that histology confirmation was 
not the reference standard because bone biopsies are not common practice 
and lymph node dissection is recommended only in patients who are suitable 
for further salvage therapy. These studies often had patients who had differing 
primary therapies either RP or EBRT. 
 
3.2.5.4 Clinical implications 
Whilst WB-MRI may have high specificity and negative predictive value, as 
discussed above, compared with standard of care tests to detect recurrent 
cancer post primary treatment, concordance between these imaging tests is 
low. Therefore, at present WB-MRI cannot be fully relied upon to detect 
radiorecurrent disease.  
 
3.2.5.5 Future research 
Larger studies with longer follow up is required before WB-MRI can fully 
replace bone scan and Choline PET/CT. One issue with these studies is 
metastatic disease and histopathological confirmation. There will have to be 
further ethical consideration as to whether bone biopsy can be incorporated 
and in which patients this will be feasible. Another issue is reporting bias as, 
clinicians should be blinded to the results of WB-MRI and not allow this to 
affect treatment plans as WB-MRI is yet to be validated. We have overcome 
this in our study as WB-MRI was not discussed at MDT outcomes and 
treatments were made in accordance to Choline PET/CT and bone scan as 
this is our current standard of care. Thus, longer follow up with a larger cohort 
of patients within the FORECAST study is likely to give an accurate outcome 
of the detection rates of WB-MRI and the concordance between this and 
standard of care tests. Overall this may add to growing evidence as to the 
clinical utility of WB-MRI and whether this can replace Choline PET/CT and 
bone scan in the diagnosis of radio-recurrent disease.  
 
3.2.6 Conclusion 
WB-MRI has similar detection rates of recurrent disease compared to bone 
scan and Choline PET/CT. However further studies are required to determine 
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if WB-MRI can replace these standard of care tests. Increased sample size as 
FORECAST completes recruitment and repeat WB-MRI imaging during follow 
up will determine the accuracy of WB-MRI to determine radiorecurrent 
disease thereby stratifying those patients amenable to further salvage 
therapy.   
  
 
65 
Chapter 4 Diagnosis of localised radiorecurrent prostate cancer 
 
In this section the role of mpMRI, mpMRI targeted biopsies (MRI-TB) and 
template mapping biopsies (TPM) in the diagnosis of local radiorecurrent 
prostate cancer will be discussed. The first study is a retrospective analysis of 
men undergoing cognitive mpMRI-TB and TPM. The second study is a 
prospective study analysing the outcomes of mpMRI in the FORECAST Study 
in the detection of radiorecurrent disease. In the third study the outcomes of 
template mapping biopsy and implications for focal salvage therapy will be 
discussed.  
 
4.1 Targeted transperineal prostate biopsy in the detection of radiorecurrent 
prostate cancer 
 
4.1.1 Introduction 
 
For local salvage therapy to be delivered appropriately, an accurate 
determination of the presence or absence of localised recurrence is important. 
Although transrectal ultrasound (TRUS) systematic 10-12 core (87) guided 
biopsies can be used to detect or rule out local disease, they have inherent 
inaccuracies as a diagnostic strategy and may lead to inappropriate 
therapeutic decisions. As discussed above in section 1.5 TRUS-guided 
biopsies can miss clinically significant disease, can misclassify significant 
disease as insignificant and may detect small volume clinically insignificant 
disease that may inappropriately be attributed as the cause of biochemical 
failure, when actually micro-metastatic disease may be the cause of a rising 
prostate-specific antigen (PSA) (88,89). These errors may lead to a patient 
undergoing improper management such as being started on ADT rather than 
potentially curative local therapy or unnecessary local salvage therapy with 
the presumption that metastases are not present.  
 
Transperineal Template Mapping biopsies (TPM) overcomes these errors as  
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biopsy cores are taken every 5-10 mm. This is a highly accurate technique as 
the prostate gland is thoroughly sampled with co-ordinates to guide the 
process and recorded to correlate with any suspicious areas in the prostate as 
identified by MRI. Indeed in a treatment-naive prostate gland, when compared 
with current standard TRUS biopsy, 5mm TPM has been shown to be a more 
accurate diagnostic method (39,40).  
 
Multi-parametric magnetic resonance imaging (mpMRI) using T2weighted, 
dynamic contrast enhanced (DCE-MRI) and diffusion weighted imaging 
(DWI), has gained much interest in the diagnosis of prostate cancer in the 
primary setting (90,91). A limited number of studies have shown that mpMRI 
may have encouragingly high performance characteristics in the radio-
recurrent setting (43,44,92-94).  
 
In this study cancer detection rates of biopsies targeted to an mpMRI-
detected lesion (MRI-targeted biopsy: MRI-TB) was compared against TPM in 
men with rising PSA after prior radiotherapy. The use of TPM in this setting 
allowed us to compare the performance of targeted biopsies in all men who 
underwent mpMRI due to biochemical failure without selection bias. This 
study is START and STARD compliant (95).  
 
4.1.2 Methods and Materials 
 
 Research ethics committee exemption was granted for this study by the 
institutional research office. A retrospective analysis identified 147 
consecutive men, between July 2006 and May 2014, referred with suspicion 
of radio-recurrent prostate cancer due to rising PSA post-external beam 
radiotherapy (EBRT) or brachytherapy, a lesion suspicious for cancer on 
mpMRI and who subsequently underwent TPM biopsies. We contacted all 
referring physicians and sent reminders to collate all pre-radiotherapy 
baseline disease characteristics. All men had no evidence of distant disease 
based on a combination of radioisotope bone scan and computed 
tomography/positron emission tomography scans (FDG initially and later 18F-
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choline). This is the standard of care for such patients referred to our 
institution for consideration of local salvage therapy. 70 men were excluded 
as they did not have MRI-TB. Therefore our cohort comprised 77 men who 
underwent an MRI-TB at the same time as TPM biopsies. MRI-TB was taken 
first, followed by TPM. Eight men were referred having been started on ADT 
and underwent imaging while on hormones. Eleven men underwent biopsy 
while on hormonal treatment, which had been started post-imaging in three. 
The mean time for hormonal treatment in these eleven was 8 months. 
Complications were assessed on review of subsequent clinic appointments.  
 
4.1.3 Magnetic Resonance Imaging  
 
The MRI scans were prospectively reported (blind to all histology). Reports 
were conducted by several expert uro-radiologists. Radiologists had access to 
all baseline clinical data, including pre-radiotherapy disease characteristics 
and post-radiotherapy PSA kinetics, where available. Due to the nature of the 
aims of our study (to determine the clinical validity of MRI targeting) there was 
no need for double reporting, as the targeting was based on the report issued 
at the time. Each prostate was divided into four sectors in three sections 
(base, mid-gland, apex) with the urethra as the anatomical dividing point 
between right and left and anterior and posterior. Each of the 12 resulting 
sectors and seminal vesicles were scored using the five-point Likert scale (1, 
highly likely no tumour; 5, highly likely tumour) (96).  
 
As this is a retrospective study, from the period 2007-2014 scans were 
reported before the European Consensus report on prostate MRI and the 
ESUR guidelines on reporting of prostate MRI (96,97). However, our three 
senior uro-radiologists were formally involved in both guidelines and much of 
how we reported the scans in this series is currently incorporated into the 
ESUR and British Society of Uro-Radiology guidelines (98).  
 
Patients were scanned on the 1.5T scanner (Symphony or Avanto, Siemens 
AG, Munich, Germany) using a pelvic phased-array coil. The sequences were 
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evaluated in the following manner. First, the T2 sequences were used to 
provide morphology and anatomical localisation. DCE played a greater role 
for the peripheral zone with the additional reference of the DWI scans. A 
score of 1 or 2 was given if there was no enhancement; a score of 3 was 
given if symmetrical diffuse enhancement was seen; if there was focal or 
asymmetrical enhancement 3 mm and no abnormality seen on DWI, a score 
of 4 was given; if there was focal or asymmetrical enhancement 3 mm and/or 
corresponding DWI abnormality in the same anatomical location, a score of 5 
was recorded. A similar technique was used to report for lesions in the 
transition zone, with DWI sequences given greater weighting compared with 
DCE. DCE shows more enhancement of adenomas in this zone, especially 
after radiotherapy. However, an equivocal score of 3 based on DWI could be 
upgraded to 4 or 5 if there was an associated obvious DCE abnormality in the 
same anatomical location (44).  
 
4.1.4 Transperineal prostate mapping biopsy 
 
A 5 mm transperineal brachytherapy grid was used to take biopsies 
transperineally under general anaesthetic using TRUS guidance. Individual 
lesions that scored 3-5 were first targeted using the template grid with two to 
four cores taken per target. This was followed by TPM biopsies from the 
remainder of the prostate, which included the targeted biopsy area. If the 
prostate apex-base length was greater than the core length, two biopsies 
were taken at the same grid coordinate and labelled separately. Biopsies 
were taken in 20 sectors with one to two cores per sector according to the 
size of the prostate (Figure 1 - Transperineal Prostate Mapping Modified 
Barzell Zones) (39). 
 
Biopsy cores were analysed and reported by two dedicated expert uro-
pathologists with over 10 years of experience in the diagnosis of prostate 
malignancy. Biopsy results were grouped into four regions of interest per 
prostate, reflecting the mpMRI reporting. Pathologists were aware of clinical 
details and MRI findings.  
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Statistical Analysis 
 
The analysis was carried out at the whole prostate level. Two-by-two and 
three-by-three tables of agreement were drawn up comparing the detection of 
clinically significant, clinically insignificant and no cancer by each of the two-
biopsy techniques.  
 
The primary outcome was the detection rate of clinically significant prostate 
cancer (defined using UCL/Ahmed definition 2 (Gleason ≥3+4 and/or 
maximum cancer core length (MCCL) ≥4 mm) (99).  
 
Secondary outcomes were set for a target definition of UCL/ Ahmed definition 
1 cancer only (Gleason ≥4+3 and/or MCCL ≥ 6 mm only), excluding those that 
met criteria of UCL/ Ahmed definition 2), any Gleason pattern 4 or greater and 
‘all cancer’. The UCL definitions were used as they were developed 
specifically and validated for the presence of 0.2 cm3 and 0.5 cm3 lesions on 
a TPM sampling strategy (99). For each target condition, the difference 
between the biopsy techniques was compared using McNemar’s test. Data 
were analysed using SPSS version 22 (IBM Corp 1989, 2013 Release 
22.0.0.0). A P value < 0.05 was chosen for indicating a statistically significant 
difference.  
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Figure 1 – Transperineal Prostate Mapping Modified Barzell Zones 
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1  Left Parasagital Anterior Apex
2  Left Parasagital Anterior Base
3  Right Parasagital Anterior Apex
4  Right Parasagital Anterior Base
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7  Left Medial Anterior Apex
8  Left Medial Anterior Base
9  Right Medial Anterior Apex
10 Right Medial Anterior Base
12 11
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11 Left Lateral
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13 Left Parasagital Posterior Apex
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17 Left Medial Posterior Apex
18 Left Medial Posterior Base
19 Right Medial Posterior Apex
20 Right Medial Posterior Base
61620
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4.1.5 Results  
 
Of 77 patients included, the mean age was 70 years (range 61-82; standard 
deviation 5.03). The median PSA at the time of radiotherapy was 14 ng/ml 
(range 4.5-143; interquartile range 7.83-32.50). Information on pre-
radiotherapy stage and risk was available for 63 patients. Further baseline 
information is available in Table 18. Adverse event data were available in all 
77; one reported haematospermia (1.3%), three (3.9%) reported dysuria with 
no associated infection/sepsis and one (1.3%) had fever and bowel 
disturbance treated with oral antibiotics for presumed gastrointestinal 
infection.  
 
Table 18 Baseline demographics of patients undergoing transperineal 
biopsies for suspicion of radio-recurrent prostate cancer 
 
Baseline Demographics 
Total no. patients  77  
Mean age (range) years (standard 
deviation)  
70.48 (61-82) (5.03)  
Median PSA (ng/ml at) EBRT 
(range) (IQR)  
14 (4.5-143; IQR 7.83-32.5)  
D’Amico risk score at time of EBRT, 
n (%)  
 
Risk information known  
 
63 (100) 
1 High risk: PSA > 20, G > 8, T2c - 
3a 
33 (52.4)  
2 Intermediate risk: PSA ≥ 10 ≤ 20, 
G7, or T2b 
19 (30.2)  
Low risk: PSA < 10, G < 6, T1-T2a 11 (17.5)  
Time between EBRT and 
biochemical failure (months), median 
(range) (IQR)  
60 (5-156; IQR 36.75-85.00)  
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PSA at time of MRI (ng/ml), median 
(range) (IQR)  
4.68 (0.54-20; IQR 2.68-7.60)  
Time between EBRT and TPM 
(months), median (range) (IQR)  
78 (15-199; IQR 61.5-110)  
Time between mpMRI and TPM 
(months), median (IQR) 
2.76 (1.58-4.34) 
 
4.1.5.1 Primary Outcome  
 
4.1.5.1.1 Detection of Clinically Significant Cancer  
 
Using University College London (UCL)/Ahmed definition 2 (Gleason ≥3+4 
and/or maximum cancer core length (MCCL) ≥4 mm), 60 patients (77.9%) on 
MRI-TB compared with 66 patients (85.7%) on TPM (Table 19) were 
identified. In terms of agreement, three (3.9%) classified as clinically 
insignificant or no cancer on TPM were found to have clinically significant 
cancer on MRI-TB. Nine (11.7%) reported as having no cancer or clinically 
insignificant cancer on MRI-TB were found to have clinically significant cancer 
on TPM (p=0.15) (Table 20). Eight of these cases were of cancer in the 
targeted area (targeting error) and one had cancer outside of the targeted 
area (mpMRI detection error). This patient had an overall mpMRI score of 3/5 
in all areas of the prostate, the left posterior on TPM biopsy was found to be 
positive for Gleason 4+3 MCCL 1 mm. The posterior midline was targeted in 
this patient, but this did not reveal any cancer.  
 
On a per core analysis, 190/381 (50%) of MRI-TB cores were positive for 
clinically significant cancer compared with 425/2392 (17.8%) of TPM cores 
(Table 4). For the detection of clinically significant prostate cancer, 2.0 MRI-
TB cores had to be taken versus 5.6 cores on TPM biopsy (Table 21).  
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Table 19 Cancer detection rates using transperineal prostate mapping (TPM) 
and magnetic resonance imaging-targeted biopsies (MRI-TB) in patients with 
radio-recurrent prostate cancer 
 
 TPM n (%) MRI-TB n (%) 
Total 77 (100) 77 (100) 
No cancer 8 (10.4) 14 (18.2) 
Clinical insignificant 
(Gleason 3+3 and ≤3 
mm) 
3 (3.9) 3 (3.9) 
UCL/Ahmed definition 2 
(Gleason ≥3+4 and/or 
maximum cancer core 
length (MCCL) ≥4 mm) 
11 (14.3) 8 (10.4) 
UCL/Ahmed definition 1 
Gleason ≥4+3 and/or 
MCCL ≥ 6 mm 
55 (71.4) 52 (67.5) 
 
Table 20 Comparison of clinically significant cancer detection between 
transperineal prostate mapping (TPM) and magnetic resonance imaging-
targeted biopsies (MRI-TB) cognitive, visual-estimation method in patients 
with radio-recurrent prostate cancer 
 
   TPM  
  No 
cancer/clinically 
insignificant 
cancer 
UCL/Ahmed 
definition 2 or 
UCL/Ahmed 
definition 1 
Total 
 No 
cancer/clinically 
insignificant 
cancer 
8 9 17 
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MRI-TB UCL/Ahmed 
definition 2 or 
UCL/Ahmed 
definition 1 
3 57 60 
 Total 11 66 77 
 
 
 
Table 21 Core-based comparison of the detection of any cancer, clinically 
significant cancer and cancer Gleason 7 between transperineal prostate 
mapping (TPM) and magnetic resonance imaging-targeted biopsies (MRI-TB) 
cognitive, visual-estimation method in patients with radio-recurrent prostate 
cancer 
 
 TPM (%) MRI-TB (%) 
Total number of cores 2392 (100) 380 (100) 
Any cancer 428 (17.9) 203 (53.4) 
UCL/Ahmed definition 2 or 
UCL/Ahmed definition 1 
425 (17.8) 190 (50.0) 
Gleason score ≥7 419 (17.5) 181 (47.6) 
UCL/Ahmed definition 1 379 (15.8) 177 (46.6) 
 
4.1.5.2 Secondary Outcomes  
 
First, MRI-TB had a similar rate of detection of UCL/ Ahmed definition 1 
disease compared with TPM; 52 patients (68%) versus 55 patients (71%). For 
the detection of clinically significant prostate cancer, 2.2 MRI-TB cores had to 
be taken versus 6.3 cores on TPM biopsy.  
 
Second, TPM had a higher detection rate of Gleason 3+4 cancer compared 
with MRI-TB; 65 patients (84.4%) versus 58 patients (75.3%). For the 
detection of Gleason cancer ≥3+4, 2.1 MRI-TB cores had to be taken versus 
6.3 cores on TPM biopsy.  
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Third, TPM had a higher all cancer detection rate of 69 patients (89.6%) 
compared with 63 patients (81.8%) for MRI-TB. TPM misclassified one patient 
(1.3%) as no cancer but was found to have cancer on MRI-TB. However, 
MRI-TB misclassified seven patients (9.1%) as no cancer but were found to 
have cancer on TPM biopsy. These cases were of cancer in the targeted area 
(targeting error) in seven cases (P = 0.07) (Table 22). Fourth, based on MRI 
score, 67/77 patients (87.0%) scored PIRADS ≥4 (Table 23), of which 60/67 
patients (90.0%) were found to have clinically significant cancer on TPM and 
57/67 patients (85.1%) on MRI-TB (Table 24). Ten of 77 had an mpMRI score 
of ≤ 3/5. Of these, 6/10 (60%) had clinically significant cancer on TPM (all had 
Gleason score ≥ 7). On MRI-TB, 3/10 (30%) had clinically significant cancer 
(with two of these having Gleason score ≥ 7).  
 
Table 22 Comparison of cancer detection between transperineal prostate 
mapping (TPM) and magnetic resonance imaging-targeted biopsies (MRI-TB) 
cognitive, visual-estimation method in patients with radio-recurrent prostate 
cancer 
 
   TPM  
  No cancer Any cancer Total 
 No cancer 7 7 14 
MRI-TB Any cancer 1 62 63 
 Total 8 69 77 
 
  
  
 
76 
Table 23 Magnetic resonance imaging (MRI) score and detection of any 
cancer, clinically significant cancer and Gleason ≥7 by transperineal prostate 
mapping in patients with radio-recurrent prostate cancer 
 
 
MRI 
score  
n (%)  Any 
cancer  
n (%) 
UCL/Ahmed 
definition 2 
or 
UCL/Ahmed 
definition 1  
n (%) 
Gleason 
≥7 
n (%)  
UCL/Ahmed 
definition 1  
n (%) 
1. 
Clinically 
significant 
disease is 
highly 
unlikely to 
be 
present  
0 0 0 0 0 
2. 
Clinically 
significant 
cancer is 
unlikely to 
be 
present  
1 0 0 0 0 
3. 
Clinically 
significant 
cancer is 
equivocal  
9 6 6 6 2 
4. 
Clinically 
significant 
25 22 20 19 17 
  
 
77 
cancer is 
likely to 
be 
present  
5. 
Clinically 
significant 
cancer is 
highly 
likely to 
be 
present  
42 41 40 40 36 
Total 77 69  66 65 55 
 
Table 24 Magnetic resonance imaging (MRI) score and detection of any 
cancer, clinically significant cancer and Gleason 7 by MRI-targeted biopsies 
cognitive, visual-estimation method in patients with radio-recurrent prostate 
cancer 
 
MRI 
score  
n (%)  Any 
cancer  
n (%) 
UCL/Ahmed 
definition 2 
or 
UCL/Ahmed 
definition 1  
n (%) 
Gleason 
≥7 
n (%)  
UCL/Ahmed 
definition 1  
n (%) 
1. 
Clinically 
significant 
disease is 
highly 
unlikely to 
be 
present  
0 0 0 0 0 
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2. 
Clinically 
significant 
cancer is 
unlikely to 
be 
present  
1 0 0 0 0 
3. 
Clinically 
significant 
cancer is 
equivocal  
9 3 3 2 2 
4. 
Clinically 
significant 
cancer is 
likely to 
be 
present  
25 21 19 19 17 
5. 
Clinically 
significant 
cancer is 
highly 
likely to 
be 
present  
42 39 38 37 33 
Total 77 63 60 58 52 
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4.1.6 Discussion  
 
4.1.6.1 Summary of Results 
 
MRI-TB detected 77.9% of patients with clinically significant cancer 
(UCL/Ahmed Definition 2 disease), whereas TPM biopsy had an 85.7% 
detection rate (p=0.146). On a per core analysis, 190/381 (50%) of MRI-TB 
cores were positive for clinically significant cancer compared with 425/2392 
(17.8%) of TPM cores (Table 4). For the detection of clinically significant 
prostate cancer, 2.0 MRI-TB cores had to be taken versus 5.6 cores on TPM 
biopsy (Table 4).  
First, MRI-TB had a similar rate of detection of UCL/ Ahmed definition 1 
disease compared with TPM (52 patients (68%) versus 55 patients (71%) 
(P=0.629)). However, TPM biopsy had a higher detection rate of Gleason 3+4 
and all cancer detection rate compared with MRI-TB ((65 patients (84.4%) 
versus 58 patients (75.3%) (p=0.092) and 69 (89.6%) compared with 63 
patients (81.8%) (p=0.70). 
 
4.1.6.2 Limitations  
 
Before discussing the clinical implications of our findings, our study does have 
some limitations. First, the retrospective design and small sample size limits 
the external validity of our findings. Second, as nearly all of our patients were 
referred from external centres, there was incomplete information on 
radiotherapy doses, initial PSA and initial Gleason scores. Third, although the 
notion of clinically important disease is gaining acceptance in primary prostate 
cancer, such a notion has not been adequately explored in radiorecurrent 
disease. To mitigate this, we evaluated outcomes using a number of 
histological target definitions. It has been reported that delayed tumour 
regression and eventual conversion to negative biopsies occurs at a mean 
time of 30 months (100) [20]. However, within our study, only one patient was 
sampled within 30 months (at 15 months) of completion of radiotherapy. The 
average time after EBRT for biopsy was 86 months. Thus, any cancer 
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detected will probably be a true recurrence and not a continuing change in 
prostate tissue morphology from radiation. 
 
4.1.6.3 Comparison with Existing Studies  
 
Sensitivity and specificity of mpMRI have been reported as high as 86-100% 
(43,94,101). However, these studies used TRUS biopsy as the reference 
standard, so the mpMRI detection error may have been under-reported. There 
are limited data available about the use of targeted biopsy in the radio-
recurrent setting. Rud et al. (102) examined the detection rate of DWI and 
MRI-US fusion-targeted biopsy (MRI-US fusion-TB) in men with radio-
recurrent prostate cancer. MRI-US fusion-TB had a higher rate of detection of 
cancer compared with random TRUS-guided biopsies - 83% versus 21%, 
respectively. However, a poor reference standard was used in this study and 
random biopsies were not carried out in the area where a targeted biopsy had 
been undertaken. Instead random TRUS-guided biopsies were taken in the 
contralateral lobe.  
 
In order to further place our data in the context of targeted biopsy series, we 
have to turn to the primary setting. There are several studies that report on 
the improved detection of cognitive MRI-TB and now MRI-US fusion-TB 
compared with whole-gland sampling in the primary setting. One study 
showed similar detection rates of MRI-TB versus TPM in primary prostate 
cancer of 57% versus 62% (P = 0.174). This study also showed a higher 
proportion of cores positive for cancer with MRI-TB (38%) than with TPM 
(14%) (42). MR-US fusion biopsies have reported higher cancer detection 
rates compared with standard sampling. One study compared MRI-US fusion-
TB with transperineal biopsy in the primary setting and found that 46.0% of 
MRI-US fusion-TB versus 7.5% of systematic TPM detected Gleason ≥7 
cancers. TPM biopsy missed 20.9% Gleason ≥7 cancers compared with 
12.8% for MRI-US fusion-TB (103).  
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A more recent study also showed that MRI-US fusion-TB resulted in 22% and 
67% additional cases of Gleason ≥3+4 and Gleason ≥4+3 prostate cancer 
than 12 core systematic biopsy, respectively (104).  
 
Two recent systematic reviews have shown MRI-TB to be superior when 
compared with whole-gland transrectal systematic sampling. Moore et al. 
(105) examined MRI-TB compared with whole-gland sampling in the primary 
setting. Core-based analysis showed that just 7% of systematic cores were 
positive for any cancer compared with 30% on MRI-TB. On a per patient 
basis, MRI-TB had a higher cancer detection rate of 48% versus 36% for 
standard biopsy. Both targeted and standard biopsy detected clinically 
significant cancer in 43% with similar rates of missing cancer (23.4% versus 
21.6%, respectively).  
 
Another systematic review (106) reported on cancer detection rates of MRI-
US fusion-TB in comparison with systematic biopsy. Clinically significant 
cancer was detected in 33.3% versus 23.6%, respectively. MRI-US fusion 
biopsy was again re-ported to be more efficient, with four times the number of 
cores needed in systematic sampling compared with an MR-US fusion-TB 
approach. MRI-US fusion biopsies also detected a median of 9.1% additional 
clinically significant cancers that were missed by standard biopsy alone. 
Conversely, standard biopsies detected a median of 2.1% additional clinically 
significant cancers that were missed by MRI-US fusion-TB.  
 
It is important to note that these systematic reviews predominantly examined 
targeted biopsy in the primary setting. If our results are reproducible in further 
studies and larger numbers across multiple sites, it is possible that in future, 
men who fail radiation therapy and who wish to consider local salvage therapy 
should undergo an mpMRI with targeted biopsies to suspicious areas to 
confirm histological local recurrence. As with all diagnostic tests and 
strategies, a balance between accuracy and burden of the test(s) needs to be 
evaluated. The additional number of biopsy cores that are taken from TPM do 
lead to a 10% higher detection rate, but in themselves are not perfect either 
as misclassification does occur. Patients and their physicians need to make 
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an individualised decision, weighing up the additional detection rate with the 
requirement for TPM to be carried out under general anaesthetic with a high 
number of cores and the side-effects that these cause. Future research needs 
to focus on whether image-fusion targeting has any clinical utility in this 
setting or whether mpMRI cognitive, visually directed biopsies, as we have 
carried out in our study, is sufficient. Furthermore, mpMRI with targeted 
biopsy confirmation may facilitate greater acceptance or delivery of local 
salvage therapies, such as radical prostatectomy, or minimally invasive 
approaches, such as tissue-preserving focal salvage therapy (107). 
 
4.1.6.4 Clinical Implications 
 
To our knowledge, this is the first study to compare cancer detection rates of 
MRI-TB and TPM biopsies in the radio-recurrent prostate cancer setting. We 
found that MRI-TB has an encouraging and acceptable detection rate for 
clinically significant prostate cancer using any number of definitions (68.0-
77.9%). Although TPM biopsies had 10% higher detection rates for a more 
conservative definition of clinically significant cancer, the performance was 
similar for a higher threshold of disease burden. MRI-TB was also consistently 
more efficient, with fewer biopsies required compared with TPM; 1 core 
versus 2.8 cores for the detection of clinically significant disease; 1.00 core 
versus 2.9 cores for UCL/Ahmed definition 1 disease, respectively. MRI-TB 
misclassified seven patients (9.1%) as no cancer but were found to have 
cancer on TPM biopsy. These cases were of cancer in the targeted area 
(targeting error) in seven cases (P = 0.07).  
 
4.1.6.5 Future Research 
 
To further improve the targeting accuracy of MRI-TB US-Fusion and live MRI-
TB holds promise. At time of biopsy, patient position (lithotomy) and presence 
of a transrectal probe can alter the shape of the gland resulting in differences 
of target sites identified on pre-operative MRI. These newer fusion techniques 
can be compared to cognitive and TPM biopsy, eventually providing more 
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evidence as to the best strategy to identify local radiorecurrent disease that 
causes least morbidity to the patient.  
 
4.1.7 Conclusions  
 
MRI-TB show some promise in the diagnosis of clinically significant radio-
recurrent prostate cancer when compared with a systematic biopsy approach 
using TPM biopsies. Further prospective multicentre trials are needed to 
determine if these results are stable and reliable across a larger number of 
men. 
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4.2 Multiparametric MRI in detection of radiorecurrent disease 
 
4.2.1 Introduction 
 
Accurate localization of radiorecurrent disease is paramount in providing focal 
salvage therapy. Multi-parametric MRI (MpMRI) has been shown to have 
promise in the diagnosis of radiorecurrent disease as discussed above. The 
detection rate of mpMRI within the FORECAST Study will now be discussed 
and the detection rates of TPM biopsy versus MRI-TB.  
 
4.2.2 Methods and Materials 
Patient selection 
Eligibility criteria for the trial primarily include men who biochemical failure 
after having had previous external beam radiotherapy or brachytherapy with 
or without neo-adjuvant/adjuvant hormone therapy. Biochemical failure as 
defined by the Phoenix criteria (PSA nadir + 2 ng/ml).  
 
See Appendix 10.1 for protocol with full inclusion and exclusion criteria.  
 
Imaging 
 
All patients underwent Choline PET/CT, radio-isotope bone-scan (if not 
already carried out in the last 6 months and whole-body MRI (See above  
Flowchart 1 – FORECAST Study). If these investigations revealed metastatic 
disease they were withdrawn from the trial.  
 
Multi-parametric Resonance Imaging (mpMRI) 
 
As discussed above in Chapter 4.1 - Targeted transperineal prostate biopsy in 
the detection of radiorecurrent prostate cancer patients were scanned on the 
1.5T scanner (Symphony or Avanto, Siemens AG, Munich, Germany) using a 
pelvic phased-array coil. The MRI scans were prospectively reported (blind to 
all histology). Reports were conducted by several expert uro-radiologists. 
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Radiologists had access to all baseline clinical data, including pre-
radiotherapy disease characteristics and post-radiotherapy PSA kinetics, 
where available.  
 
As discussed above in Chapter 4.1 each prostate was divided into four 
sectors in three sections (base, mid-gland, apex) with the urethra as the 
anatomical dividing point between right and left and anterior and posterior. 
Each of the resulting sectors and seminal vesicles were scored using the five-
point MRI and the ESUR guidelines on reporting of prostate MRI (96,97) 1, 
highly likely no tumour through to  5, highly likely tumour.  
 
Biopsy Strategies  
 
Patients then underwent transperineal prostate mapping biopsy (as described 
above (see Chapter 4.1 Targeted transperineal prostate biopsy in the 
detection of radiorecurrent prostate cancer) using a modified version of that 
described by Barzell et al. (74) (See Figure 1 - Transperineal Prostate 
Mapping Modified Barzell Zones above- Chapter 4.1 Targeted transperineal 
prostate biopsy in the detection of radiorecurrent prostate cancer).  
 
If mpMRI prior to biopsy identified a visible lesion, MRI cognitive targeted 
sampling were taken by comparing the pre-intervention mpMRI to the live 
intra-operative prostate ultrasound on two different screens (cognitive or 
visually targeted). TPM biopsies were performed as described above using a 
5 mm brachytherapy template grid with two to four cores taken per target. 
This was followed by TPM biopsies from the remainder of the prostate, which 
included the targeted biopsy area. (39,44).  
 
Biopsy cores were analysed and reported by two dedicated expert uro-
pathologists with over 10 years of experience in the diagnosis of prostate 
malignancy. Biopsy results were grouped into four regions of interest per 
prostate, reflecting the mpMRI reporting. Pathologists were aware of clinical 
details and MRI findings.  
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Statistical Analysis 
 
The analysis was carried out at the whole prostate level. Two-by-two tables of 
agreement were drawn up comparing the detection of any cancer, clinically 
significant UCL Definition 1 and Clinically significant cancer UCL Definition 2 
disease. To calculate the sensitivity and specificity, scores of PIRADS ≥ 4 
were considered positive and further analysis of scores PIRADS ≥ 3 as 
positive. The primary outcome was the detection rate of clinically significant 
prostate cancer (defined using UCL/Ahmed definition 2 (Gleason ≥3+4 and/or 
maximum cancer core length (MCCL) ≥4 mm) (99). Secondary outcomes 
were set for a target definition of UCL/ Ahmed definition 1 cancer only 
(Gleason ≥4+3 and/or MCCL ≥ 6 mm only), excluding those that met criteria 
of UCL/ Ahmed definition 2), and any cancer. The UCL definitions were used 
as they were developed specifically and validated for the presence of 0.2 cm3 
and 0.5 cm3 lesions on a TPM sampling strategy (99).  
 
Data were analysed using SPSS version 24 (IBM Corp 1989, 2013 Release 
22.0.0.0). A P value < 0.05 was chosen for indicating a statistically significant 
difference.  
 
4.2.2.1 Results 
 
Of 36 patients included, the mean age was 69 years (range 54-85; standard 
deviation 7.09). The median PSA at the time of radiotherapy was 14.8 ng/ml 
(range 3.6-358; interquartile range 7.32-32.35). Information on pre-
radiotherapy stage and risk was available for 34 patients. 8.8% (3/34), 29.4% 
(10/34) and 61.8% (21/34) were low, intermediate risk and high risk D’Amico 
Score at baseline prior to radiotherapy respectively.  
 
4.2.2.1.1 Primary Outcome 
 
For detection of clinically significant cancer as defined by UCL Definition 2 
(Gleason =3+4 OR any grade of cancer length 4-5mm) using PIRADS ≥ 4, 
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Sensitivity, specificity, PPV and NPV was 90%, 81.3%, 85.7% and 86.7% 
respectively. Area under ROC Curve (AUROC) was 0.856 (SE 0.07 p=0.000) 
(See Table 25 and Figure 3 below).  
 
Table 25  – Detection of Clinically significant cancer using UCL 2 Definition – 
MRI PIRADS 4 as positive 
  UCL Definition 2 TPM 
 
MRI  
PIRADS 4 
 No  Yes Total 
No 13 2 15 
Yes 3 18 21 
Total 16 20 36 
 
Table 26 - Detection of Clinically significant cancer using UCL 1 Definition – 
MRI PIRADS 4 as positive 
 
  UCL Definition 1 TPM 
 
MRI Any 
cancer 
PIRADS 4 
 No  Yes Total 
No 13 2 15 
Yes 4 17 21 
Total 17 19 36 
 
 
 
 
 
 
 
Table 27 - Detection of any cancer– MRI PIRADS 4 as positive 
 
  Any cancer on TPM 
 
MRI Any 
cancer 
 No  Yes Total 
No 12 3 15 
Yes 3 18 21 
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PIRADS 4 Total 15 21 36 
 
 
Figure 3 UCL Def 2 on TPM - MRI Score PIRADS 4 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 - UCL Def 1 on TPM - MRI Score PIRADS 4 
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For detection of clinically significant cancer as defined by UCL Definition 1 
(Gleason >/=4+3 OR any grade of cancer length >/=6mm) PIRADS ≥ 4 had a 
sensitivity, specificity, PPV and NPV was 89.5%, 76.5%, 81% and 86.8% 
AUROC was 0.83 (SE 0.074 p=0.001) (See Table 26 and Figure 4). 
Sensitivity, specificity, PPV and NPV of MRI score ≥4 for detection of any 
cancer was 85.7%, 80%, 85.7% and 80% respectively (p=0.00), (AUROC) 
was 0.829 (SE 0.075 p=0.01) (See Table 27 and Figure 5). 
 
Figure 5 - Any cancer on TPM - MRI Score PIRADS 4 
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Table 28 – Detection of Clinically significant cancer using UCL 2 Definition – 
MRI PIRADS 4 as positive 
 
  UCL Definition 2 TPM 
 
MRI Any 
cancer 
PIRADS 3 
 No  Yes Total 
No 12 2 14 
Yes 3 14 17 
Total 15 16 31 
 
Table 29 - Detection of Clinically significant cancer using UCL 1 Definition – 
MRI PIRADS 4 as positive 
 
  UCL Definition 1 TPM 
 
MRI Any 
cancer 
PIRADS 3 
 No  Yes Total 
No 12 2 14 
Yes 4 13 17 
Total 16 15 31 
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Table 30 - Detection of any cancer– MRI PIRADS 4 as positive 
 
  Any cancer on TPM 
 
MRI Any 
cancer 
PIRADS 3 
 No  Yes Total 
No 11 3 14 
Yes 3 14 17 
Total 14 17 31 
 
 
Figure 6 - UCL Def 2 on TPM - MRI Score PIRADS 3 
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Using MRI Score >3 for detection of clinically significant cancer as defined by 
UCL Definition 2 Sensitivity, specificity, PPV and NPV was 87.5%, 80.0%, 
82.4% and 85.7% respectively and AUROC was 0.563 (SE 0.1 p=0.52). 
Sensitivity, specificity, PPV and NPV to detect clinically significant cancer as 
defined by UCL Definition 1 was 86.7%, 75.0%, 76.5% and 85.7% (AUROC) 
was 0.559 (SE 0.098 p=0.55). Sensitivity, specificity, PPV and NPV of MRI to 
detect any cancer was 82.4%, 78.6%, 82.4% and 78.6% AUROC was 0.567 
(SE 0.1 p=0.5) (See tables 28-30 and Figure 6).  
 
Table 31 – TPM Vs. MRI-TB Core based analysis 
 
1254 cores taken using TPM biopsy of which 149 cores (11.9%) were 
positive. 150 targeted biopsies (up to 3 areas being targeted) were taken, of 
which 54 were positive (36%) (See Table 31). 
 
Table 32 – MRI-TB vs. TPM in detection of clinically significant cancer UCL 
Definition 2  
 
Detection of UCL Definition 2 Cancer 
 TPM 
 
MRI-TB 
 No  Yes Total 
No 16 6 22 
Yes 0 14 14 
Total 16 20 36 
 
When comparing the detection rate of TPM vs. MRI-TB in the detection of  
clinically significant disease as defined by UCL –Definition 2, TPM and MRI-
TB were concordant in 14 cases as being positive, 16 cases as negative and 
no cases on TPM misclassifying disease. Whereas there were 6 cases 
 TPM MRI-TB 
Total Cores n (%) 1254 (100) 150 (100) 
Any cancer cores n (%) 149 (11.9) 54 (36) 
UCL Def 1 Cores n (%) 128 (10.2) 50 (33.3) 
UCL Def 2 Cores n (%) 134 (10.7) 70 (46.7) 
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misclassified on MRI-TB as negative for clinically significant cancer, that were 
found to be positive on TPM (See Table 32).  
 
 
Table 33 – MRI-TB vs. TPM in detection of clinically significant cancer UCL 
Definition 1 
 
UCL Definition 1 
 TPM 
 
MRI-TB 
 No  Yes Total 
No 17 5 22 
Yes 0 14 14 
Total 17 19 36 
 
Both MRI-TB and TPM detected clinically significant cancer as defined by 
UCL Definition 1 disease in 14 cases and was negative in 17 cases. TPM did 
not misclassify any patients however MRI-TB reported 5 cases to be negative 
for UCL Definition 1 disease that was positive on TPM biopsy (See Table 33) 
 
Table 34 – MRI-TB vs. TPM in detection of any cancer  
 
Any cancer 
 TPM 
MRI-TB  No  Yes Total 
No 15 7 22 
Yes 0 14 14 
Total 15 21 36 
 
In the detection of any cancer, both techniques were concordant in 29 cases, 
(14 positive for cancer and 15 negative for cancer). 7 cases on MRI-TB were 
classified as negative that were positive on TPM, no cases were misclassified 
by TPM. (See Table 34) 
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4.2.3 Discussion 
 
4.2.3.1 Summary of results 
 
MRI PIRADS 3 & 4 had a high Sensitivity, specificity, PPV and NPV for the 
detection of clinically significant cancer (UCL definition 2) of 87.5%, 80.0%, 
82.4% and 85.7% respectively and 90%, 81.3%, 85.7% and 86.7% 
respectively.  
 
TPM biopsy and MRI-TB were concordant in the majority of cases for 
detection of clinically significant cancer for both UCL Definition 1 & 2 disease, 
however, MRI-TB misclassified up to 6 patients as having no cancer, when 
clinically significant cancer was present on TPM biopsy. 
 
4.2.3.2 Methodological limitations 
 
Our study does have some limitations. The small sample size does limit the 
external validity of our findings. Clinically significant radiorecurrent cancer is 
yet to be defined and so a number of different definitions as used in primary 
prostate cancer diagnosis were evaluated. The average time after EBRT for 
biopsy was 78 months. Within our study only 2 patients were sampled within 
30 months of finishing EBRT. Thus, any cancer detected is likely due to a true 
recurrence and not a continuing change in prostate tissue morphology from 
radiation which can occur if sampling occurs within 30 months (100).  
 
Several studies (43,92,94,108)    report on the utility of DCE as part of mpMRI 
in imaging radiorecurrent prostate cancer as after EBRT, it is difficult to 
distinguish between recurrence and treated prostate tissue which has low 
signal intensity with indistinct zonal anatomy on T2W. A limitation of this study 
is that individual mpMRI sequences were not explored to determine any 
increase in detection rates. 
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4.2.3.3 Comparison with Existing Studies  
 
A meta-analysis performed by Wu et al. (109) found that mpMRI had a pooled 
sensitivity and specificity of 82% (95% CI 75-88%) and 74% (95% CI 64- 
82%), respectively with AUROC of 0.87 in the detection of recurrent cancer 
after radical treatment. Therefore, our study has also shown similar detection 
rates. Our study is also likely to be more accurate as previous studies 
examining the detection rate of mpMRI use TRUS biopsy (43,94,101)   as 
reference standard which has high rates of under sampling. Some studies use 
salvage radical prostatectomy as reference standard. Pucar et al. (64) 
explored the role of MRI and MR spectroscopy in the detection of 
radiorecurrent cancer compared to DRE and TRUS biopsy. Whilst MRI and 
MRSI had higher sensitivity 68% and 77% respectively than TRUS and DRE, 
specificity of MRI was similar 96% vs. 95% and 96% respectively. MRSI had a 
specificity 78% vs. 95% and 96% compared to TRUS and DRE. However, the 
importance of this study is that sites of recurrence were the same pre-EBRT 
and post-EBRT and were clinically significant foci of cancer. Only 2 small 
insignificant cancer foci (small volume) were found that were not detected on 
post EBRT MRI. 
 
Overall whilst MRI-TB may be more efficient in detecting radiorecurrent 
cancer, there are still misclassifications that occur similar to our previous 
reported study (Chapter 4.1 Targeted transperineal prostate biopsy in the 
detection of radiorecurrent prostate cancer). This can be due to several 
reasons; patient positioning at time of biopsy may not allow for access to 
target MRI lesions. Lesions seen on MRI may not be visible on US and 
therefore difficult to localise. The key to improving efficiency and accuracy of 
biopsy is to find a technique that aids accurate disease localization, MRI-US 
fusion may be an option as there may be less misregistration (110).  
 
Yakar et al. examined MRI-Guided TRUS biopsy (MRI-GB) in the detection of 
radiorecurrent prostate cancer in 20 patients. 38 lesions were identified on 
pre-biopsy MRI. PPV of MRI-GB was found to be 78% in all patients and 68% 
in each of the tumour suspicious regions. This study does not report whether 
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there were further TRUS biopsies performed at the time of MRI-GB and so 
there is no comparison between guided and TRUS biopsies in the detection of 
cancer.  
 
Menard et al. (111) examined MRI-guided transperineal prostate biopsy 
versus transperineal prostate biopsy – six cores were taken using each 
technique. Diagnostic accuracy of mpMRI was up to 0.82. However again 
within this study a direct comparison of MRI-GB versus systematic biopsies 
was not performed. 82% of patients within this study had unifocal recurrent 
disease which suggests patients presenting with radiorecurrent prostate 
cancer may be suitable to focal salvage therapy only as opposed to whole 
gland salvage therapy. This study however found that MRI was not sufficient 
to delineate tumour boundaries for focal salvage treatment.  
 
Our study is one of the few studies that examines detection of clinically 
significant disease using an accurate reference standard. Compared with a 
recent systematic review (105) which compared MRI-TB to whole gland 
sampling in the primary based setting, our MRI-TB and systemic sampling 
had a higher detection rate of cancer 36% vs. 20% and 11.9% vs. 7% 
respectively. However, within this current study, there was a lower rate of 
clinically significant cancer UCL Definition 1 but a higher rate of UCL definition 
2 cancer compared to systematic review, 50 vs. 43% and 70 vs. 43% 
respectively. It must be noted that there was not a single definition of clinically 
significant cancer within the systematic review as this varied according to 
each study included in the review. 
 
4.2.3.4 Clinical implications 
 
Our study has shown that mpMRI does have a role in the detection of 
radiorecurrent disease. PIRADS ≥4 has high detection rates of radiorecurrent 
cancer. MpMRI Score 3 however has a poor detection rate of clinically 
significant radiorecurrent cancers and therefore, lesions scoring PIRADS 3 
should be biopsied. 
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4.2.3.5 Future research 
 
Larger studies are required to further validate our findings. Each parameter of 
mpMRI – DWI, DCE, should be examined and compared to TPM biopsy to 
determine which has the highest detection rate of clinically significant 
radiorecurrent cancer. A definition for clinically significant radiorecurrent 
cancer should also be examined to see if these patients progress in a similar 
manner to primary cancer patients. Overall, further imaging and 
histopathological findings in radio-recurrent disease should be examined to 
reach a consensus on the most appropriate time, imaging and biopsy 
technique to accurately identify radiorecurrent disease. Currently the large 
majority of work is based in the primary cancer setting. It is important to 
achieve the same guidelines in the radiorecurrent setting to identify those men 
in need of and who may benefit the most from salvage treatment.  
 
4.2.4 Conclusion 
 
We have shown that mpMRI is a useful tool in diagnosing localised 
radiorecurrent cancer.  As certain studies have shown that radiorecurrent 
prostate cancer (64,111) may have a dominant focus and this may be 
amenable to focal therapy. It is important to be able to characterize this 
accurately using the best imaging and biopsy techniques that could further 
guide targeted therapy. A combination of mpMRI and Template mapping 
biopsy may be the best technique to predict those suitable for focal therapy. 
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4.3 Radiorecurrent prostate cancer features on template biopsy: Implications 
for focal salvage therapy 
 
4.3.1 Introduction 
 
Radiotherapy is an effective treatment for localised prostate cancer. However, 
approximately, one in four men who receive primary radiotherapy for localised 
prostate cancer may develop biochemical failure within 8 years as witnessed 
with rising PSA levels (8).  Focal salvage therapy (FST) may be a suitable 
treatment method in these men who have localised recurrent disease for 
example using cryosurgery, HIFU or brachytherapy techniques. For this to be 
delivered appropriately, an accurate determination of the presence or 
absence of localised recurrence, and where in the gland disease resides, is 
necessary.  
 
Transperineal prostate mapping (TPM) biopsy samples the entire prostate at 
5mm intervals, has been shown to have high detection rates for radiorecurrent 
clinically significant cancer and importantly can be used as reference test for 
what may be present in the prostate without reverting to whole-mount 
pathology (45).  We sought to evaluate the proportion of men presenting with 
presumed localized radiorecurrent prostate cancer who might be suitable for 
FST based on TPM biopsies. 
 
4.3.2 Methods and Materials 
 
Ethics committee exemption was granted by the University College London 
Hospitals Joint Research Office. Our TPM biopsy registry (December 2007 to 
May 2014) identified 145 consecutive men, referred with suspicion of radio-
recurrent prostate cancer due to rising PSA following external beam 
radiotherapy (EBRT) or brachytherapy who subsequently underwent TPM 
biopsies. All men had no evidence of distant disease based on a combination 
of pelvic MRI, radioisotope CT/PET scans (FDG initially and later 18F-choline) 
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and/or bone-scan. This is the standard of care for such patients referred to 
our institution for consideration of local salvage therapy.  
 
Transperineal Template Mapping Biopsy (TPM) 
 
As discussed above in Chapter 4.1 Targeted transperineal prostate biopsy in 
the detection of radiorecurrent prostate cancer) using a modified version of 
that described by Barzell et al. (74). (See Figure 1 - Transperineal Prostate 
Mapping Modified Barzell Zones above- Chapter 4.1 Targeted transperineal 
prostate biopsy in the detection of radiorecurrent prostate cancer). Biopsy 
cores were analysed and reported by two dedicated expert uro-pathologists 
with over 10 years of experience in the diagnosis of prostate malignancy. 
Pathologists were aware of clinical details. 
 
Antibiotic prophylaxis was used with single-dose gentamicin, cefuroxime, and 
metronidazole at the time of induction. Complications were assessed on 
review of subsequent clinic appointments.  
 
Outcome measurements  
 
Suitability for focal therapy required the cancer to be (1) unifocal, (2) 
unilateral, (3) bilateral/bifocal with at least one neurovascular bundle avoided, 
or (4) bilateral/multifocal with one dominant index lesion and secondary 
lesions with Gleason ≤3 + 3 and cancer core involvement ≤3 mm. (See Figure 
7 - Type of focal salvage treatment as predicted by Transperineal Mapping 
biopsy) 
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1 – Quadrant ablation 
2 – Hemiablation 
3 – Hemi-ablation with extension across midline 
4 – Index Lesion ablation 
 
Figure 7 - Type of focal salvage treatment as predicted by Transperineal Mapping 
Biopsy 
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4.3.3 Statistical Analysis 
 
Normally distributed variables are expressed as mean +/- the standard 
deviation. Variables with a skewed distribution are depicted as median with 
their corresponding interquartile range (IQR). Categorical variables are  
denoted as absolute numbers with percentages. Comparisons between 
categorical variables are done with the Pearson’s χ2 test.  
 
With univariable and multivariable logistic regression, odds radios (ORs) with 
95% confidence intervals (95% CIs) were obtained to assess the influence of 
clinical characteristics on suitability of FST. A two-tailed p <0.05 was 
considered statistically significant. Factors with p<0.05 were retained in the 
final model. Other factors were excluded, starting with the least significant 
one.  
 
Statistical analysis was performed using SPSS version 23.0 (SPSS, IBM 
Corporation, New York) and the R language environment (R Core Team 
2015, version 3.2.1). SPSS was used for descriptive statistics and the rms 
package in R for the modelling process.  
 
4.3.4 Results 
 
The mean age was 70.7 (SD 5.8) years with mean time from radiotherapy to 
biochemical failure of 64.2 (SD 34.5) months. Baseline D’Amico risk score at 
time of biochemical failure and prior to mpMRI and TPM was available for 121 
men. Of these, 49.7% (72/121) were classified as high risk (PSA ≥ 20ng/ml, 
Gleason ≥8, T2c-3a), 24.8% (36/121) were intermediate risk (PSA 10-
20ng/ml, Gleason 7, or T2b) and 10.7% (13/121) were low risk (PSA 
<10ng/ml, Gleason </=6, T1-2a) (Table 35). 17 were on hormones at the time 
of biopsy. Reported complications included haematospermia 0.7% (1/145), 
1.4% dysuria 1.4% (2/145) and urine retention 0.7% (1/145). Baseline or 
follow up erectile function was not recorded.  
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Table 35 - Baseline characteristics and TPM-characteristics 
 
Baseline characteristics and TPM-characteristics 
Variable Value Missing (%) 
Age at RT (mean±sd) 70.7 (5.8) 0 (0%) 
PSA at RT (median [IQR]) 15.5 (8.1-30.5) 43 (29.7%) 
Time between RT&BF 
(mean±sd) 
64.2 (34.5) 38 (26.2%) 
RT dose (median [IQR]) 64 (55-74) 107 (73.8%) 
Brachytherapy (n) (%) 15 (10.3) NA 
Stage at RT (n) (%) 
     <T2 
     T3a 
     T3b 
     T3bN1 
 
44 (30.3) 
14 (9.7) 
14 (9.7) 
3  (2.1) 
70 (48.3%) 
Adjuvant ADT (n) (%) Yes 75 (51.7) 
No 12 (8.3) 
58 (40%) 
Gleason pre-RT (n) (%) 
     2-6 
     7 
     8-10 
 
47 (32.4) 
49 (33.8) 
23 (15.9) 
26 (17.9%) 
D’Amico Risk category pre-
original RT 
    Low risk (PSA <10, G <6, 
T1-2a) 
    Intermediate risk (PSA 10 - 
20, G7, or T2b) 
    High risk (PSA >20, G >8, 
T2c-3a) 
 
13 (9.0) 
36 (24.8) 
72 (50.0) 
24 (16.6%) 
PSA nadir after original RT 
(median [IQR]) 
0.5 (0.12-1) 84 (57.9%) 
PSA at mpMRI date (median 
[IQR]) 
4.5 (2.5-7.7) 25 (17.2%) 
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4.3.4.1 Primary outcome 
 
Overall 75.9% (110/145) were suitable for a form of FST. 40.7% (59/145) 
were suitable for quadrant ablation, 14.5% (21/145) for hemi-ablation, 14.5% 
Prostate size on mpMRI, cc 
(median [IQR]) 
26 (19-36) 6 (4.1%) 
Stage on mpMRI (n) (%) 
     <T2 
     T2N1 
     T3a 
     T3aN1 
     T3b 
     T4 
 
98 (67.6) 
1 (0.7) 
25 (17.2) 
1 (0.7) 
16 (11.0) 
4 (2.8) 
0 (0%) 
Bone scan (n) (%) 77 (53.1) 0 (0%) 
Bone scan positive (n) (%) 12 (8.3) 0 (0%) 
Choline-PET (n) (%) 87 (60) 0 (0%) 
Type of Choline (n) (%) 
     FDG  
     18F 
 
3 (3.4) 
70 (48.2) 
14 (9.7%) 
Choline-PET positive (n) (%) 80 (91.9) 0 (0%) 
Choline-PET positive 
metastases (n) (%) 
20 (22.3) 1 (0.7%) 
Gap between mpMRI & 
Biopsies (median [IQR]) 
2 (1-4)1 2 (1.4%) 
Total no. of all cores (median 
[IQR]) 
31 (23-41) 0 (0%) 
Total no. positive cores 
(median [IQR]) 
4 (1-8) 0 (0%) 
% positive cores (mean±sd) 17.6 (18.1) 0 (0%) 
MCCL (mean±sd) 4.7 (4) 0 (0%) 
%MCCL (mean±sd) 39.7 (31.7) 10 (6.9%) 
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(21/145) for bilateral lesion ablation and 6.2% (9/145) for index lesion 
ablation. 9.0% (13/145) were suitable for whole-gland treatment only. 15.9% 
(22/145) did not have any local recurrent disease and were deemed to have 
likely micrometastatic disease not visible on imaging (Table 36).  
 
Table 36 - Proportion of patients suitable for focal salvage treatment 
 
 
4.3.4.2 Secondary outcomes 
 
First, in terms of risk stratification using a TPM biopsy risk scoring system (99) 
validated in our centre, we found 3.4% (5/145) had low risk cancer (Gleason 
3+3 up to 3mm) diagnosed on TPM biopsy, 17.9% (26/145) had UCL 
definition 2 risk cancer (Gleason =3+4 OR any grade of cancer length 4-5mm) 
and 63.4% (92/145) had high risk UCL Definition 1 cancer (Gleason >/=4+3 
OR any grade of cancer length >/=6mm) (Table 37). 
 
Table 37 - Transperineal Template Mapping Biopsy Outcome 
 
Cancer detected % (N) 
No cancer 15.2 (22) 
 Low (Clinically insignificant disease Gleason 3+3 ≤ 3mm) 3.4 (5) 
 Intermediate (Gleason = 3+4 AND/OR Max Cancer length 4-5mm)  17.9 (26) 
 High Gleason >/= 4+3 AND/OR Max cancer length >/=6mm  63.4 (92) 
 
 
 
Type of focal salvage treatment N (%) 
Quadrant 59 (40.7) 
Hemiablation 21 (14.5) 
Bilateral 21 (14.5) 
Index 9 (6.2) 
Whole gland 13 (9.0) 
No Treatment 22 (15.2) 
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All low risk patients were suitable for quadrant ablation. All intermediate risk 
patients were suitable for a form of focal salvage treatment. For high risk 
patients, only 14% required whole gland ablation, whilst the remainder were 
suitable for a form of focal salvage treatment (p=0.004 Pearson χ2) (Table 38 
& 39). 
 
Table 38 - The relationship of suitability for focal therapy and risk groups 
following transperineal template prostate-mapping biopsies  
 
 
 
 
 
 
 
Outcome 
of 
template 
biopsy 
Type of Treatment 
 No 
treatment 
N (%) 
Quadrant  
N (%) 
Hemi 
ablation  
N (%) 
Bilateral  
N (%) 
Whole 
gland  
N (%) 
Index 
N (%) 
No 
cancer 
22 (15) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Low 
Risk 
0 (0) 5 (3.4) 0 (0) 0 (0) 0 (0) 0 (0) 
Interme
diate 
Risk 
0 (0) 17 (11.7) 3 (2) 4 (2.8) 0 (0) 2 (1.4) 
High 
Risk 
0 (0) 37 (25.5) 18 
(12.4) 
17 
(11.7) 
13 
(9.0) 
7 (4.8) 
Total 22 (15) 60 (41.3) 21 
(14.4) 
21 
(14.4) 
13 
(9.0) 
9 (6.2) 
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Table 39 - Relationship between suitability for focal salvage and risk group 
based on TPM biopsies – All risk groups 
 
Risk category 
based on TPM 
biopsies 
Suitable 
for focal 
salvage 
Unsuitable 
for focal 
salvage 
p-value (test) 
No cancer 0 23 0.004 
(Pearson χ2) Low risk 5  0 
Intermediate risk 22 4 
High risk 62 29 
No cancer 0 23 0.002 
(Pearson χ2) Low + 
intermediate risk 
27 4  
High risk 62 29 
 
Second, on both univariate and multivariate analyses, high risk versus low 
and intermediate risk groups combined predicted suitability for whole-gland 
salvage treatment OR 5.85 [95% CI 2.13-20.67, p=0.002] and 4.03 [1.18-
16.81 p=0.035]), respectively. On univariate analysis, total number of positive 
cores and maximum cancer core length had an OR of 1.14 (95% CI 1.07-
1.22, p=<0.0001) and 1.21 (95% CI 1.09-1.34, p=0.0002), respectively, of 
predicting suitability for whole-gland salvage treatment (Table 40).  
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Table 40 – Univariable and Multivariable analysis predicting likelihood for 
whole gland salvage treatment 
 
Variable Univariable 
OR (95% CI) 
P value Multivariable 
OR (95% CI) 
P 
value 
Age 0.99 (0.93-
1.06) 
0.78 NA NA 
PSA at RT 0.997 (0.974-
1.016) 
0.79 NA NA 
Time between RT and 
BF 
1.00 (0.987-
1.013) 
0.97 NA NA 
RT dose 1.03 (0.98-
1.10) 
0.27 NA NA 
Stage at RT (reference 
<T2) 
     T3A 
     T3B 
     T3BN1 
 
0.50 (0.07-
2.23) 
0.82 (0.16-
3.22) 
6.00 (0.53-
136.76) 
 
0.41 
0.76 
0.16 
NA NA 
Adjuvant ADT 1.58 (0.37-
10.89) 
0.58 NA NA 
Gleason score before 
RT  
     Gleason 7 
     Gleason 8-10 
 
 
 
1.22 (0.45-
3.36) 
2.71 (0.89-
8.39) 
 
 
 
0.69 
0.08 
NA NA 
Risk category pre-RT 
(reference=low risk) 
     Intermediate 
     High 
 
 
1.83 (0.39-
13.31) 
 
 
0.48 
0.46 
NA NA 
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1.83 (0.44-
12.57) 
Nadir after primary RT 1.14 (0.44-
2.56) 
0.76 NA NA 
PSA at mpMRI 1.00 (0.97-
1.015) 
0.98 NA NA 
Prostate size on mpMRI 0.972 (0.938-
0.998) 
0.08 NA NA 
Overall detection on 
mpMRI (per point 
increase on Likert scale) 
 
1.55 (0.98-
2.45) 
 
0.06 
NA NA 
SV involvement 1.46 (0.85-
2.53) 
0.16 NA NA 
mpMRI stage 
T2N1 
T3A 
T3AN1 
T3B 
T4 
 
NS  (p=0.99, 
0.49, 0.99, 
0.75, 0.87) 
 NA NA 
Time between mpMRI 
and TGB 
0.86 (0.71-
1.023) 
0.09 NA NA 
Total No. cores TPM 1.025 (1.00-
1.05) 
0.05 NA NA 
Total No. positive cores 
on TPM 
1.14 (1.07-
1.22) 
<0.0001 1.05 (0.95-
1.16) 
0.30 
% positive 1.05 (1.03-
1.08) 
<0.0001 1.03 (0.99-
1.07) 
0.11 
MCCL mm 1.21 (1.09-
1.34) 
0.0002 1.00 (0.87-
1.15) 
0.96 
MCCL % 1.02 (1.01-
1.04) 
0.0007 NA NA 
Gleason score before 
salvage (low risk as 
 
 
 
 
NA NA 
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reference) 
     Intermediate risk 
(Gleason 7) 
     High risk (Gleason 8-
10) 
2.13 (0.34-
4.14) 
3.00 (0.43-
6.07) 
0.50 
0.34 
 
High risk versus 
low+intermediate+no 
cancer 
 
 
 
5.85 (2.13-
20.67) 
 
 
 
0.002 
 
 
 
4.03 (1.18-
16.81) 
 
 
 
0.035 
 
4.3.5 Discussion 
4.3.5.1 Summary of results 
 
In summary, we have shown that in men presenting with biochemical 
recurrence following radiotherapy for treatment of non-metastatic prostate 
cancer who have presumed localised recurrence based on imaging, just over 
two-thirds were suitable for a form of focal salvage treatment. We also found 
that higher risk radiorecurrent as well as greater burden of cancer in the 
prostate (number of positive cores and amount of cancer per core) were 
factors in predicting cases that were not suitable.  
 
4.3.5.2 Methodological Limitations 
 
First, our tertiary referral base might have led to selection biases that we are 
not aware of such as PSA kinetics and co-morbidity judgements made by the 
referring oncologist. Second, these findings only apply to those men who have 
a negative metastatic screen with imaging and not the whole radiorecurrent 
group. Third, the concept of an index lesion in the radiorecurrent setting is 
controversial although longitudinal studies following index lesion ablation will 
determine clinical significance of untreated lesions and tissue. Finally, we 
accept that there is some debate around the histological grading of 
radiorecurrent cancer. After radiotherapy there can be delayed tumour 
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regression and conversion to negative biopsies at a mean time of 30 months  
(100) (23). Within our study the average time between radiation therapy and 
repeat biopsy was 82.5 months (SD 35.0). There were only 2 patients that 
were biopsied before 30 months. Further, our histopathologists have over ten 
years’ experience in identifying radiorecurrent prostate cancers and 
associated Gleason grades when there is minimal treatment effect seen 
microscopically. 
 
4.3.5.3 Comparison with other studies 
 
As discussed previously, in order for men to be suitable for focal salvage 
therapy, radiorecurrent disease must be accurately characterized. This must 
be done with accurate imaging and biopsy technique. We have previously 
discussed the accuracy of MRI and TPM, therefore this will only be discussed 
briefly now. Whilst mpMRI has been reported to have high sensitivity and 
specificity of up to 86-100% (43,94) for the detection of radiorecurrent cancer, 
these studies have used transrectal ultrasound biopsy, which is known to miss 
disease. One study examining mpMRI using TPM biopsy, found an accuracy 
(area under receiver operating characteristic curve, AUROC) of up to 0.89 
and higher risk cancers (≥3mm biopsy cancer core length) of AUROC 0.93 
(44). Our previous study above has shown TPM to detect 85.7% of clinically 
significant radiorecurrent cancers (UCL Definition 2 disease). There was a 
similar detection rate on TPM of UCL Definition 1 cancers compared with 
MRI-TB as shown above in section 4.1 (68% vs.71%) (45).  
 
This is the first study, however to correlate TPM outcomes with baseline and 
pre-salvage risks to determine suitability for focal salvage therapy. 
 
4.3.5.4 Clinical implications 
 
Our current study has further examined the utility of TPM biopsy in 
determining eligibility and planning for focal salvage treatment and we have 
shown that a large portion of our cohort (69%) was suitable for a form of focal 
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salvage treatment. We have used the same TPM risk classification of cancer 
within the prostate (UCL definitions low, intermediate and high risk prostate 
cancer) as in the primary setting (99). This has not been validated in the 
radiorecurrent setting. It may be argued that intermediate risk cancer should 
be classified as high-risk cancer. Further, high risk radiorecurrent disease 
despite possibly being suitable for focal salvage treatment, may have a higher 
risk of micro-metastatic disease and therefore it is questionable whether these 
men receive further local treatment (112). It could be argued that these men 
should receive whole gland treatment given the aggressive nature of disease, 
albeit at a cost of increased morbidity.  
 
4.3.5.5 Future Research 
 
The question about whether focal salvage therapy is a valid option is currently 
subject to a number of prospective studies including FORECAST (FOCal 
RECurrent Assessment and Salvage Treatment) study (clinicaltrials.gov 
number: NCT01883128) (113). Further comparative studies might also be 
required although the ability for the uro-oncology and urology fraternity to 
randomise in these settings has so far proven to be limited (114). It is also 
clear that a risk classification of local radiorecurrent cancer should be 
developed. This will help classify patients and provide them with the most 
suitable form of salvage treatment.  
 
4.3.6 Conclusion 
 
Men who fail radiotherapy may be suitable for focal salvage treatment. 
Accurate characterisation of radiorecurrent disease is necessary. Using 
transperineal template prostate biopsies has shown that over two-thirds of 
men with presumed localised recurrence might be suitable for a focal 
approach to salvage their disease. The effectiveness of focal salvage therapy 
is still to be determined in prospective clinical trials. 
  
  
 
112 
 
Chapter 5 Salvage Treatment 
 
This section examines the outcomes of focal salvage HIFU in a 
retrospective registry analysis. The latter discusses the early outcomes 
of focal salvage HIFU and focal-salvage cryotherapy from The 
FORECAST trial. 
 
5.1 Focal Salvage HIFU  
 
5.1.1 Introduction 
 
Up to half of the men who have localized prostate cancer treated with 
radiotherapy may experience biochemical failure (BCF) by 5–10 years 
(3,87,115). Due to inadequate patient selection, most are treated with androgen 
deprivation therapy (ADT), a palliative treatment strategy which carries 
significant side effects (12,115-117). When curative salvage is possible, whole-
gland salvage therapies are usually performed. These salvage therapies 
include radical prostatectomy (RP), brachytherapy, cryosurgery and high-
intensity focused ultrasound (HIFU). Biochemical disease-free survival (b-DFS) 
rates at 5 years of up to 82% have been reported; however, these therapies 
can have significant side effects, such as urinary incontinence (21–90%), 
impotence (in those who still had erections; 100%) and rectal injury (9.2%) 
(12,115) . Focal salvage therapy aims to treat the area of recurrent disease 
rather than the entire prostate gland. A recent review has shown promising 
biochemical control rates and low side effects of such focal strategies, including 
cryotherapy and HIFU, strategies considered experimental by the European 
Association of Urology (118,119). 
 
The aim of the present study was to assess cancer control rates and genito-
urinary and rectal complications of focal salvage HIFU (FS-HIFU) treatment. 
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5.1.2 Methods and Materials 
 
Patient Selection 
 
Analysis of an independent prospective academic HIFU registry at two 
centres (University College London Hospitals and NHS Basingstoke Trust) 
identified 150 men who underwent focal salvage HIFU between November 
2006 and August 2015. These patients' records were retrospectively reviewed 
to obtain data from their external referral centre on disease localization, 
treatment and follow-up. Institutional review board exemption was granted by 
the University College London Hospitals/University College London Joint 
Research Office. To be eligible for focal salvage HIFU, all patients had to 
have experienced BCF according to the Phoenix definition (PSA nadir + 
2.0 ng/mL) before subsequent diagnostic methods were adopted. 
 
Disease Localization 
 
Before patients are considered for salvage treatment at our institutions, 
metastatic disease must be excluded using bone scan and positron-emission 
tomography (PET) imaging (Choline-18F-FDG PET or Choline PET/CT) and 
pelvic MRI for nodal staging. There were no restrictions placed on the upper 
level of PSA or PSA kinetics, provided the imaging scans confirmed 
≤T3bN0M0 disease. We included T3b tumours if <1 cm of the seminal vesicle 
was involved. Disease was localized using prostate multiparametric MRI 
(mpMRI) studies. The prostate was divided into four sectors in three sections 
(base, mid-gland, apex), with the urethra as the anatomical dividing point 
between right and left and anterior and posterior. Each of the 12 resulting 
sectors and seminal vesicles were scored using the five-point Likert scale (1, 
highly likely no tumour; 5, highly likely tumour). The sequences were 
evaluated in the following manner. First, the T2 sequences were used to 
provide morphology and anatomical localization. DCE images played a 
greater role in the peripheral zone, with the additional reference of the DWI 
scans. Scoring was as follows: a score of 1 or 2 was given if there was no 
enhancement; a score of 3 was given if symmetrical diffuse enhancement was 
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seen; if there was focal or asymmetrical enhancement ≥3 mm and no 
abnormality seen on DWI, a score of 4 was given; and if there was focal or 
asymmetrical enhancement ≥3 mm and/or corresponding DWI abnormality in 
the same anatomical location, a score of 5 was recorded. A similar technique 
was used to report lesions in the transition zone, with DWI sequences given 
greater weighting than DCE images. DCE shows more enhancement of 
adenomas in this zone, especially after radiotherapy; however, an equivocal 
score of 3 based on DWI could be upgraded to 4 or 5 if there was an 
associated obvious DCE abnormality in the same anatomical location. 
 
Patients then had either systematic TRUS-guided biopsies or transperineal 
template prostate mapping (TPM) biopsies using a 5-mm sampling frame. The 
group who had been diagnosed via TRUS biopsy underwent hemi-ablation 
salvage HIFU when mpMRI showed a unifocal recurrence at the same site as 
the positive biopsy. This extended treatment volume was adopted because of 
insufficient location assessment with systematic TRUS-guided biopsies and 
the subsequent difficult matching with the recurrence location on MRI. 
 
HIFU Treatment  
 
Using the Sonablate 500 transrectal HIFU device (Sonacare Inc, Focus 
Surgery, Indianapolis, IN, USA), treatment was either focal (quadrant) 
ablation, hemi-ablation, or index lesion ablation (Figure 2 Methods of focal 
ablation). Index lesion ablation was performed if there was multifocal cancer, 
any untreated areas had ≤1 core with ≤3 mm Gleason 3 + 3 disease (on TPM) 
and/or no lesion on mpMRI. A margin of 5 mm was adopted around the MRI-
based tumour delineation. 
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Figure 2 - Methods of focal ablation (A) Posterior quadrant salvage ablation to 
a single lesion with focal salvage high-intensity focused ultrasound (HIFU). (B) 
Hemi-ablation of index lesion to two index lesions with focal salvage HIFU 
whilst leaving low-risk cancer untreated. 
 
Follow-Up 
 
Clinical visits occurred every 3 months to record adverse events and serum 
PSA level. Validated questionnaires were issued to all patients and included 
the IPSS, the urinary domain of the University of California Los Angeles-
Expanded Prostate Cancer Index Composite (UCLA-EPIC), and the five-item 
International Index of Erectile Function (IIEF-5) (120,121) . A higher IPSS 
indicates worsening symptoms, a lower UCL-EPIC score indicates worsening 
symptoms, and a lower IIEF-5 score indicates worsening erectile function. 
Any two consecutive rises in PSA level were investigated using mpMRI and, if 
mpMRI was positive, by further biopsies and/or staging scans, including bone-
scan or Choline PET/CT or both. 
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5.1.3 Outcomes 
 
5.1.3.1 Primary outcomes 
The primary outcome was a composite failure rate after one or two focal 
salvage HIFU procedures (BCF and/or positive localized or distant imaging 
and/or positive biopsy and/or systemic therapy and/or metastases and/or 
prostate cancer-specific death). 
 
5.1.3.2 Secondary Outcomes 
 
The secondary outcome consisted of BCF using the Phoenix-ASTRO 
definition (nadir PSA + 2 ng/mL) after one or two focal salvage HIFU 
procedures, and complications/side effects. We also assessed several factors 
predicting BCF, including baseline (before primary radiotherapy) D’Amico risk 
group, PSA level, T stage, Gleason score, external beam radiation therapy 
(EBRT) dose and ADT use. Predictive factors before focal salvage HIFU 
included PSA nadir after primary radiotherapy, T stage, prostate volume on 
MRI, Gleason score, maximum cancer core length, PSA, PSA doubling time 
(PSADT), ablation type (hemi-/focal/index lesion ablation), ADT use and 
residual cancer left untreated. PSA nadir after focal salvage HIFU was 
assessed as a post-treatment factor. 
 
Statistics 
 
Cox proportional hazards regression was used to quantify the effect of the 
determinants described above on the endpoints. Hazard ratios (HRs) with 
95% CIs are provided. Factors with P values <0.05 were included in the 
multivariable model. The R language environment (version 3.2.1; available 
at http://www.r-project.org/) (122) was used for all statistical analyses.  
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5.1.4 Results 
 
A total of 150 patients underwent focal salvage HIFU for radiorecurrent 
prostate cancer between November 2006 and August 2015 
(Tables 41 and 42). Of these, 20.7%, 23.3% and 42.0% had low-, 
intermediate- and high-risk disease prior to radiotherapy (14% missing). A 
total of 96.7% of the patients underwent EBRT and 3.3% underwent EBRT 
with a high-dose-rate brachytherapy boost. Radiation doses of 64 Gray in 32 
fractions were the most common (n = 27). The median time to BCF from 
primary radiotherapy was 80 months (95% CI 72–86). The mean (SD) age at 
focal salvage therapy was 69.8 (6.1) years and the median (interquartile 
range [IQR]) PSA level before focal salvage treatment was 5.5 (3.6–7.9) 
ng/mL. Prior to focal salvage HIFU, metastatic disease was excluded by bone 
scan or Choline PET/CT/FDG scan. Some patients underwent a 18F-Choline 
FDG PET, but this was earlier in the series before clinical practice was 
changed so that 18F-Choline PET/CT was performed instead. All patients 
underwent mpMRI and either TPM (n = 104) or TRUS biopsy (n = 40, with 
one patient undergoing MRI-guided biopsies (Table 42). From May 2012 
onwards, most patients underwent TPM biopsies (~85%), while this was 
~65% before that time. The choice of biopsy was made at the discretion of the 
treating physician, but a clear temporal trend to more TPM biopsies was 
observed. 
 
Table 41 Characteristics before primary radiation treatment 
Characteristics before 
primary radiation 
treatment 
Primary 
therapy, n (%) 
Missing, % 
EBRT 145 (96.7) 0 
EBRT + HDR-BT boost 5 (3.3) 0 
Median (IQR) initial PSA 
before primary 
treatment, ng/mL 
13.9 (8.9–26.3) 10 
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Table 42 Patient characteristics before focal salvage high-intensity focused 
ultrasound 
 
Characteristic  Missing, % 
Mean ± SD age at focal 
salvage treatment, 
years 
69.8 ± 6.1 0 
Median (IQR) PSA pre-
salvage, ng/mL 
5.5 (3.6–7.9) 0.7 
Radiological T stage pre-salvage HIFU, n (%) 
T1 11 (7.3)  
1.3 T2 102 (68) 
T3 35 (23.3) 
Gleason grade pre-salvage HIFU, n (%) 
Gleason 2-6 8 (5.3) 2.7 
D’Amico risk group, n (%) 
High: PSA 20 ng/mL, 
Gleason score ≥8 and 
T2c–T3a 
63 (42) 
 
Intermediate: PSA 10–
20 ng/mL), Gleason 
score 7 or T2b 
35 (23.3) 
14 
Low: PSA <10 ng/mL, 
Gleason score ≤6 and 
T1–2a 
31 (20.7) 
 
ADT use 
(cytoreduction/adjuvant 
or neoadjuvant) 
106 (71) 
1.3 
ADT, androgen deprivation therapy; BT, brachytherapy; EBRT, external 
beam radiotherapy; HDR, high-dose-rate; IQR, interquartile range. 
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Gleason 3 + 4 72 (48) 
Gleason 4 + 3 39 (26) 
Gleason 8–10 27 (18) 
Biopsy type, n (%) 
TPM 104 (69.3)  
3.3 TRUS-guided 40 (26.7) 
MRI-guided 1 (0.7) 
D’Amico risk group pre-salvage HIFU, n (%) 
High: PSA >20 ng/mL, 
Gleason score ≥8 and 
T2c–T3a 
62 (41.3) 
 
 
 
 
16.7 
Intermediate: PSA 10–
20 ng/mL, Gleason 
score 7 or T2b 
59 (39.3) 
Low: PSA <10 ng/mL, 
Gleason score ≤6 and 
T1–2a) 
4 (2.7) 
ADT pre-salvage 
HIFU, n (%) 
68 (45.3) 
0 
ADT, androgen deprivation therapy; HIFU, high-intensity focused ultrasound; IQR, 
interquartile range; TPM, template prostate mapping; Tx, treatment. 
 
 
Low-, intermediate- and high-risk disease using D’Amico classification, was 
present in 2.7% (4/150), 39.3% (59/150) and 41.3% (62/150) of patients prior 
to focal salvage HIFU (missing, 16.7% (n = 25)). Three forms of ablation were 
performed (Table 43): focal ablation 55% (82/150), hemi-ablation 34% 
(51/150) and index lesion ablation 11% (17/150). A total of 45.3% of patients 
(68/150) were receiving ADT (anti-androgen) and this was discontinued 6–
8 weeks after HIFU. A total of 13 patients received a second focal salvage 
HIFU procedure for localized recurrence after primary focal salvage HIFU. 
The recurrence was based on mpMRI and TPM biopsy in four patients, TPM 
biopsy with negative mpMRI in two patients, mpMRI alone in four patients and 
TPM biopsy alone in three patients. 
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Table 43 Outcomes after focal salvage high intensity focused ultrasound 
 
Outcome  Missing % 
Method of ablation 
Focal  82 (55) 0 
Hemi 51 (34)  
Index lesion (with residual 
cancer left untreated) 
 
17 (11)  
Composite endpoint: BCF, 
ADT, MRI+, biopsies + 
systemic treatment + 
metastases +, prostate 
cancer specific 
mortality, n(%) 
 
91 (60.7) 
 
0 
BCF*, n (%) 
 
77 (51.3) 
 
0 
Median (IQR) PSA-nadir after 
salvage HIFU, ng/mL 
 
0.67 (0.2–1.9 
 
2.7 
Median (IQR) follow-up after 
salvage HIFU, months 
 
35 (22–52) 
 
0 
Mortality, n (%) 
 
9 (6) 0 
Overall 
 
5 (3.3) 
 
 
Prostate cancer-specific 
 
4 (2.7) 
 
 
1. ADT, androgen deprivation therapy; BCF, biochemical failure; HIFU, 
high-intensity focused ultrasound; IQR, interquartile range. 
2. *Phoenix definition 
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5.1.4.1 Primary Outcome 
Composite failure occurred in 61% of patients (91/150) (see Fig. 2). The 
Kaplan–Meier composite endpoint free survival (CEFS) rate at 3 years was 
40% (95% CI 31–50) for the entire group. Kaplan–Meier estimates of CEFS 
were 100%, 49% and 24% at 3 years in the low-, intermediate- and high-risk 
groups, respectively, before salvage therapy. When assessing CEFS in PSA 
responders (post-treatment PSA level ≤0.5 ng/mL) alone, the estimated CEFS 
rate at 36 months was 67% (95% CI 53–82). 
 
5.1.4.2 Secondary Outcomes 
 
A total of 51% of patients (77/150) experienced BCF. The Kaplan–Meier b-
DFS rate at 3 years was 48% (95% CI 39–59) for the entire group. Kaplan–
Meier estimates of b-DFS were 100%, 61% and 32% at 3 years in the low-, 
intermediate- and high-risk groups, respectively, before salvage therapy. A 
total of 43.3% of patients (65/150) were PSA responders, achieving a PSA 
nadir of ≤0.5 ng/mL, while 59.3% (89/150) achieved a nadir of ≤1 ng/mL. 
When assessing BCF in PSA responders alone (PSA nadir ≤0.5 ng/mL), BCF 
occurred in 12% of patients (18/150) and the estimated actuarial b-DFS rate 
at 36 months was 78% (95% CI 67–92). The b-DFS rate at 2 years in patients 
who underwent re-do HIFU, was 66% (95% CI 43–100%). The additional 36-
month Kaplan–Meier estimates regarding the primary and secondary 
outcomes are provided in Table 6. 
 
Of the patients with BCF, 62 underwent mpMRI in the follow-up, 13 of whom 
had negative results. Of the 15 patients who did not undergo mpMRI during 
the follow-up, one died from disease unrelated to prostate cancer or the HIFU 
treatment, eight received ADT (three as a result of metastatic disease on a 
bone-scan and/or CT and one based on positive TPM biopsies). In six 
patients follow-up data were insufficient to assess the procedures after BCF. 
Of the 49 patients with a recurrence on mpMRI, all underwent either pelvic CT 
or radioisotope bone scan to exclude metastatic disease. Patients potentially 
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eligible for a second focal salvage HIFU procedure underwent subsequent 
TPM biopsies in all but four cases. 
 
Systemic therapy was initiated in 40.7% of patients (61/150), 6.7% of patients 
(10/150) had a positive biopsy and 9.5% (9/150) developed distant 
metastases. A total of 2.7% of patients (4/150) died from prostate cancer. The 
mean (±SD) time to ADT after HIFU was 20 (±15.9) months. 
A total of 12% of patients (18/150) underwent biopsy after HIFU. This was 
positive in 55.6% of patients (10/18); of these 10 patients, two underwent 
salvage radical prostatectomy, one received ADT and then proceeded to have 
salvage radical prostatectomy and three were started on ADT. Overall, further 
treatment was performed in 12 patients: salvage radical prostatectomy (n = 3); 
EBRT to spinal metastatic disease (n = 1); irreversible electroporation (n = 1); 
cryotherapy (n = 1); chemotherapy (n = 4); and other drug therapy (n = 2). 
There were nine deaths overall, four of which were prostate cancer-related. 
The Kaplan–Meier overall survival estimate at 60 months was 92% (95% CI 
85–99). One patient was in the high-risk group prior to radiotherapy and had 
Gleason 3 + 4 T3b disease before undergoing focal salvage HIFU. After HIFU 
his PSA level continued to rise, he was started on hormone treatment and 
went on to receive further EBRT. A second patient had intermediate-risk 
disease before radiotherapy and Gleason 4 + 4 and T3a disease before hemi-
ablation salvage HIFU. After HIFU his PSA nadir was 0.0 ng/mL, he 
developed BCF 15 months later and went on to develop metastases 
37 months later. A third patient had high-risk disease before radiotherapy and 
had PSA 4.12 ng/mL, Gleason 4 + 3, and T3a disease before focal salvage 
HIFU. After HIFU his PSA level rose to 5.63 ng/mL and he was started on 
hormone therapy and subsequent chemotherapy 24 months later. The fourth 
patient had high-risk disease at baseline and had a PSA level 7.26 ng/mL, 
Gleason 4 + 5 and T2b disease before undergoing hemi-ablation salvage 
HIFU. After HIFU his PSA nadir was 0.11 ng/mL and he developed BCF 
9 months later and was started on chemotherapy at 54 months. 
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5.1.4.3 Complications 
 
Complications included UTI in 11.3% of patients (17/150), epididymitis in 
1.3% (2/150), bladder neck strictures in 8% (12/150), rectourethral fistula after 
first HIFU in 2% (3/150) and osteitis pubis in 0.7% (1/150). For the patients 
who experienced recto-urethral fistula, one spontaneously resolved, one was 
managed with urinary diversion with suprapubic catheter and one was 
surgically repaired (Table 44). 
 
Table 44 – Clavien- Dindo Classification of  Surgical Complications 
 
Clavien- Dindo Classification of Surgical Complications 
1 Any deviation from the normal intra-operative or postoperative course, 
including the need for pharmacological treatment other than antiemetics, 
antipyretics, analgesics, diuretics, electrolytes or physiotherapy 
19 
(12.7) 
2 Complications needing only the use of i.v. medications, total i.v. nutrition, 
or blood transfusion  
0 (0) 
3a Complications needing surgical, endoscopic or radiological intervention 
under local anaesthesia  
25 
(16.3) 
3b Complications needing surgical, endoscopic, or radiologic intervention 
under general anaesthesia  
16 (11) 
4a Life-threatening complications requiring intensive care unit 
management: single-organ dysfunction 
0 (0) 
4b Life-threatening complications requiring intensive care unit 
management: multiorgan dysfunction  
0 (0) 
5 Death of the patient 0 (0) 
 
In patients with available data from pre- and post-HIFU functional 
questionnaires (UCLA-EPIC, IPSS and IIEF-5), of those pad-free at baseline, 
87.5% (42/48) remained pad-free at 2 years. A total of 70.8% (34/48) had 
drip-free urinary continence at baseline and 67.6% (23/34) remained drip-free 
postoperatively at 2 years. Baseline IIEF scores were available for 31 
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patients: 38.1% (12/31) reported a baseline score >2 for question 2 of the 
IIEF, which meant that erections were mostly sufficient for penetration, and 
58.3% (7/12) still had score of >2 at follow-up (Table 45). 
 
Table 45 Functional Outcomes 
 
Functional 
outcomes 
 
Pre-focal salvage HIFU 
 
Post-focal salvage HIFU (6–
36 months) 
 
Median (IQR) 
IPSS 
8 (4–15) 
 
11 (7–18) 
 
Drip-free status, 
% (n/N) 
 
67 (50/75) 
 
46 (28/61) 
 
Pad-free status, 
% (n/N) 
 
97 (70/72) 
 
78 (46/59) 
 
IIEF Q2 score >2, 
% (n = 31) 
 
38 (n = 12) 
 
22 (n = 7) 
 
Median (IQR) 
IIEF score 
 
15 (7–39) (n = 54) 
 
13 (7–24 months) (n = 42) (3–
72 months) 
 
PDE-5 use, % 
(n/N) 
21 (12/57) 24 (11/45) 
 
 
5.1.4.4 Univariable and Multivariable Analyses for Composite Endpoint 
 
In univariable analyses, components that achieved statistical significance for 
the composite endpoint included primary Gleason score 8–10 HR 1.88 ([95% 
CI 1.06–3.32]; P = 0.03), time to radiological recurrence HR 0.989 ([95% CI 
0.982–0.996]; P = 0.002), T stage 3 vs T stage 1 and 2 before salvage HIFU 
  
 
125 
HR 1.70 ([95% CI 1.09–2.65]; P = 0.02), pre-salvage HIFU PSA HR 1.06 
([95% CI 1.02–1.11]; P = 0.004), D’Amico pre-salvage high risk vs low risk HR 
2.57 ([95% CI 0.89–7.38]; P = 0.08) and PSA-nadir post-salvage HR 1.26 
([95% CI 1.19–1.32]; P < 0.001).  
 
In multivariable analyses components that achieved statistical significance for 
the composite endpoint included T stage 3 vs T stage 1 and 2 pre-salvage 
HIFU HR 1.96 ([95% CI 1.13–3.39]; P = 0.02) and PSA-nadir post-salvage 
HIFU HR 1.29 ([95% CI 1.20–1.38]; P < 0.001). The CEFS rate at 36 months 
(Table 46) in those with a pre-salvage HIFU PSADT of ≥12 months was 51% 
(95% CI 37–70) compared with 24% (95% CI 14–41; P = 0.003) in those with 
a PSADT of <12 months (Fig. 2A) and 51% (95% CI 39–67) vs 31% (95% CI 
21–46; P = 0.002) in men with a pre-salvage HIFU PSA level <5 ng/mL 
compared with those with a pre-salvage HIFU PSA level ≥5 ng/mL (Fig. 2B). 
For patients with MRI prostate volume < 25 mL rates of CEFS at 36 months 
were 48% (95% CI 35–65) vs 34% (95% CI 24–49; P = 0.13) in those with 
MRI volume ≥25 mL (Fig. 2C). In men with a PSA nadir after salvage HIFU of 
<0.5 ng/mL CEFS at 36 months was 67% (95% CI 53-82) vs 21% (95% CI 
13–33; P < 0.001) in those with PSA nadir ≥0.5 ng/mL (Fig. 2D). 
 
Table 46 Kaplan-Meier estimates for composite endpoint-free survival (CEFS) 
rates and biochemical disease-free survival (B-DFS ) rates at 36 months. 
 
 CEFS, % (95% 
CI) 
B-DFS , % 
(95% CI) 
Entire group 40 (31–50) 48 (39–59) 
D’Amico low risk 100 (NA) 100 (NA) 
D’Amico intermediate risk 49 (36–68) 61 (48–79) 
D’Amico high risk 24 (14–40) 32 (20–49) 
D’Amico low + intermediate risk 51 (38–69) 62 (49–79) 
D’Amico high risk 24 (14–40) 32 (20–49) 
PSA nadir <0.5 ng/mL 67 (53–82) 78 (67–92) 
PSA nadir ≥0.5 ng/mL 21 (13–33) 26 (17–39) 
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PSADT ≥12 months 51 (37–70) 60 (45–79) 
PSADT <12 months 24 (14–41) 30 (19–49) 
PSA <5 ng/mL 51 (39–67) 62 (50–77) 
PSA ≥5 ng/mL 31 (21–46) 37 (27–53) 
Prostatic volume <25 mL 48 (35–65) 60 (47–77) 
Prostatic volume ≥25 mL 34 (24–49) 41 (30–56) 
CEFS, composite endpoint-free survival; B-DFS , biochemical disease free 
survival; PSADT, PSA doubling time. 
 
 
Fig. 2 (A) Composite endpoint-free survival (CEFS) according to PSA 
doubling time before focal salvage high-intensity focused ultrasound (HIFU). 
(B) CEFS according to PSA level pre-focal salvage HIFU. (C) CEFS 
according to MRI prostate volume. (D) CEFS according to PSA nadir after 
focal salvage HIFU. 
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Fig. 3 (A) Biochemical disease free survival (B-DFS ) rates according to PSA 
doubling time before focal salvage high-intensity focused ultrasound (HIFU). 
(B) B-DFS  according to PSA level before focal salvage HIFU. (C) B-DFS  
according to MRI prostate volume. (D) B-DFS  according to PSA nadir after 
focal salvage HIFU. 
 
 
 
For the intermediate- and high-risk groups the CEFS rates at 36 months were 
49% (95% CI 36–68) and 24% (95% CI 14–40; P = 0.006), respectively 
(Fig. 4A). When the low- and intermediate-risk groups were combined, CEFS 
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at 36 months was 51% (95% CI 38–69) vs 24% (95% CI 12–38; P = 0.001) for 
the high-risk group (Fig. 4B). 
 
Fig. 4 (A) CEFS according to D’Amico risk classification before focal salvage 
high-intensity focused ultrasound (HIFU). (B) CEFS according to D’Amico low- 
and intermediate-risk groups combined vs high-risk group before focal 
salvage HIFU. (C) b-DFS according to D’Amico risk group before focal 
salvage HIFU. (D) b-DFS according to D’Amico low- and intermediate-risk 
groups combined vs high-risk group before focal salvage HIFU. 
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Because low-risk recurrences are uncommon, we also performed 
multivariable analysis after excluding patients in the low-risk group (n = 4); 
these analyses are shown in Table 47. For BCF, MRI prostate volume and 
PSA nadir after salvage HIFU remained statistically significant after the 
exclusion of patients in the low D’Amico risk group. For the composite 
endpoint, PSA nadir after salvage HIFU remained statistically significant. 
 
Table 47 - Multivariable analysis for biochemical failure and the composite 
endpoint without D’Amico low risk patients 
 
Determinants 
BF 
HR (95% CI) p-value Determinants 
CE 
HR 
(95% 
CI) 
p-value 
MRI volume 1.01 (1.001-
1.028) 
0.03    
PSA-nadir 
post-salvage 
1.28 (1.19-
1.38) 
<0.0001 PSA-nadir 
post-salvage 
1.28 
(1.19-
1.38) 
<0.0001 
Abbreviations: BF=Biochemical Failure; HR=Hazard Ratio; CI=Confidence 
Interval; CE=Composite Endpoint; PSADT=PSA-doubling time. 
 
5.1.4.5 Univariable and Multivariable Analyses for Biochemical Failure 
(Phoenix Definition) 
 
In univariable analyses components that achieved statistical significance for 
BCF included primary Gleason Score 8–10 HR 2.06 ([95% CI 1.10–3.85]; P = 
0.02), time to radiological recurrence HR 0.988 ([95% CI 0.980–0.995]; P = 
0.002), T stage 3 vs T stages 1 and 2 pre-salvage HIFU HR 1.78 ([95% CI 
1.11–2.87]; P = 0.002), MRI volume HR 1.014 ([95% CI 1.003–1.025]; P = 
0.01), PSA pre-salvage HIFU HR 1.07 ([95% CI 1.02–1.12]; P = 0.003), and 
PSA nadir after salvage HIFU HR 1.26 ([95% CI 1.19–1.32]; P < 0.001).  
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In multivariable analyses, components that achieved statistical significance for 
BCF included T stage 3 vs T stages 1 and 2 pre-salvage HIFU HR 1.99 ([95% 
CI 1.14–3.46]; P = 0.02), MRI prostate volume HR 1.014 ([95% CI 1.002–
1.027]; P = 0.03) and PSA nadir after salvage HIFU HR 1.29 ([95% CI 1.20–
1.38]; P < 0.001). 
 
There were significant differences in b-DFS  (Table 6) at 36 months for 
patients with a PSADT of ≥12 months pre-salvage HIFU: 60% (95% CI 45–79) 
compared with 30% (95% CI 19–49; P < 0.001) for those with a PSADT of 
<12 months (Fig. 3A). For those with pre-salvage HIFU PSA <5 ng/mL vs 
those with PSA ≥5 ng/mL, B-DFS  was 62% (95% CI 50 to −77) vs 37% (95% 
CI 27–53; P < 0.001 [Fig. 3B]). Patients with a prostate volume of <25 mL 
before undergoing focal salvage HIFU had a b-DFS  rate at 36 months of 60% 
(95% CI 47–77) compared with those with prostate volume ≥25 mL, who had 
a b-DFS  rate of 41% (95% CI 30–56; P = 0.02 [Fig. 3C]). At 36 months those 
who had a PSA nadir of <0.5 ng/mL had a b-DFS  rate of 78%, (95% CI 67–
92) compared with those who achieved a PSA nadir ≥0.5 ng/mL, who had a b-
DFS  rate of 26% (95% CI 17–39; P<0.001 [Fig. 3D]). For the intermediate- 
and high-risk D’Amico groups b-DFS  rates at 36 months were 61% (95% CI 
48–79) and 32% (95% CI 20–49; P = 0.008), respectively (Fig. 4C). When the 
low- and intermediate-risk groups were combined, the b-DFS  rate at 
36 months was 62% (95% CI 49–79) vs 32% (95% CI 20–50; P = 0.002) for 
the high-risk group (Fig. 4D). 
 
5.1.5 Discussion 
 
5.1.5.1 Summary of results 
 
The present results show that focal salvage HIFU has potential in the 
treatment of radiorecurrent prostate cancer. In our relatively high-risk cohort, 
BCF occurred in 51% of patients (78/150) and composite failure in 61% 
(91/150). The Kaplan–Meier CEFS rate at 3 years was 40% (95% CI 31–50) 
for the entire group and 48% (95% CI 39–59) for b-DFS.  
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5.1.5.2 Methodological Limitations 
 
A limitation of the present study is that we had limited information on baseline 
and postoperative erectile and urinary function, despite issuing questionnaires 
to most patients. Lack of baseline data may be attributable to no symptoms at 
initial consultation and therefore no assessment of symptoms using an 
objective method. Also, as this was not conducted as part of a research trial, 
patients were not obligated to return questionnaires, which may explain the 
lack of responses. As these functional data were so frequently missing, a valid 
conclusion is hard to link to the outcomes so far. Patients with severe 
deterioration might not have returned the questionnaires, thereby biasing the 
comparison in a significant way. Further, there is still some debate in the 
literature about radiation effect, delayed tumour regression and timing of 
biopsy after radiotherapy. Whilst there is some uncertainty, our team consists 
of expert uro-pathologists whose published work on clinically significant 
prostate cancer includes the use of different biopsy strategies in primary and 
radiorecurrent settings (44,99,123-125). Our experts only report a Gleason 
score when there is minimal radiation effect seen on the biopsies, and so feel 
that they are able to identify recurrent prostate cancer, when present, in 
radiation-affected tissues with a high degree of accuracy and to assign a 
grade to these. 
 
A further limitation of the study is that no validated definition for failure is 
available in the (focal) salvage setting after radiotherapy failure; therefore, a 
composite endpoint was chosen as a combined failure definition, 
incorporating biochemical outcomes, imaging (mpMRI, Choline-PET/CT, 
radioisotope bone scan), biopsy results, systemic therapy initiation and 
metastatic disease/prostate cancer-specific mortality. This definition more 
clearly reflects failure in the early to medium term after focal salvage therapy 
because the Phoenix definition is not validated in the focal salvage setting and 
can be biased as a result of ADT use before focal salvage, which was present 
in a substantial number of patients (n = 68). The estimates from the Kaplan–
  
 
132 
Meier analyses and multivariable analyses, however, are very similar for BCF 
and the composite endpoint, potentially indicating the validity of a failure 
definition based on biochemical outcomes. This is also visible in the 
verification of BCF with mostly MRI (n = 51) or biopsies (n = 11). 
Nevertheless, 13 patients still achieved the composite recurrence outcome 
without previous BCF. In the absence of a clear failure definition, we therefore 
recommend subsequent imaging and biopsy verification of patients with BCF 
after focal salvage HIFU. 
 
Another limitation of the present study is the absence of detailed criteria for 
response assessment or adoption of subsequent diagnostic techniques in 
case of disease progression; however, most patients (62/77) with BCF 
received mpMRI in case of BCF after focal salvage HIFU. Results of mpMRI 
in the radiorecurrent setting are at least equal, if not better, which is 
hypothesized to be attributable to increased contrast of tumour with the 
surrounding fibrotic prostate tissue. Negative and positive predictive values of 
90–95% are described (43,94,101,126,127). We have also demonstrated very 
high negative predictive values of a post-treatment MRI in men treated with 
focal HIFU who all underwent a biopsy within a clinical trial. To our 
knowledge, there are no results of mpMRI and/or biopsies in the setting after 
both radiotherapy and focal salvage HIFU in the literature. 
 
5.1.5.3 Comparison to other studies 
 
The present series potentially reflects higher-risk disease than other salvage 
series. This is observed in the median pre-focal salvage PSA level of 
5.5 ng/mL in the present study. The mean/median PSA level ranges from 2.8 
to 5.5 ng/mL in other focal salvage series in the literature (12), but 
comparisons regarding D’Amico risk groups are more difficult because this 
information is not usually provided in focal salvage series. 
The results of the present study show that patients in the higher-risk group 
can also benefit from focal salvage HIFU. Even though failure is still common 
and subsequent treatment is initiated, in a substantial number of patients, 
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follow-up whole-gland or systemic treatment can be postponed or prevented 
and quality of life therefore potentially improved. 
 
Excluding patients in the low D’Amico risk group (n = 4) further limits the 
patient sample and, for this reason, coincidental statistical significance cannot 
be excluded. The main statistical analysis was therefore performed with the 
low-risk group included. Furthermore, MRI prostate volume and PSA nadir 
after salvage HIFU remained the most significant and influential factors; 
therefore, exclusion of the low D’Amico risk group did not change factors 
associated with risk of BCF or with achieving the composite endpoint. 
The present study was pragmatic in that it did not limit the entry criteria for 
focal salvage HIFU other than to exclude metastatic disease and substantial 
seminal vesicle invasion. We did not select patients on an upper threshold 
such as PSA level or PSA kinetics, but allowed many men with probable 
micro-metastatic disease to be treated. The present series therefore reflects 
higher-risk disease than other salvage series. As a result, we could determine 
more robustly the upper limit of what is possible in a focal salvage strategy for 
future trial design and possibly clinical practice. 
 
Repeat treatment with a second HIFU was not classified as failure, as this 
was probably attributable to failure of adequate targeting during initial 
treatment as opposed to recurrence of disease after first focal salvage 
treatment. Second HIFU was therefore classified as completion of treatment. 
One of the key attributes for ablative therapies is repeatability, and the 
literature usually reports outcomes after one or two ablative therapies. 
 
Focal salvage therapy after EBRT provides patients with a further chance at 
cancer control whilst potentially avoiding systemic therapies (107) and the 
morbidity of whole-gland salvage surgery or ablation. Salvage radical 
prostatectomy has been reported to have 5-year B-DFS  rates of between 47 
and 82% (115), complications such as rectal injury (0–28%) (115) and rates of 
incontinence (21–90%) (115) and erectile dysfunction (80–100%) (115) are 
high owing to fibrosis and poor wound healing as a result of radiation. Bladder 
neck strictures still occurred relatively frequently in this cohort (n = 12, 8%), 
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but this rate compares favourably with whole-gland salvage HIFU and salvage 
radical prostatectomy procedures, for which the bladder neck stricture rate is 
~20% in the literature (12). The bladder neck stricture rate in the present 
study does compare somewhat unfavourably with other focal salvage series 
performed to date (12); however, these series had significantly fewer patients.  
 
A systematic review of salvage focal cryotherapy found b-DFS  rates of 50–
68% at 3 years, recto-urethral fistula rates of 0% and erectile dysfunction 
rates of 60–71% (128). b-DFS rates after whole-gland salvage HIFU are 25–
53% (56,57). Incontinence (10–50%), erectile dysfunction (66.2–100%) and 
recto-urethral fistula (3–16%) have also been reported (56,57,60). Overall, 
functional outcomes are generally poorly reported in the literature because of 
the retrospective nature of the studies. 
 
As discussed above, there is no validated definition for failure is available in 
the (focal) salvage setting after radiotherapy failure. Most of our patients with 
BCF received mpMRI in case of recurrence after focal salvage HIFU. Results 
of mpMRI in the radiorecurrent setting are at least equal, if not better, which is 
hypothesized to be attributable to increased contrast of tumour with the 
surrounding fibrotic prostate tissue. Negative and positive predictive values of 
90–95% are described (43,94,101,126,127). We have also demonstrated very 
high negative predictive values of a post-treatment MRI in men treated with 
focal HIFU who all underwent a biopsy within a clinical trial. To our 
knowledge, there are no results of mpMRI and/or biopsies in the setting after 
both radiotherapy and focal salvage HIFU in the literature. 
 
5.1.5.4 Clinical Implications 
 
Furthermore, because of the broader patient selection in the present study 
(including patients with seminal vesicle involvement), more extensive disease 
was potentially treated, thereby increasing the risk of side effects. Only 
comparative studies, however, would provide a robust estimate of side effects 
of different salvage techniques. 
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5.1.5.5 Future Research 
 
It is quite clear that prospective studies are required. The Focal Recurrent 
Assessment and Salvage Treatment for Radiorecurrent Prostate Cancer 
(FORECAST) study (113) will examine focal salvage cryotherapy and HIFU 
as well as the role of imaging in excluding metastatic disease and diagnosing 
local recurrence. We are also planning comparative studies, although accrual 
of patients is often difficult (114). 
 
5.1.6 Conclusion 
 
In conclusion, focal salvage HIFU confers relatively low complication and side 
effect rates. CEFS and biochemical control in the short to medium term is 
reasonable, especially in this relatively high-risk cohort, but still on the low 
side compared with current whole-gland salvage therapies. Focal salvage 
therapy may offer disease control in patients at high risk, whilst minimizing 
additional treatment morbidities. 
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5.2 Focal Salvage Therapy for radiorecurrent prostate cancer 
 
5.2.1 Introduction 
 
Throughout this discussion, it has been made clear the necessity to treat men 
with radiorecurrent prostate cancer with a modality that offers the least 
morbidity and mortality with optimum cancer control. Focal salvage therapy 
using either HIFU or cryotherapy may be suitable options. In order to provide 
focal salvage therapy, disease must be localized accurately to ensure high 
grade disease is not left untreated which could lead to further disease 
progression. We now report on the prospective outcomes of focal salvage 
HIFU (FS-HIFU) and cryotherapy (FS-cryotherapy) from the FORECAST 
study.  
 
5.2.2 Methods and Materials 
 
As described above in Chapter 3.2 WB-MRI vs. Choline PET/CT and bone 
scan in detection of radiorecurrent disease: 
 
Patient selection 
 
Eligibility criteria for the trial primarily include men who biochemical failure 
after having had previous external beam radiotherapy or brachytherapy with 
or without neo-adjuvant/adjuvant hormone therapy. Biochemical failure as 
defined by the Phoenix criteria (PSA nadir + 2 ng/ml).  
 
See Appendix 10.1 for protocol with full inclusion and exclusion criteria.  
 
Imaging 
 
All patients underwent Choline PET/CT-CT, radio-isotope bone-scan (if not 
already carried out in the last 6 months, mpMRI Pelvis/prostate and whole-
body MRI (See above Flowchart 1 – FORECAST Study). If these 
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investigations revealed metastatic disease they were withdrawn from the trial. 
Patients then underwent TPM biopsy (see Chapter 4.1  Targeted 
transperineal prostate biopsy in the detection of radiorecurrent prostate 
cancer) using a modified version of that described by Barzell et al. (74). (See 
Figure 1 - Transperineal Prostate Mapping Modified Barzell Zones above- 
Chapter 4.1 Targeted transperineal prostate biopsy in the detection of 
radiorecurrent prostate cancer). If mpMRI prior to biopsy identified a visible 
lesion, MRI cognitive targeted sampling were taken by comparing the pre-
intervention mpMRI to the live intra-operative prostate ultrasound on two 
different screens (cognitive or visually targeted).  
 
Following biopsy, results were reviewed in MDT alongside imaging to 
determine suitability for focal salvage treatment. 
 
Focal Salvage Treatment 
 
As described above in Chapter 2 – Hypotheses - Focal salvage treatment 
could be provided if: 
 
- Disease was confined to a quadrant of the prostate provided that less than 
one half of the lobe is affected.  
 
 - At least one neurovascular bundle was avoided by ensuring a minimum 
distance of ablation zone to contralateral neurovascular bundle of 10 mm.  
 
- In men in whom both lobes met criteria for clinically insignificant cancer (≤3 
mm and absence of Gleason pattern 4), the lobe with the dominant disease 
burden was treated.  
 
If there is identical bilateral disease burden, the side with the highest score for 
probability of malignancy on mpMRI will be treated. If this is also equivalent, a 
second re-view of the biopsies will be requested by the trial pathologist and 
the dominant side treated. Only those patients with exactly equivalent disease 
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bilaterally following these three reviews will be excluded from the trial. See 
Appendix 10.1 Protocol for methods of focal salvage therapy.  
 
Focal salvage treatment was not offered if cancer was seen at the overlapping 
or going into the apical sphincter on mpMRI.  
 
Treatment methods 
 
The decision between focal cryotherapy or HIFU salvage ablative methods 
will be based on the location of recurrent disease. Patients were more likely to 
undergo cryotherapy if the tumour was predominantly anterior and HIFU if the 
tumour was posterior and/or apical. This is to ensure optimum energy delivery 
as HIFU can often not deliver energy in the upper parts of the prostate whilst 
the cryoprobes can be placed directly into the area of the tumour. The 
decision in those which are basal-middle and posterior will be pragmatically 
chosen by physician and patient as would happen in standard care.  
 
Follow-up  
 
This took place at 4 weeks, 3 months, 6 months, 9 months and 12 months 
post-treatment. At each follow-up appointment, the patient had either a 
telephone consultation or clinic visit to discuss their results and review any 
adverse events using National Cancer Institute Common Terminology Criteria 
(NCI CTC) classification system. IPSS, IPSS QoL, UCLA-EPIC Bowel 
Questionnaire, erectile dysfunction, the IIEF-15 questionnaires were 
completed during follow up to assess any change in urinary, bowel or sexual 
function and a PSA blood test. At 12 months, patients had mpMRI to see if 
there is any evidence of residual disease. If post treatment, there is a PSA 
doubling time of less than 3 months or fails by PHOENIX/ASTRO Definition 
(PSA nadir + 2 ng/ml) patients underwent repeat prostate mpMRI and if 
warranted repeat mpMRI targeted biopsy+/staging scans (Choline PET/CT or 
Bone Scan).  
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Patients were excluded from analysis if they are withdrawn from the study or 
unable to undergo the reference test after one of the index test, or are unable 
to have focal salvage treatment. 
 
 
5.2.3 Objectives 
 
5.2.3.1 Primary Objectives 
1. To determine the complications and side-effect profile of focal salvage 
therapy to treat localised radiorecurrent prostate cancer.  
 
2. Presence of urinary incontinence (any pad usage plus any leakage of 
urine) as determined by the UCLA-EPIC urinary continence questionnaire 
(See Appendix 10.2), at 12 months, in those men with no urinary 
incontinence at baseline.  
 
 
3. Assess further functional outcomes using validated questionnaires. 
 
The IPSS – International Prostate Symptom score -  comprises of 8 
questions in total, 7 on urinary function and 1 on Quality of Life (QOL) 
(See Appendix 10.2). Scoring is as follows; Mild lower urinary tract 
symptoms (LUTS) (symptom score less than or equal to 7), Moderate 
LUTS (symptom score range 8-19) and Severe LUTS (symptom score 
range 20-35).  
 
The 15-question International Index of Erectile Function (IIEF) 
Questionnaire.  is a validated, multidimensional, self-administered 
investigation that assesses erectile dysfunction and has been used to 
assess treatment outcomes in clinical trials. A score of 0-5 is awarded to 
each of the 15 questions that examine the 4 main domains of male sexual 
function: erectile function, orgasmic function, sexual desire and 
intercourse satisfaction. (121). Maximum score is 75 with higher scores 
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indicating good sexual function.(See appendix 10.2) Specific questions 
that were analysed for this study were erectile functional questions 
specifically looking at patients were able to satisfactorily obtain and 
maintain an erection sufficient for sexual intercourse.  
Other questionnaires used to examine urinary and bowel function post 
treatment are University of California-Los Angeles - Expanded Prostate 
Index Composite (EPIC) which examines Quality of Life issues in patients 
with Prostate cancer (120,129) . These questions examined urinary and 
bowel urgency (A low score indicated poor control <12), leakage (low 
score indicated poor control <12), and the use of any pads (high score >2 
indicated increased pad usage). Quality of life was also assessed in these 
questionnaires (scores >15 indicated poor quality of life).  
 
5.2.3.2 Secondary Objectives 
 
To provide preliminary data on short term disease control outcomes after one 
or two focal salvage therapy (PSA kinetics, imaging evidence of localised 
recurrence, rate of ADT and metastases/death). BCF using the Phoenix-
ASTRO definition (nadir PSA + 2 ng/mL) after FST, and a composite failure 
that consisted of failing by one of the following parameters; BCF and/or 
positive localized or distant imaging and/or positive biopsy and/or systemic 
therapy and/or metastases and/or prostate cancer-specific death, was also 
calculated.  
 
Statistical Analysis 
 
Cox proportional hazards regression was used to quantify the effect of the 
determinants described above on the endpoints. Hazard ratios (HRs) with 
95% CIs are provided. Factors with P values <0.05 were included in the 
multivariable model. The R language environment (version 3.2.1; available 
at http://www.r-project.org/) (122) was used for all statistical analyses.  
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5.2.4 Results 
 
A total of 19 patients have undergone focal salvage therapy so far between 
June 2014 and September 2015. Of these, 21.1% (4/19), 15.8% (3/19) and 
52.6% (10/19) had low-, intermediate- and high-risk disease prior to 
radiotherapy (10.5% 2/19 missing). A total of 94.7% (18/19) of the patients 
underwent EBRT and 5.3% (1/19) underwent brachytherapy. The median time 
to BCF from primary radiotherapy was 89.5 months (95% CI 53.2-88.5). The 
mean (SD) age at focal salvage therapy was 68.7 (8.2) years and the median 
(interquartile range [IQR]) PSA level before focal salvage treatment was 5.6 
ng/mL (2.5-7.7). (See Table 48 – Baseline Data) 
 
Table 48 -  Baseline Characteristics 
Baseline Characteristics (N=19) 
Determinant Mean/median/n (SD, IQR, %) Missing, 
n (%) 
Patient age 68.7 (8.2) 0 (0%) 
D’Amico Risk at Baseline prior to 
radiotherapy 
 
1 = Low risk  T1-T2b GG <6 PSA 
<10 
 
2 = Intermediate risk T2b and/or 
GG 7 and or PSA 10-20 
 
3 = High risk >T2c  and/or 
Gleason 8-10 and/or PSA >20 
 
 
 
4 (21.1%) 
 
 
3 (15.8%) 
 
 
 
10 (52.6%) 
 
 
 
 
2 
(10.5%) 
Nadir PSA post-treatment 0.13 (0.10-0.53) 1 (5%) 
Referral PSA 4.6 (2.5-5.8) 0 (0%) 
SD=standard deviation; IQR=interquartile range; BF=biochemical failure; 
EBRT=external beam radiotherapy; Gy=Gray; PSA=prostate specific antigen.  
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15 patients underwent FS-HIFU and 4 patients underwent FS-cryotherapy.  
Forms of ablation performed consisted of quadrant 63.1%(12/19), 
hemiablation 15.8% (3/19), dog-leg ablation 15.8% (3/19) and subtotal 
ablation 5.3% (1/19) forms of ablation were performed. 89.5% (17/19) patients 
had whole area of disease recurrence treated and 10.5% (2/19) had Index 
lesion ablation. In the patients who had index lesion ablation, remaining 
untreated disease consisted of Gleason 3+3 MCCL 7.5mm in midline in one 
patient and another had Gleason 3+4 MCCL 5mm on same side.    
 
5.2.4.1 Primary Objective Outcomes 
 
5.2.4.1.1 Side effects 
 
Side effects directly related to focal salvage treatment included persistent 
debris post operatively (n=1), straining to pass urine (n=1) and urethral 
soreness (n=1). Other medical complaints post operatively included 
lightheadiness due to tamsulosin use (n=1), development of glaucoma (n=1) 
and neck pain (n=1). The patient who had debris postoperatively, later 
developed urethral stricture and underwent urethral dilation one year after 
treatment. The patient who was straining to pass urine, developed perineal 
pain and this is currently being conservatively managed. 
 
Only 2 patients underwent repeat MRI due to rising PSA within 12 months of 
treatment. Both of whom scored PIRADS 4 (clinically significant cancer is 
likely to be present). One of these patients underwent biopsy post FST due to 
MRI findings. Biopsy revealed Gleason 3+4 MCCL 5mm on same side of 
initial salvage treatment and he went on to have a further FST with FS-
Cryotherapy. The remaining patient was started on hormonal therapy as 
Choline PET/CT revealed nodal disease. One patient who developed nodal 
metastases 10 months after FST received cyberknife to these metastases.  
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5.2.4.1.2 Urinary Leakage 
 
All patients still had urinary control without leakage at 12 months post FST. 
No patient reported pad use at baseline or 12 months post FST. 
 
5.2.4.1.3 Functional Outcomes 
 
Using paired t test baseline and functional scores were assessed at 4 weeks, 
3 months, 6 months and 12 months post focal salvage treatment. For this 
discussion, functional outcomes at 12 months only will be discussed. These 
are shown in Table 49. (For full outcomes please see Appendix 10.3) 
 
Table 49 – Functional outcomes– Baseline scores of functional questionnaires 
and 12 months.  
 
 Mean Median SD 
Baseline IPSS (n=18) 9.67 8.00 5.531 
Baseline IPSS QOL 1.44 1.00 1.247 
Baseline IIEF-15 (n=18) 21.61 15.00 19.162 
Baseline IIEF -1 1.978 .50 1.50 
Baseline IIEF-2 1.33 .00 1.910 
Baseline IIEF-3 1.17 .00 1.886 
Baseline IIEF-4 1.06 .00 1.862 
Baseline IIEF – 5 (n=16) 1.69 1.00 1.352 
Baseline UCLA EPIC URINE 
(n=17) 
23.53 23.00 3.145 
Baseline UCLA EPIC URINE 1 4.65 5.00 .862 
Baseline UCLA EPIC URINE 4 3.76 4.00 .437 
Baseline UCLA EPIC URINE 5 .00 .00 .000 
Baseline UCLA EPIC BOWEL 
(n=18) 
24.17 23.00 3.808 
Baseline UCLA EPIC BOWEL 1 4.72 5.00 .752 
Baseline UCLA EPIC BOWEL 2 5.00 5.00 .000 
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Baseline UCLA EPIC BOWEL 8D .22 .00 .428 
12 MTH IPSS (N=8) 11.88 11.50 6.379 
12 MTH IPSS QOL 2.13 2.50 1.126 
12 MTH IIEF-15 15.63 13.50 7.999 
12 MTH IIEF -1 .50 .00 .756 
12 MTH IIEF-2 .38 .00 .518 
12 MTH IIEF-3 .25 .00 .707 
12 MTH IIEF-4 .13 .00 .354 
12 MTH IIEF - 5 1.13 1.00 .354 
12 MTH UCLA EPIC URINE 26.13 25.00 3.944 
12 MTH UCLA EPIC URINE 1 4.63 5.00 .518 
12 MTH UCLA EPIC URINE 4 3.50 3.50 .535 
12 MTH UCLA EPIC URINE 5 .00 .00 .000 
12 MTH UCLA EPIC BOWEL 25.63 24.50 6.501 
12 MTH UCLA EPIC BOWEL 1 4.75 5.00 .463 
12 MTH UCLA EPIC BOWEL 2 4.88 5.00 .354 
12 MTH UCLA EPIC BOWEL 8D .50 .00 .756 
 
Baseline overall IPSS score was 11.38 and at 12 months was 11.88 (p=0.83). 
IPSS QOL scores at baseline and 12 months was 1.50 and 2.13 respectively 
(p=0.14). Baseline IIEF-1 which asks how often patients get an erection 
during sexual activity, baseline score was 1.38 and at 12 months this was 
0.50 (p = 0.11).  Baseline IIEF-2 score was 1.25 and 0.38 at 12 months 
(p=0.18). Baseline IIEF-3 score at baseline and 12 months was 1.00 and 0.25 
(p=0.17). Baseline IIEF-4 scores was 0.88 and 0.13 at 12 months (p=0.20). 
Baseline IIEF-5 score was 1.57 and 1.14 at 12 months (p=0.20). Baseline 
EPIC – Urine score 1 was 4.88 and at 12 months was 4.63 (p=0.17). Baseline 
EPIC – Urine score 4 was 3.88 and 3.50 at 12 months(p=0.20). UCLA –EPIC 
Bowel 1 was 5.00 and 4.75 at 12 months (p=0.17). UCLA –EPIC Bowel 2 was 
5.00 and 4.88 at 12 months (p=0.35). Baseline EPIC Bowel 8D – was 0.00 
and 0.50 at 12 months (p=0.10). For further outcomes please see Table 50 –  
Paired t –test Functional outcomes – in Section 10.3.2) 
 
  
 
145 
5.2.4.2 Secondary objectives 
5.2.4.2.1 Biochemical Failure 
 
b-DFS at 6 months for the entire group, was 95% (95% CI  86-100) and at 12 
months, was 75% (95% CI  56-100).  (See Figure 8) All patients who achieved 
a PSA nadir of <0.5ng/ml had b-DFS rate of 100% at 6 and 12 months 
(p=0.02). For those who achieved a PSA nadir of >0.5ng/ml b-DFS rates were 
90% (95% CI  73-100) at 6 months and 46% (95% CI  21-100) at 12 months 
(p=0.02) (See Figure 9). Patients who underwent focal salvage HIFU had a b-
DFS rate of 93% (95% CI  80-100) at 6 months, and 73% (95% CI  51-100) at 
12 months (p=0.95). For patients who underwent focal salvage cryotherapy, 
b-DFS rates at 6 months and 12 months were 100% and 67% (95% CI  30-
100) respectively (p=0.95) (See Figure 10).  
 
Figure 8 Biochemical Disease Free Survival – Entire Group 
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Figure 9 Biochemical Disease Free Survival according to PSA Nadir Failure  
 
 
 
 
Figure 10 Biochemical Disease Free Survival according to Focal Salvage 
Treatment Type  
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5.2.4.2.2 Composite Endpoint 
 
Composite endpoint free survival (CEFS) for the entire group, was 85% (95% 
CI 71-100) at 6 months and 18% (7-51%) at 12 months. All patients who 
achieved a PSA nadir of <0.5ng/ml had CEFS rate of 100% at 6 months and 
but at 12 months this was only 11% (95% CI 2-71). For those who achieved a 
PSA nadir of ≥0.5ng/ml and CEFS rates of 70% (95% CI 47-100) at 6 months 
and 28% (95% CI 9-88) at 12 months (p=0.37). Patients who underwent focal 
salvage HIFU had a CEFS rate of 86% (95% CI 69-100) at 6 months, and 8% 
(95% CI 1-51) at 12 months. For patients who underwent focal salvage 
cryotherapy, CEFS rates at 6 months and 12 months were 75% (95% CI 43-
100) and 0% respectively (p=0.41) (See Figures 11-13).  
 
Figure 11 - Composite endpoint free survival (CEFS) for the entire group 
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Figure 12 - Composite endpoint free survival according to PSA nadir 
 
 
 
Figure 13 - Composite endpoint free survival according to Focal Salvage 
treatment type 
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5.2.5 Discussion 
 
5.2.5.1 Summary of results 
 
Our study has shown the potential of focal salvage HIFU and cryotherapy as a 
salvage treatment post radiotherapy. b-DFS rates post FS-HIFU was 93% 
(95% CI  80-100) at 6 months, and 73% (95% CI  51-100) at 12 months 
(p=0.95). For focal salvage cryotherapy this was 100% and 67% (95% CI  30-
100) respectively (p=0.95). Only one patient developed Clavien 3b 
complication – urethral stricture requiring dilation - and there are no prostate 
cancer related deaths at present.  
 
5.2.5.2 Methodological Limitations 
 
The key limitation to this current study, is our small study population. As a 
result, it was not possible to perform univariable and multivariable analysis for 
factors predicting biochemical failure or failure by composite endpoint. Our 
small sample size also hindered analysis between focal salvage treatments 
i.e. comparing functional and cancer control outcomes between focal salvage 
HIFU and focal salvage cryotherapy.  
 
5.2.5.3 Comparison to other studies 
 
Our initial outcomes have shown good rates of b-DFS. In comparison to 
Ahmed et al.  (70) which examined focal salvage HIFU in 39 patients, b-DFS 
rates at one year for the overall group was 69%. For our group who 
underwent FS-HIFU, (n=15) all patients who achieved a PSA nadir of 
<0.5ng/ml had b-DFS rate of 100% at 12 months (p=0.02) compared with 
86% in Ahmed’s group (70). However our b-DFS rates were lower for those 
who had PSA nadir of 46% vs. 49% respectively at 12 months.  
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Eisenberg et al. is another small study providing b-DFS rates at one year. In 
this study 19 men focal salvage cryotherapy (hemi-gland treatment) and had a 
B-DFS  survival rate of 89% at 12 months and 69% at 2 years (69). Only 4 
patients in our analysis have undergone FS-cryotherapy therefore whilst our 
rates of b-DFS  do appear to be favourable, further analysis once FORECAST 
has completed recruitment will likely result in larger numbers being treated 
with focal salvage cryotherapy providing more robust data for comparison.  
 
In terms of functional outcomes; patients (n=8) had moderate LUTS at 
baseline which did not significantly change post treatment and this was the 
same with QOL where patients were mostly satisfied with their LUTS pre-and 
post FST. Examining successful maintenance of an erection sufficient for 
intercourse, there was no significant change between baseline and 12-month 
erectile function. All patients still had urinary control without leakage at 12 
months’ post FST. No patient reported pad use at baseline or 12 months’ post 
FST. Again, there was no increase in rectal urgency, or leakage of stool post 
FST at 12 months. There was only a small change in losing control of stool 
from no problem to very small problem however this was not significant. In 
comparison to our previous study (130), 32.4% had reported urinary leakage 
and 12.5% started using pads at 2 years. Bladder neck strictures requiring 
dilation rates in current literature are 3-8% (12/150) (69,70,130). Currently 
within this study there are no patients who have suffered from recto-urethral 
fistula.  
 
5.2.5.4 Clinical implications 
 
Focal salvage treatment in the form of HIFU or cryotherapy appears to have 
good short to medium term outcomes with minimal morbidity. Ours is the first 
study to use a composite endpoint - this can be employed in future studies to 
determine outcomes of salvage treatment. 
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5.2.5.5 Future research 
Upon completion of the FORECAST Study – a larger sample size will provide 
much needed data on intermediate outcomes for disease control and side 
effects of focal salvage therapy. This study will also provide information on 
radiological and histopathological investigations in radiorecurrent disease. 
This will enable further clinical discussion on how to best investigate 
biochemical failure post radiotherapy which in turn can help patients towards 
the most suitable form of salvage treatment.  
 
5.2.6 Conclusion 
 
Focal salvage therapy holds promise in further treatment of radio-recurrent 
prostate cancer. We have shown no change in baseline function of urinary or 
bowel symptoms. Whilst our biochemical rates appear favourable, further 
completion of recruitment to the FORECAST study will provide more data for 
comparison to current literature.   
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Chapter 6 Summary and Clinical Implications 
 
Each chapter in this thesis is an attempt to follow a patient’s journey from 
biochemical failure through to diagnosis of radiorecurrent disease and 
ongoing further salvage treatment. This chapter offers a critical discussion of 
the studies included in this thesis. 
 
6.1 Choline PET/CT VS. Bone Scan  
 
Current standards of care for staging patients at time of biochemical failure 
post radiotherapy include Choline PET/CT and bone scan. These scans are 
limited by their detection of metastases at high levels of PSA (PSA>20ng/ml). 
However, these scans had to be included in the thesis as they are currently 
not superseded by another imaging test. The question remains, can only bone 
scan or Choline PET/CT be used in the diagnosis of distant radiorecurrent 
disease? Thereby reducing the burden on the patient and saving costs.  
 
In Chapter 3.1 a retrospective study was performed that compared Choline 
PET/CT to bone scan in the detection of metastatic radiorecurrent disease. 97 
patients were examined and Median PSA pre-imaging was 4.80 ng/ml (IQR 
2.7-7.3). Average (±SD) time from biochemical failure to bone scan and 
Choline PET/CT scan was 9 months (±13.2).  Bone scan was positive in 3.1% 
(3/97), equivocal in 15.5% (15/97) and negative in 81.4% (79/95). Choline 
PET/CT scan was positive for metastatic disease in 5.2% (5/97) and 
equivocal in 3.1% (3/97).  Concordance between bone scan and Choline 
PET/CT occurred in only 3 cases, (kappa value 0.024). Bone scan was 
equivocal in 15 cases, in comparison with choline positive metastatic disease 
specifically (11 cases), concordance was reached in one case, was equivocal 
in a further case and negative on Choline PET/CT for 9 cases (kappa value 
0.14). Choline PET/CT was positive for metastatic bony disease in 5 cases. In 
one case, Choline PET/CT and bone scan was concordant, in one case bone 
scan was equivocal and in three cases, bone scan was negative (kappa value 
0.14). When bone scan positive and equivocal results were combined (n=14) 
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and compared with Choline PET/CT, only 2 cases were concordant with one 
case being equivocal and 11 cases being negative for metastatic disease 
(kappa value 0.13). 
 
6.1.1 Clinical implications 
 
Throughout the analysis, it was shown that concordance between Choline 
PET/CT and Bone scan had low kappa scores - (kappa value 0.024 – 0.14) 
indicating very unlikely to be concordance between these tests. This indicates 
that neither scan can be replaced with one of the other in the detection of 
metastatic disease. The key limitations in this paper, is that the PSA value at 
time of imaging is 4.80 ng/ml (IQR 2.7-7.3). Average (±SD) time from 
biochemical failure to bone scan and Choline PET/CT scan was 9 months 
(±13.2). Metastatic disease can declare itself up to 2 years post biochemical 
failure and more importantly it is widely shown that both imaging tests have 
higher rates of detection of metastatic disease at higher PSA levels >20ng/ml. 
This is an issue that is difficult to overcome in this study as salvage treatment 
is felt to be most beneficial in patients with PSA <20ng/ml. Overall it would still 
be justified to perform both tests to rule out metastatic disease, as Choline 
PET/CT was still positive in 23 patients (nodal and metastatic disease) and 
bone scan was positive (positive and equivocal combined) in up to 18 
patients. Ultimately a more accurate imaging test is required to diagnose 
metastatic disease with at a lower PSA threshold.  
 
6.2 WB-MRI VS Choline PET/CT and Bone Scan  
 
In this study results from the prospective FORECAST trial were analysed.   
WB-MRI is an innovative technique that can scan the body in 60 minutes 
without the need for radioactive tracer. This single test may have the ability to 
replace current standard of care nuclear medicine scans if it is capable of 
detecting metastatic disease at low PSA levels (PSA <20ng/ml).   
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In this study, WB-MRI was compared to Choline PET/CT and Bone Scan to 
diagnose radiorecurrent prostate cancer. Patients were classified as low 6% 
(5/48), intermediate 30.9% (30/48) and high-risk disease 49.5% (48/48) 
according to D’Amico classification at baseline prior to external beam 
radiotherapy (EBRT) (Missing baseline data in 2 cases). The time from EBRT 
to re-imaging was 78.9 (IQR 48.5-93.8) The median PSA at the time of 
imaging was 3.29 ng/ml (interquartile range 2.40-5.30).  
 
WB-MRI identified local tumour in 52% (26/50) of cases, nodal disease being 
positive or equivocal in 6% (3/50) and 26% (13/50) of cases respectively. WB-
MRI reported metastatic bony disease as positive in 4% (2/50), equivocal 10% 
(5/50). Choline PET/CT was positive for local disease in 66% (33/50) of 
cases, and negative in 28% (14/50), nodal disease in 24% (12/50), tissue 
metastases in 4% (2/50) and in bony metastatic disease was positive in 6% 
(3/50) and equivocal 2% (1/50). Bone scan was positive and equivocal in 4% 
of cases (2/50) respectively.  
 
Concordance between WB-MRI and Choline PET/CT occurred in 20 cases for 
local disease Kappa score 0.311 (p=0.056). Of 19 patients where nodal status 
was reported kappa score indicating concordance between WB-MRI and 
Choline PET/CT was up to 0.548 (p=0.00032). Concordance between WB-
MRI and Choline PET/CT for bony metastatic disease had a kappa score 
0.411 (p<0.0001). Concordance was achieved in only one case for bone 
metastatic disease between WB-MRI and Bone scan (kappa score 0.333 
p=0.157).  
 
Concordance between Choline PET/CT and bone scan was achieved in 2 
cases for bony metastatic disease was detected on Choline PET/CT and bone 
scan. Kappa score = 0.333 (p=0.46)).  
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6.2.1 Clinical implications 
 
Overall there was better concordance between WB-MRI and standard of care 
tests compared to concordance between standard of care tests. Moderate 
agreement with a kappa score of 0.548 of WB-MRI and Choline PET/CT for 
nodal disease is promising. However, it does not appear yet that WB-MRI can 
replace Choline PET/CT for identification of local disease as kappa score was 
again only fair at 0.311 nor can WB-MRI replace bone scan for identification 
of bony lesions (kappa score of 0.333).  
 
Several limitations of this study include low PSA at time of imaging, (median 
PSA at the time of imaging was 3.29 ng/ml (interquartile range 2.40-5.30), low 
patient numbers (n=50) and no histopathological confirmation of local, nodal 
or bony metastatic disease. For local disease however, it may be possible in 
the future to examine TPM outcomes of patients who proceed to biopsy and 
then examine which of three imaging test – WB-MRI, Choline PET/CT and 
pelvic mpMRI – has the greatest sensitivity and specificity in identifying local 
disease. Scans may have to be re-reviewed to perform this analysis, so that a 
per quadrant based report of the prostate, is fulfilled for each scan. This can 
then be confirmed with histopathological results of TPM biopsy.  
 
Currently we have been unable to support whether WB-MRI has greater 
sensitivity for the detection of metastases in radio-recurrent disease 
compared to standard of care tests. This is in part to not having 
histopathological conformation, but also to the fact that there were limited 
number of bony lesions found (7/50 in total for all imaging) and repeat imaging 
post treatment/end of follow up is yet to be performed. Further analyses to 
determine accuracy of WB-MRI will be to determine the persistence of lesions 
post salvage treatment. This will be reported in the final outcomes of the 
FORECAST Study. 
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6.3 Targeted transperineal prostate biopsy in the detection of radiorecurrent 
prostate cancer 
 
mpMRI has gained acceptance in the diagnosis of localised prostate cancer. 
The aim of this retrospective study was to examine biopsies targeted to a MRI 
lesion compared with whole gland TPM sampling to determine which of the 
techniques had the higher accuracy. Clinically significant cancer was defined 
using University College London (UCL)/Ahmed definition 2 (Gleason ≥3+4 
and/or maximum cancer core length (MCCL) ≥4 mm). 77 patients were 
included and median PSA was 4.68ng/ml (0.54-20; IQR 2.68-7.60). TPM had 
a better detection rate of clinically significant cancer compared with MRI-TB 
85.7% vs. 77.9% respectively.  
On a per core analysis MRI-TB was more efficient as 50% of MRI-TB cores 
were positive for clinically significant cancer compared with 17.8% of TPM 
cores. MRI-TB had a similar rate of detection of UCL/Ahmed definition 1 
disease compared with TPM 68% versus 71%. TPM had a higher detection 
rate of Gleason 3+4 cancer compared with MRI-TB 84.4% versus 75.3%.  
TPM had a higher all cancer detection rate of 89.6% compared with 63 
patients 81.8% for MRI-TB.  
 
6.3.1 Clinical Implications 
 
Overall TPM biopsy was better at detecting clinically significant prostate 
cancer compared to MRI-TB. As a result, it would not be advised that only 
MRI-TB should be performed. In order to improve the accuracy of MRI-TB 
several strategies can be considered such as US-Fusion biopsies that 
conform pre-operative MRI to live US images of the prostate. This allows for 
changes in the gland due to patient position. Another possibility is live MRI 
targeting, however this would require a dedicated unit with specialized 
equipment and trained staff. Cases may also take longer, meaning that 
operating lists are less efficient as fewer patients can be biopsies on one list 
compared to current TPM biopsy lists. This study did show that TPM biopsy 
had a 90% detection rate of clinically significant cancer with PIRADS score ≥ 
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4 and MRI-TB had a detection rate of 85.1%. This is reassuring and does 
support the hypothesis that abnormalities seen with mpMRI are associated 
with clinically significant prostate cancer in the radio-recurrent prostate cancer 
setting.  
 
 
6.4 Multiparametric MRI in detection of radiorecurrent disease 
 
Accurate localization of radiorecurrent disease is paramount in providing focal 
salvage therapy. Multi-parametric MRI (MpMRI) has been shown to have 
promise in the diagnosis of radiorecurrent disease as discussed above. The 
detection rate of mpMRI within the FORECAST Study was examined using 
Likert Score as described above - (1, highly likely no tumour; 5, highly likely 
tumour) (96). TPM biopsy was used as the reference test. 
 
Data was available for 36 patients who underwent mpMRI as part of the 
FORECAST Trial. Metastatic disease had been ruled out prior to mpMRI by 
bone scan and Choline PET/CT. Overall mpMRI PIRADS ≥4 was shown to 
have high sensitivity, specificity, PPV and NPV for detection of UCL definition 
1 and 2 disease 89.5%, 76.5%, 81% and 86.8% AUROC was 0.83 (SE 0.074 
p=0.001) and 90%, 81.3%, 85.7% and 86.7% (AUROC) was 0.856 (SE 0.07 
p=0.000)) respectively. For detection of any cancer this was 85.7%, 80%, 
85.7% and 80% respectively (p=0.00), (AUROC) was 0.829 (SE 0.075 
p=0.01).  
 
For detection of clinically significant cancer as defined by UCL Definition 2 
MRI PIRADS Score ≥3, Sensitivity, specificity, PPV and NPV was 87.5%, 
80.0%, 82.4% and 85.7% respectively and AUROC was 0.563 (SE 0.1 
p=0.52). For detection of UCL Definition 1 disease, this was 86.7%, 75.0%, 
76.5% and 85.7% (AUROC) was 0.559 (SE 0.098 p=0.55). Sensitivity, 
specificity, PPV and NPV of MRI to detect any cancer was 82.4%, 78.6%, 
82.4% and 78.6% AUROC was 0.567 (SE 0.1 p=0.5).  
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Whilst TPM biopsy and MRI-TB were concordant in most cases, for detection 
of clinically significant cancer for both UCL Definition 1 & 2 disease, however, 
MRI-TB misclassified up to 6 patients as having no cancer, when clinically 
significant cancer was present on TPM biopsy. 
 
6.4.1 Clinical Implications 
 
mpMRI shows high accuracy in the detection of clinically significant 
radiorecurrent prostate cancer. Whilst PIRADS Score ≥4 shows high accuracy 
rates PIRADS ≥ 3 had a lower specificity and AUROC. This would suggest 
that all PIRADS 3 lesions should be biopsied. This study still showed that 
TPM biopsy outperformed MRI-TB and therefore we would not advocate that 
sole MRI-TB can replace TPM at present.  
 
6.5 Radiorecurrent prostate cancer features on template biopsy: Implications 
for focal salvage therapy 
 
In this chapter, we sought to evaluate the proportion of men presenting with 
presumed localized radiorecurrent prostate cancer who might be suitable for 
FST based on TPM biopsies. 
 
A retrospective study on 145 men was performed. All patients had undergone 
metastatic screening to ensure no presence of metastatic disease. Median 
PSA at imaging and subsequent biopsy 4.5ng/ml (2.5-7.7). 60% of patients 
were found to be suitable for a form of focal salvage therapy. 40.7% (59/145) 
were suitable for quadrant ablation, 14.5% (21/145) for hemiablation, 14.5% 
(21/145) for bilateral lesion ablation and 6.2% (9/145) for index lesion 
ablation. Only 9.0% (13/145) would require whole-gland treatment only. 
15.9% (22/145) did not have any local recurrent disease and were deemed to 
have likely micrometastatic disease not visible on imaging. Of patients found 
to have high risk cancer -UCL Definition 1 cancer (Gleason >/=4+3 OR any 
grade of cancer length >/=6mm)- 14% required whole gland ablation, whilst 
the remainder were suitable for a form of focal salvage treatment (p=0.004 
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Pearson χ2). Both patients classified as low and intermediate risk (UCL 
Definition 2 or less), could have a form of focal therapy and did not require 
whole gland treatment.  
 
Patients classified as high risk had a higher odds ratio compared to those of 
low and intermediate risk of requiring whole gland therapy (odds ratio 5.85 
[95% CI 2.13-20.67, p=0.002] and 4.03 [1.18-16.81 p=0.035]), respectively. 
  
6.5.1 Clinical Implications 
 
Patients found to have high risk cancer post radiotherapy are more likely to 
require whole gland ablation, however our study shows that only 14% will 
require whole gland treatment, whilst the remainder could be managed with a 
form of focal therapy. It is still important to note that a definition for clinically 
significant cancer post radiotherapy has not been defined and therefore the 
definitions used in this study may still result in a different outcome for those 
higher risk patients.  
 
Our study is valuable in adding to the literature to determine a definition for 
clinically significant radiorecurrent cancer as in our univariate analysis showed 
that total number of positive cores and maximum cancer core length had an 
odds ratio of 1.14 (95% CI 1.07-1.22, p=<0.0001) and 1.21 (95% CI 1.09-
1.34, p=0.0002), respectively, of predicting suitability for whole-gland salvage 
treatment. This is vital in determining a threshold of Gleason grade, MCCL 
and potentially number of cores into classifying patients post radiotherapy into 
low, intermediate and high risk. Ultimately there must be a consensus on 
these classifications as this will best direct patients towards the most suitable 
salvage treatment.  
 
6.6 Focal Salvage HIFU  
 
Focal salvage treatment has been shown to carry lower side effects than 
whole gland salvage treatments. HIFU has the ability of providing focal 
  
 
160 
treatment to an area of localised prostate cancer. The aim of this retrospective 
study was to determine composite failure as defined by BCF and/or positive 
localized or distant imaging and/or positive biopsy and/or systemic therapy 
and/or metastases and/or prostate cancer-specific death, was also calculated.  
 
A total of 150 patients underwent focal salvage HIFU. Median (interquartile 
range [IQR]) PSA level before focal salvage treatment was 5.5 (3.6–7.9) 
ng/mL. Prior to focal salvage HIFU, metastatic disease was excluded by bone 
scan or Choline PET/CT/FDG scan. Low-, intermediate- and high-risk disease 
using D’Amico classification, was present in 2.7% (4/150), 39.3% (59/150) 
and 41.3% (62/150) of patients prior to focal salvage HIFU (missing, n = 25 
[16.7%]). Three forms of ablation were performed: focal ablation (55%; 
82/150); hemi-ablation (34%; 51/150); and index lesion ablation (11%; 
17/150).   
 
 Composite failure occurred in 61% of patients (91/150). The Kaplan–Meier 
composite endpoint free survival (CEFS) rate at 3 years was 40% (95% CI 
31–50) for the entire group. Kaplan–Meier estimates of CEFS were 100%, 
49% and 24% at 3 years in the low-, intermediate- and high-risk groups, 
respectively, before salvage therapy. When assessing CEFS in PSA 
responders (post-treatment PSA level ≤0.5 ng/mL) alone, the estimated CEFS 
rate at 36 months was 67% (95% CI 53–82). A total of 51% of patients 
(77/150) experienced BCF. The Kaplan–Meier biochemical disease-free 
survival (b-DFS) rate at 3 years was 48% (95% CI 39–59) for the entire group. 
Kaplan–Meier estimates of b-DFS were 100%, 61% and 32% at 3 years in the 
low-, intermediate- and high-risk groups, respectively, before salvage therapy. 
When assessing BCF in PSA responders alone (PSA nadir ≤0.5 ng/mL), BCF 
occurred in 12% of patients (18/150) and the estimated actuarial b-DFS rate 
at 36 months was 78% (95% CI 67–92). The b-DFS rate at 2 years in patients 
who underwent re-do HIFU, was 66% (95% CI 43–100%).  
 
Complications included UTI in 11.3% of patients (17/150), epididymitis in 
1.3% (2/150), bladder neck strictures in 8% (12/150), rectourethral fistula after 
first HIFU in 2% (3/150) and osteitis pubis in 0.7% (1/150).  
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In patients with available data from pre- and post-HIFU functional validated 
questionnaires (UCLA-EPIC, IPSS and IIEF-5), of those pad-free at baseline, 
87.5% (42/48) remained pad-free at 2 years. A total of 70.8% (34/48) had 
drip-free urinary continence at baseline and 67.6% (23/34) remained drip-free 
postoperatively at 2 years. Baseline IIEF scores were available for 31 
patients: 38.1% (12/31) reported a baseline score >2 for question 2 of the 
IIEF, which meant that erections were mostly sufficient for penetration, and 
58.3% (7/12) still had score of >2 at follow-up. 
 
6.6.1 Clinical Implications 
 
Overall Focal Salvage HIFU is a well-tolerated salvage treatment with low 
rates of significant complication. The hypotheses that the conduct of focal 
salvage therapy in men with radiorecurrent prostate cancer is both feasible 
and acceptable can be supported. From this study, patients most likely to 
benefit from FS-HIFU, are those of low and intermediate risk as these carry 
the highest b-DFS rate at 3 years (100% and 66% respectively).  
 
Ours is the first study to incorporate all methods of failure and not just 
biochemical failure post salvage treatment. Using this composite endpoint, 
low risk groups again had CEFS of 100% at 3 years although those at 
intermediate risk had a poorer CEFS rate (48%) rate.  A composite failure rate 
could be examined in other studies to report on the success of salvage 
treatments. Our multivariable analysis showed that higher Gleason Score, T 
stage 3 and High risk D’Amico pre-salvage were factors in predicting failure 
by composite endpoint (HR 1.88 [95% CI 1.06–3.32]; P = 0.03), (HR 1.70 
[95% CI 1.09–2.65]; and (HR 2.57 [95% CI 0.89–7.38]; P = 0.08)) 
respectively. These are all factors that can be analysed in future studies to 
determine whether these too are risk factors for failure post salvage 
treatment. This is important as currently risk groups are still classified 
according to D’Amico risk which is prior to radiotherapy. Prediction models 
can then be made that classify patients into low, intermediate and high risk to 
determine those most suitable for focal salvage treatment.  
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6.7 Focal Salvage Treatments 
 
In this chapter, focal salvage HIFU and cryotherapy as part of the prospective 
FORECAST trial were examined. The main objectives were to report on 
functional outcomes, biochemical failure rates and composite failure rates as 
described above. 
 
A total of 19 patients were examined of which 21.1% (4/19), 15.8% (3/19) and 
52.6% (10/19) had low-, intermediate- and high-risk disease prior to 
radiotherapy (10.5% 2/19 missing). The median (interquartile range [IQR]) 
PSA level before focal salvage treatment was 5.6 ng/mL (2.5-7.7). 15 patients 
underwent FS-HIFU and 4 patients underwent FS-cryotherapy.  Forms of 
ablation performed consisted of quadrant 63.1%(12/19), hemiablation 15.8% 
(3/19), dog-leg ablation 15.8% (3/19) and subtotal ablation 5.3% (1/19) Side 
effects directly related to focal salvage treatment included persistent debris 
post operatively (n=1), straining to pass urine (n=1) and urethral soreness 
(n=1). Baseline overall IPSS score was 11.38 and at 12 months was 11.88 
(p=0.83). IPSS QOL scores at baseline and 12 months was 1.50 and 2.13 
respectively (p=0.14).  
 
b-DFS  at 6 months for the entire group, was 95% (95% CI  86-100) and at 12 
months, was 75% (95% CI  56-100). Patients who underwent focal salvage 
HIFU had a b-DFS rate of 93% (95% CI  80-100) at 6 months, and 73% (95% 
CI  51-100) at 12 months (p=0.95). For patients who underwent focal salvage 
cryotherapy, b-DFS rates at 6 months and 12 months were 100% and 67% 
(95% CI  30-100) respectively (p=0.95).  
 
Composite endpoint free survival (CEFS) for the entire group, was 85% (95% 
CI 71-100) at 6 months and 18% (7-51%) at 12 months. Patients who 
underwent focal salvage HIFU had a CEFS rate of 86% (95% CI 69-100) at 6 
months, and 8% (95% CI 1-51) at 12 months. For patients who underwent 
focal salvage cryotherapy, CEFS rates at 6 months and 12 months were 75% 
(95% CI 43-100) and 0% respectively (p=0.41).  
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6.7.1 Clinical Implications 
 
This study shows that Focal Salvage HIFU and cryotherapy are feasible 
methods of salvage treatment in radiorecurrent disease with acceptable side 
effects and with good short term biochemical disease control. In terms of 
functional outcomes; patients with moderate LUTS at baseline are unlikely to 
have significant impact on their symptoms post treatment. Men who were 
potent pre-salvage treatment maintained their potency at 12 months. No new 
urinary or faecal incontinence was reported. These results however must be 
interpreted with caution. Importantly, this study had very low numbers with 
currently very short follow up – 12 months. Also, direct comparison of focal 
salvage HIFU to cryotherapy could not be examined. By the end of the 
FORECAST study – the outcomes of each type of therapy will be reported 
and compared. With a larger patient population and longer follow up more 
accurate results of how these treatments fare as a curative option for 
radiorecurrent disease will be seen.  
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Chapter 7 Main Conclusions 
 
The hypotheses of this thesis were: 
 
1) Whole body MRI has a greater sensitivity for the detection of 
metastases in patients with radio-recurrent prostate cancer compared 
to Choline PET/CT and bone scan. 
 
2) Abnormalities seen with multi-parametric MRI are associated with 
clinically significant prostate cancer in the radio-recurrent prostate 
cancer setting.  
 
3) The conduct of focal salvage therapy in men with radiorecurrent 
prostate cancer is both feasible and acceptable.  
 
Based on the results of the studies discussed the following conclusions can 
be drawn: 
 
Study 3.2 Whole body - MRI  vs. Choline PET/CT and Bone Scan in detection 
of radio-recurrent prostate Cancer 
 
Whole-body MRI can locate nodal metastatic disease however cannot yet 
replace bone scan in the detection of bony metastatic lesions. There are 
limitations to calculating the sensitivity of WB-MRI disease as discussed 
above. Therefore, at present we are unable to confirm or reject Hypotheses 1. 
However, at the completion of The FORECAST Trial, we will be able to 
provide results on the accuracy of WB-MRI in the detection of radiorecurrent 
disease. 
 
Chapter 4.2 Multiparametric MRI in detection of radiorecurrent disease 
 
mpMRI PIRADS 4 showed high accuracy in the detection of clinically 
significant (UCL Definition 2 (Gleason =3+4 OR any grade of cancer length 4-
5mm)) radiorecurrent prostate cancer. This study therefore did support the 
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hypothesis that abnormalities seen with multi-parametric MRI are associated 
with clinically significant prostate cancer (using UCL definition) in the radio-
recurrent prostate cancer setting.  
 
Chapter 5.1 Focal Salvage HIFU and Chapter 5.2 Focal Salvage treatments 
 
Both of our studies did show that the conduct of focal salvage therapy in men 
with radiorecurrent prostate cancer is both feasible and has acceptable rates 
of side effects and with good short term biochemical disease control. 
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Chapter 8 Discussion 
 
This chapter will now discuss the main outcomes of the study, further 
limitations and future trials.  
 
8.1 Background 
 
Radiotherapy for prostate cancer is effective but almost 50% of patients can 
develop biochemical failure within 7 years with the development of 
metastases with 5 years of this (3,89,131)  . Further local therapy is an option 
for these men, however high morbidity rates such as urinary fistula (1%), 
rectal injury (9%) and bladder neck contracture (14%) associated with radical 
prostatectomy make it an unfavourable salvage treatment (132). There is an 
urgent need to deliver salvage treatment(s) with minimal side effects and 
optimum cancer control. Throughout this thesis the importance of accurate 
staging and localization of disease to deliver an appropriate salvage therapy 
has been discussed.  
 
8.2 Limitations 
 
8.2.1 Trial Limitations 
 
There were several challenges that were faced during the setup and conduct 
of the FORECAST Study. 
 
8.2.1.1 Patient selection 
 
Radiotherapy treatment has transformed in the last two decades. Prior to the 
1990s, EBRT was delivered in a 2D manner using X-ray and bony landmarks 
to guide treatment resulting in unknown dosages of radiotherapy delivered to 
other pelvic organs such as bladder and bowel. As a result, the development 
of 3D planning using CT allowed for more precise delivery decreasing genito-
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urinary (GU) and gastrointestinal (GI) side effects. There has been a change 
in recommended radiation dosage. Prior to the 1990s it was limited to 64-70 
Gy to minimise toxicity however studies have shown dose-escalation of 74-80 
Gy to have improved disease-free survival (133). Kuban et al. (134) showed 
that in 5 year biochemical/clinical failure free survival was 73% vs. 50% at 10 
years in patients receiving 78 Gy versus 70 Gy, (p = 0.004) respectively. 
Further advances in 3D conformational radiotherapy has led to intensity-
modulated RT (IMRT) which delivers radiation beams in different angles at 
increased intensity whilst decreasing doses delivered to other organs at risk 
(133). Dose escalated IMRT of up to 80 Gy has reported 5-year biochemical 
relapse rate of 28% compared to 39% in those 70 Gy (135).  
 
However higher radiation doses have resulted in higher ≥ grade 2 GI toxicity 
was 13% vs. 26% for patients treated with 70 Gy compared to those treated to 
78 Gy (p=0.013) (133,134). Zelefesky et al. (136) compared IMRT and 
3DCRT in (n=171 and n= 61 respectively) and reported 2-year actuarial risk of 
grade 2 bleeding was 2% for IMRT and 10% for conventional 3D-CRT 
(P<0.001). (Acute and late urinary (GI) and rectal (GU) toxicity was scored 
according to the Radiation Therapy Oncology Group morbidity grading scale) 
For patients who received 81 Gy in either treatment, IMRT still had lower 
acute GI toxicity compared to 3D-CRT (Grade 1 toxicity 33% vs. 46% and 
Grade 2 toxicity 12% vs. 15% p=0.05 respectively. Late rectal toxicity was 
better in the IMRT group 0.5% vs. 13% (p=0.0001) compared with 3DCRT 
group.  
 
Brachytherapy has also been widely incorporated into treatment of prostate 
cancer. The direct delivery of radioactive sources into the prostate 
significantly reduces radiation doses to surrounding organs such as the 
bladder and rectum (133). Brachytherapy can be either high dose where there 
is temporary insertion of high energy radioactive isotope such as Iridium-192 
or low dose where permanent seed implants (either Iodine-125 or Pallidium-
103) are placed. Brachytherapy has the advantage of being used as a single 
therapy in low to intermediate risk cancer, but also as an adjuvant to EBRT in 
high risk cancer. Hoskin et al. (137) performed a randomised phase-III trial 
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compared external beam radiotherapy (EBRT) alone with EBRT combined 
with high-dose-rate brachytherapy boost (HDR-BTb). The biochemical relapse 
free survival rate at 7 years was higher in those who received the 
brachytherapy boost, compared to those who received EBRT alone 66% vs. 
48% p=0.04 respectively.  
 
Rodda et al. (138) examined side effects of dose escalation EBRT (up to 78 
Gy) and ADT compared with low dose rate (LDR) brachytherapy boost. Late 
Effects of Normal Tissue Somatic, Objective, Management, Analytic (LENT-
SOMA) scale was used to determine toxicity outcomes. The cumulative 
incidence of late grade 3 GU morbidity at 2 and 5 years was 7.7% and 18.4% 
for LDR brachytherapy boost, versus 3.4% and 5.2% for dose escalated 
EBRT p < 0.01. The prevalence of grade 3 GU morbidity after brachytherapy 
boost was 7.0% at 2 years and 8.6% at 5 years, compared with 1.1% at 2 
years (P = 0.005) and 2.2% at 5 years ( p= 0.058) for those who received 
dose escalated EBRT. Overall, it has been accepted that brachytherapy boost 
may be suitable in patients with more aggressive cancer for a higher 
likelihood of potential cure at the risk of bowel or urinary toxicity (133).  
 
Hypofractionated radiotherapy which involves giving larger doses over a 
shorter period of time (119,133). Current standard of care for radiation doses 
include 75.6 Gy or higher, which is delivered in 1.8 to 2 Gy daily fractions 
delivering 75.6 Gy or higher, and so treatment duration us typically 8 to 9 
weeks. Phase 3 of the RCT Conventional or hypofractionated high dose 
intensity modulated radiotherapy for prostate cancer (CHHIP) trial as reported 
by Dearnley et al. (139) delivered hypofractionation doses of or 57 Gy in 19 
fractions over 3.8 weeks (n=1077), 60 Gy in 20 fractions over 4 weeks 
(n=1074) or 57 Gy in 19 fractions over 3.8 weeks (n=1077) in comparison with 
conventional 74 Gy delivered in 37 fractions over 7.4 weeks (n=1065). The 5-
year biochemical or clinical failure-free rates were 85·9% (83.4 - 88.0) in the 
57 Gy group, 90·6% (88.5 – 92.3) in the 60 Gy group and 88.3% (95% CI 86.0 
– 90.2) in the 74 Gy group. According to (National Comprehensive Cancer 
Network (NCCN) low-risk, intermediate-risk, and high-risk groups had 5 year, 
biochemical and clinical failure-free rates were 90.9% (85.1 – 94.5), 86% 
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(83.1 – 88.5), and 78.3% (69.2 - 85) for the 57 Gy group, respectively 96.6% 
(92.1 – 98.6), 90.2% (87.7 – 92.3), and 84.2% (75.7 – 90.0) for the 60 Gy 
group; and 96.7% (95% CI 92.3 – 98.6), 86.8% (84.0 – 89.1), and 86.5% 
(78.4 – 91.7) for the 74 Gy group respectively (139). Hypofractionated 
radiotherapy was delivered with fewer treatments can increase the 
convenience for the patient and lower costs for the health care system. EAU 
(119) advises that only evidence based fractionation schedules should be 
used outside of clinical trials and higher doses such as 5-10 Gy per fraction 
delivered in five to seven fractions should still be considered as 
investigational.  
 
Stereotactic body radiation therapy delivers 7 to 10 Gy per fraction and 
completing treatment in 4 to 5 total fractions. King et al. (140) performed a 
pooled analysis of multiple phase II trials which had total of 1,100 patients; 
these patients received a total of 35 to 40 Gy in 5 fractions or 39 Gy in 4 
fractions. The 5-year biochemical relapse free survival rates (b-RFS) was 
93% for patients receiving a dose 35 Gy vs. 90.7% for dose 36.25 Gy 
(p=0.08) and 95.8% for those doses 38 - 40 Gy (p=0.83). The 5-year b-RFS 
was 97% for this entire cohort, 99% for patients with low-risk and 93% for 
patients with intermediate-risk (p = 0.11). 
 
Another form of radiotherapy is proton beam therapy. Protons have the ability 
of delivering high dose of radiation at a prescribed depth and then a rapid 
dose fall off after this point (133). There are few studies that provide survival 
data of proton therapy compared with standard radiation therapy. Therefore, 
at present it is unknown the likely recurrence rate and suitability of these 
patients for further salvage therapy. 
 
Due to differences in patients’ primary radiation treatment several issues arise 
when these patients are selected for further salvage treatment. Firstly, it is 
often difficult to gather primary D’Amico risk information, radiotherapy doses, 
accurate PSA levels following radiotherapy and the time of biochemical failure 
in patients who had treatment in the early 1990s. Differences in outcomes 
following FST therefore may be due to their baseline risk. The wide variation 
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between patients impedes analysis as it is difficult to group patients and 
therefore correlate those who may benefit from FST. Secondly, without this 
baseline data, patients may have had high doses of radiotherapy and thus 
may be at increased risk of significant side effects such as recto-urethral 
fistula. The introduction of brachytherapy and again the changes in types and 
radiation doses delivered have the same problems above. 
 
8.2.1.2 Trial set-up and work flow 
Gaining ethical approval for the number of initial scans was challenging. As 
patients are undergoing four initial diagnostic scans, this can be quite onerus 
on patients especially considering this requires two hospital visits. Standard of 
care options, would not typically require patients to undergo bone scan with 
PSA <20ng/ml. As discussed above this is unlikely to yield established 
metastatic disease and potentially exposing patients to radiation that was not 
yet warranted. This was overcome as several studies do indicate that salvage 
treatment should not be offered unless metastatic disease is ruled out and 
that is with Choline PET/CT+/- Bone scan and both are often performed in 
other experimental trials (37,56,70).  
 
Whilst this did gain ethical approval, the same challenge of the number of 
initial scans was met by both imaging departments and patients. It was 
essential to co-ordinate patient scans in a timely and efficient manner, 
minimizing the number of visits but also dealing with the standard of care 
workload in both MRI and nuclear medicine departments. It was advised that 
patients could not have Choline PET/CT and bone scan on the same day, 
instead they had to be over two days. For patients travelling long distances 
this was sometimes difficult as they had to come back for two days incurring 
travel and accommodation expenses. This also delayed reporting and further 
management as patients could not sometimes attend two days in a row, but 
sometimes up to two weeks apart. However as above, normal investigations 
outside of the trial prior to any salvage treatment, would typically involve 
Choline PET/CT, bone scan and mpMRI would have been advised and 
therefore, a minimum of two visits were likely.  
 
  
 
171 
The reporting of scans for MDT pre-biopsy also posed some difficulty as time 
had to be set with the radiologists who had both clinical and research trial 
work. This could sometimes be delayed for up to two weeks which further 
delayed MDT discussion and importantly patient management. At time of 
MDT, extra time had to be allowed for FORECAST patients as – 3 scans had 
to be reviewed (WB-MRI to remain blinded) and patients discussed to 
determine suitability for salvage treatment, this again increased workload on 
all members of MDT. To help decrease burden on radiologists, images were 
electronically transferred to other hospitals where radiologists were working 
anonymised reports were sent back. To help decrease burden on MDT, only 
the research fellow responsible for FORECAST (myself) presented the cases 
as full clinical information was already known due to the initial patient visit. 
The clinical research fellow, could then co-ordinate further patient 
management based on MDT outcome – either book for biopsy or withdraw 
from the trial (for example if metastatic disease was present). 
 
Another issue was the presence of metastatic disease which resulted in the 
exclusion of several patients post imaging. Although it was expected that 50% 
would be excluded, it did lead to poor recruitment and retainment numbers 
initially proceeding to further biopsy and treatment. This was overcome by 
setting up two further recruitment centres at Basingstoke and North 
Hampshire Hospital and Queen Elizabeth hospital in Kings Lynn. We were 
approached by these centres due to their interest in our trial and whilst Queen 
Elizabeth Hospitals could not offer focal salvage treatment, they could perform 
all other scans and biopsy and refer patients to us if still suitable for the 
salvage treatment. Basingstoke hospitals could offer salvage HIFU but those 
suitable for salvage cryotherapy, were referred to UCLH.   
 
Another problem initially faced, was length of follow up. Obviously the greater 
the length of follow up, the more information available regarding biochemical 
recurrence and further disease progression. However, there is a risk of loss to 
follow up. To decrease burden on patients they had face to face follow up at 4 
weeks and 12 months, the latter to coincide with final pelvic mpMRI. The 
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interim visits at 3, 6 and 9 months could be performed via telephone with local 
PSA results being forward on to our centre for data collection.  
 
An important aspect of any treatment and particularly salvage treatment is 
evidence of recurrence. In this trial, we did not incorporate further biopsy at 
the end of one year follow up as it was not felt to be in the patients best 
interest. 
Patients would be having a third general anaesthetic, perineal biopsies are 
known to be painful with some side effects of perineal bruising, haematuria 
and sepsis (141). Also, it is unlikely patients would undergo a third treatment 
to the prostate due to the increased risk of developing a rectourethral fistula. 
In relation to biopsy, we also could not justify bone biopsy in patients with 
metastatic disease. It is rare for this to be performed even as standard of care 
in metastatic prostate cancer, as it carries side effects such as pain, infection 
and bleeding. Although this would confirm the accuracy of the imaging tests, 
this was not incorporated in the trial. To overcome this, WB-MRI outcomes 
remains blinded till patients reach the end of the trial and was not used to 
dictate clinical decisions. Unlike previous trials discussed above in Section 
3.2.6.3 where WB-MRI is used to dictate treatment alongside Choline PET/CT 
and bone scan (23). WB-MRI is yet to be validated and therefore novel 
imaging should not be used to alter patients’ management until proven to be 
of high accuracy. Patients are offered to undergo a repeat WB-MRI as part of 
the LOCATE trial. At the end of both trials, comparison of WB-MRI to standard 
of care tests pre-and post-salvage treatment can show if metastatic disease 
was detected, and whether there was any regression or progression of 
metastatic disease following local treatment.  
 
8.2.1.3 Advances in diagnostics 
 
Other challenges have been the development of newer imaging tests and 
further molecular advances in the diagnosis of metastatic disease. 
Advances in Choline PET/CT involves the development of a target radioligand 
that binds to Prostate Specific Membrane Antigen (PSMA). PSMA is a cell 
surface protein overexpressed in prostate cancer compared to other organs 
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such as the kidney, small intestine and salivary glands. (142). One study 
examined PSMA expression in 184 radical prostatectomy specimens without 
previous treatment and found an incremental increase in PSMA expression 
from benign epithelium to high-grade carcinoma (143,144).  
 
Several studies have examined its use in recurrent cancer post primary 
treatment and have shown accuracies up to 89% (142,145). These studies 
however examine patients who have had differing primary treatments such as 
radical prostatectomy, radiotherapy and brachytherapy. One such study 
performed by Bluemel et al. (145) examined 125 patients who had PSA rise 
following primary treatment found that 68Ga-PSMA PET/CT identified a 
further 43.8% of patients with recurrent disease that 18F-choline-PET/CT had 
reported as negative. Thus, the combination of both scans had a detection 
rate of 85.6%. 18F-choline-PET/CT detected recurrence in 89.4% compared 
to 71.4% of patients by 68Ga-PSMA PET/CT with PSA >2ng/ml. A sequential 
approach of 18F-choline-PET/CT followed by 68Ga-PSMA PET/CT had the 
highest detection rate of detection with PSA >2ng/ml 97%. Another similar 
study performed by Verburg et al. found that 68Ga-PSMA PET/CT had a 
higher detection rate of recurrent lesions when PSA > 2ng/ml VS. <1ng/ml 
89% vs. 44% (p<0.001). However, this study lacked histopathological 
confirmation and did not use verification scans.  
 
Einspieler et al. examined the detection rate of 68Ga-PSMA PET/CT in 118 
patients post radiotherapy.  (146) 45 were patients were on ADT at time of 
scanning. The detection rates also increased with a higher PSA were 96.8% 
(30/31) for PSA ≥ 10ng/ml vs. 81.8% (36/44), for PSA of 2 to <5ng/ml (p = 
0.0377). Surprisingly detection of recurrent cancers were higher in patients on 
ADT compared to those not on ADT 97.7% (44/45) of patients with ADT and 
86.3% (63/73) (p = 0.0381), however the PSA was higher in the group 
receiving ADT compared to those not on ADT 7.7ng/ml (2.2-65.0, 4.6-15.6) 
(n=45) vs. 5.9 ng/ml (2.2-158.4, 3.9-8.9) (n=73). There is no discussion of the 
time from initiation of ADT to time of imaging. It is also unclear how many 
patients underwent histopathological confirmation but local (n=6) and 
metastatic recurrence (n=1) was confirmed. Further correlation studies were 
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performed (PET/CT, PET/MRI, BS, CT) in 29 patients. This was concordant 
with positive findings of 68Ga-PSMA PET/CT of metastatic or local 
recurrence. The study does not further expand on negative 68Ga-PSMA 
PET/CT and concordance with other local or distant imaging.   
 
Currently there is a clear lack of guidance with PSMA-Choline PET/CT, there 
is potential in increasing diagnostic accuracy with sequential imaging 
alongside 18F-Choline. This was not initially available at the time of set up in 
FORECAST Study at our centre. As it is part of Choline PET/CT sequencing, 
it may be possible to perform this at the same time as 18F-Choline, Further 
discussion with nuclear medicine and ethical approval would have to be 
gained.  
 
8.2.1.4 Circulating Tumour Cells 
 
Circulating Tumour Cells (CTC) have been found to spread despite a 
carcinoma being in situ. (147). The problem with CTC is that they do not have 
the genomic abnormalities that characterize and do not evolve in parallel to 
the primary tumour. CTC are considered to be en-route to or from 
disseminated sites and reflective of metastasis and can be identified via blood 
sample (147). CTC undergo a transition from epithelial cells to mesenchymal 
cells (EMT – Epithelial to mesenchymal transition) in order to leave 
neighbouring epithelial cells and become more mobile, invasive, and capable 
of seeding (147). These are all hallmarks of increased malignancy. Once 
target organs (host tissues) are reached a reversal process need to occur 
from mesenchymal cells to an epithelial form, to regain their ability to 
proliferate (144,148). However, despite CTC circulating throughout the body, 
distant metastases only occur in a few sites, predominantly bone. Studies 
have reported on a complex paracrine/autocrine pathway allowing growth of 
metastatic prostate cancer cells within bone (144,149). Studies suggest that 
0.01% of circulating tumour cells can produce a single bone metastasis, and 
at least 104 circulating tumour cells are required for the development of a 
metastatic focus (144,150). 
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The identification of CTC has proved challenging. Reverse transcriptase 
polymerase chain reaction (RT-PCR) techniques have been used however 
presence of other cellular contaminants, such as red blood cells, normal 
epithelial cells, and leukocytes lower specificity (144). Immunomagnetic 
selection (IMS) techniques use nanometer-sized magnetic beads coated with 
cell-specific antibodies to target epithelial cell specific antigens. In prostate 
cancer, the epithelial cell-adhesion molecule (EpCAM) has been used (144) 
IMS detects only intact cells, whereas PCR detects living cells, dead cells, 
and free DNA, thus there is a risk of false-positive results. The CellSearch 
system, uses microscopic iron particles (called ferrofluids) coated with anti-
EpCAM antibodies to immunomagnetically enrich epithelial cells in a 
peripheral blood sample drawn from a patient (144,151). The CellSearch 
System has been approved by the US Food and Drug Administration for use 
in breast, colorectal, and prostate cancer. CellSearch System has been 
examined in a few studies.  
 
A study performed by Thalgott et al. (152) examined CTC in healthy controls, 
patients with metastatic, locally advanced and taxane refractory prostate 
cancer. The CellSearch technique was used to isolate CTC. Patients with 
bone and visceral disease had the highest CTC count 26 (range 0-207), 
however healthy controls and patients with soft tissue disease, had 
comparable CTC levels. Previously, a threshold of ≥ 5 CTCs per 7.5 ml 
venous blood was determined as prognostic significant for overall survival 
(OS) (152). Healthy controls had no CTC detected and only one patient in the 
locally advanced prostate cancer (LAPC) group had CTC detected. Patients 
with metastatic cancer had a median of 9 CTC and this was detected in 84% 
which was significantly elevated compared to controls and LAPC group (p < 
0.001). Patients who had metastatic disease resistant to taxane therapy had a 
higher number of CTC present (n=15) (median number of 14 CTCs (range 0-
2,437)) present in 93% of patients compared to those who had metastatic 
disease prior to starting docetaxel (n=14) (median CTC count of 7.5 (range 0-
225)) in 80% of the group. Kaplan-Meier analyses demonstrated in metastatic 
patients with <5 CTCs a significantly longer OS compared to patients 
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harboring >5 CTCs (median 158 days; n = 32 (p = 0.003)). Focusing on the 
absolute PSA level, no correlation was found for CTC count. 
 
8.2.1.5 Disseminated Tumour Cells 
Bone marrow aspirate have been analysed to determine the presence of 
Disseminated Tumour Cells (DTC). Berg et al. (153) examined 266 patients 
who had bone marrow (BM) aspirate analysis at baseline prior to radiation 
treatment or hormonal treatment. DTCs were present in BM of 48 (18%) of the 
patients. Positive BM-status was significantly associated with increasing 
percentage of Gleason 4/5 cancer (p=0.04) and increasing Gleason Score (p 
= 0.04). 131 patients went on to have radiotherapy, and of these, BM was 
positive for DTCs in 20% (26/131) of patients. There were 12 deaths overall, 9 
were prostate cancer related. 20 patients had failure following definitive 
EBRT, 6% (8/131) had locoregional failure and 9% (12/131) developed distant 
metastases. The 7-year cumulative risk of distant metastases as first clinical 
relapse was 21% for BM-positive patients vs. 6% for BM-negative patients (p 
= 0.07) (153). It is important to note that despite the number of DTC present, 
there was no higher risk of distant metastases with an increased number of 
DTC. Patients with Gleason Score ≥7 and positive BM had a higher 7-year 
cumulative risk of DM as first clinical relapse of 34% vs. 10% for those with 
negative BM (p = 0.04). 75 patients did not receive ADT following EBRT and 
7-year cumulative risk of DM as first clinical relapse was 28% vs. 9% in those 
with positive BM versus negative BM respectively. However, in these patients, 
cancer related death had a 7-year cumulative risk of failure of 7% in those 
with positive BM vs. 9% risk in those with negative BM. There was no 
association with a higher PSA level or T-stage to the number of DTC or an 
increased rate of DM. This study also found that patients with a Gleason 
Score <7 did not develop distant metastases despite 10 patients having 
positive BM for DTC. 
  
Whilst we would not perform bone marrow biopsy in our patients, as we want 
to minimise invasive procedures on our patients, we could perform peripheral 
blood sampling and use the Cell Search technique. This could easily be 
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incorporated at the initial clinical visit where patients have a sample taken for 
PSA. This would require further funding and ethical approval.  
 
8.3 Strengths of the Study  
 
Issues currently facing clinicians is guiding their patients to the best salvage 
treatment post radiotherapy. At present, there is no single best imaging test to 
diagnose radiorecurrent disease, no definition of clinically significant cancer 
post radiotherapy and several salvage treatment options available all with 
differing cancer control and side effect profiles. 
 
A recent international consensus discussing the set up of prospective trials 
examining focal salvage ablative therapy (Salvage Ablative Trial SAT) (154) 
proposed the following objectives: 
 
 
1) The primary objective of a SAT trial should be to assess the efficacy of 
the treatment for negative biopsy rate at 12 months posttreatment.  
 
2) The secondary objectives include  
 
a. Assessment of quality of life (QOL);  
b. Treatment safety profile defined by adverse events and side 
effects; 
c.  3-year and long-term biochemical disease-free survival (b-
DFS); 
d. Progression- free survival, defined as the time without findings 
of local recurrence or distant metastasis.  
 
There was no agreed consensus on entry trial PSA nor minimum doubling 
time of PSA at inclusion. However, patients with a PSA nadir +2 plus positive 
prostate biopsy would be considered suitable for trial entry. Patients with all 
Gleason Grades should be included provided there was no extracapsular 
extension.  
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Salvage therapies to be examined included HIFU and cryotherapy in w hole 
gland, hemi-gland or focal ablative manner. Before inclusion, it was 
recommended to exclude metastases by performing bone scan MRI or 
Choline PET/CT. There was agreement that patients should be excluded if 
metastatic disease was present. Consensus was reached to stop androgen 
deprivation therapy and not to stop usage of 5α-reductase inhibitors.  
 
Assessing QOL and baseline function using EPIC, the IIEF-5, and the IPSS 
was recommended. 
 
mpMRI including diffusion-weighted imaging and dynamic contrast-enhanced 
imaging was recommended as the imaging technique to guide salvage 
ablative treatments.  
 
Follow-up In the first-year post treatment, patients need to be followed up 
every 3 months with PSA check at these intervals. In the second year and the 
third year, patients should be followed up biannually and thereafter annually. 
The second year and thereafter, PSA testing has to be done twice a year with 
follow up mpMRI. Imaging and biopsies should be performed at time points 
based on the discretion of the investigators. Minimal duration for follow-up 
was recommended as 5 years.  
 
The FORECAST study already incorporates several of these 
recommendations and follows patient through from biochemical failure post 
radiotherapy to potential further salvage treatment. This is the first prospective 
study that combines novel imaging, accurate characterization using template 
mapping biopsy and two focal salvage treatment options. The outcomes from 
this trial are likely to be substantial. 
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8.4 Future of FORECAST 
 
8.4.1 Future Trials 
 
FORECAST may allow for future randomized prospective trials. Patients who 
may not be eligible for treatment due to metastatic disease, could be 
randomized into trials examining surveillance vs. ADT vs. chemotherapy. 
These patients could all be followed up with further bone scan, Choline 
PET/CT and WB-MRI during this time to see the effectiveness of treatments 
providing further evidence to the accuracy of these techniques.  
 
As discussed above, incorporation of new imaging techniques may be 
feasible, such as Choline PET/CT PMSA. This can be added alongside 
current Choline PET/CT sequences. Further expansion of the trial, if deemed 
accurate enough could be randomization of patients undergoing PSMA-
Choline PET/CT and 18-F Choline – these could be further compared to see 
which is more accurate in the detection of metastatic disease.  
 
Treatment of oligometastic disease in the primary setting is also being 
examined currently in the literature (155). However, there is no evidence of 
this in being effective/trialled in radiorecurrent disease. Using a combination of 
CTC and distant imaging tests, oligometastatic disease may be identified and 
targeted treatment or systemic treatment could occur to these metastases in 
combination with local treatment. Based on the outcomes of these treatments, 
patients who present with oligometastatic disease who are likely to benefit 
from further disease treatment and those who are likely to benefit from 
conservative management without the added risk of treatment burden can be 
managed accordingly.  
 
Treatment of nodal disease is also being explored. Patients found to have 
nodal disease only could be treated with targeted focused treatment or 
hormonal therapy. Follow up with Choline PET/CT, Bone scan and WB-MRI 
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could determine the effectiveness of treatment and the accuracies of these 
imaging techniques.  
 
Comparison of treatments of localized radiorecurrent disease could also be 
employed. Patients with high risk localized disease amenable to salvage 
radical prostatectomy, those with intermediate focal disease could be targeted 
with HIFU, Cryotherapy and brachytherapy. Follow up of these patients would 
determine cancer control of each salvage treatment and associated side 
effects. Analysing baseline and pre-salvage risk factors could allow for a 
prediction model to be formulated to determine the best treatment according 
to a patient’s risk.    
 
8.4.2 Risk Scoring and Prediction Modelling 
 
At present, there is no definition of clinically significant cancer post 
radiotherapy. D’Amico risk score is commonly attributed but this is based on 
primary cancer setting and this system was developed on TRUS biopsy 
outcomes which is known to misclassify disease. This will be the first 
prospective study that can combine PSA, imaging and biopsy findings in 
radiorecurrent disease. These patients are likely to be followed up long term 
either because of salvage treatment or following the start of systemic therapy. 
Further analyses can then be performed to classify patients in a similar 
manner of low, intermediate and high risk following radiotherapy– a prediction 
model of those who are likely to benefit from local or systemic disease control 
can be calculated. This model using logistical regression, could incorporate 
baseline data and re-staging outcomes prior to salvage treatment to better 
stratify those patients who would benefit from systemic, nodal or local 
treatment.   
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8.5 Conclusion 
 
In summary FORECAST is a prospective diagnostic and treatment trial which 
is likely to have significant implications on the management of patients with 
radiorecurrent prostate cancer.  
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10.2 Quality of life Questionnaires 
 
Patient Questionnaire – Post Treatment……Months 
 
Please add the date in which you fill the questionnaires here: 
 
Patient Identity:  
               
Please answer all parts of the following trial questionnaires. The phrasing 
used is from the official questionnaires, which we are unable to alter. 
However, please adapt each question as appropriate to your own sexual 
orientation and status. 
 
A. International Prostate Symptom Score (IPSS) 
 
Please Circle Answers 
 
How often over 
the past month, 
Not at 
all 
Rarely 
Less 
than 
half 
About 
half 
More 
than 
half 
Almost 
always 
Have you felt that 
you did not empty 
your bladder 
completely? 
0 1 2 3 4 5 
Have you had to 
pass water more 
than once in two 
hours? 
0 1 2 3 4 5 
Has the flow 
stopped and 
started? 
0 1 2 3 4 5 
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Did you have to 
rush quickly to get 
to the toilet? 
0 1 2 3 4 5 
Was the force of 
the stream 
reduced? 
0 1 2 3 4 5 
Did you have 
difficulty starting 
to pass water? 
0 1 2 3 4 5 
 
How many times 
do you typically 
get up at night to 
urinate? 
0 1 2 3 4 
5 or 
more 
 
Total IPSS Score (Maximum: 35)………………………….. 
 
IPSS-Quality of Life 
How would you feel if you had to spend the rest of your life with your 
waterworks the same as they are now? 
Delighted Pleased 
Mostly 
satisfied 
Mixed 
Mostly 
Dissatisfied 
Unhappy Terrible 
0 1 2 3 4 5 6 
 
 
B. 15-Item International Index of Erectile Function (IIEF-15) 
 
Please answer the following questions as honestly and clearly as possible.  
In answering these questions, the following definitions apply: 
 
 Sexual activity includes intercourse, caressing, foreplay and masturbation 
 Sexual intercourse is defined as vaginal penetration of the partner (you 
entered your partner) 
 Sexual stimulation includes situations like foreplay with a partner, looking 
at erotic pictures, etc. 
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 Ejaculate is the ejection of semen from the penis (or the feeling of this) 
 
Please Circle One Number 
 
1. Over the past 4 weeks how often were you able to get an erection during 
sexual activity? 
No sexual activity 0 
Almost never/never 1 
A few times (much less than half the time) 2 
Sometimes (about half the time) 3 
Most times (much more than half the time) 4 
Almost always/always 5 
 
2. Over the past 4 weeks when you had erections with sexual stimulation, 
how often were your erections hard enough for penetration?   
No sexual activity 0 
Almost never/never 1 
A few times (much less than half the time) 2 
Sometimes (about half the time) 3 
Most times (much more than half the time) 4 
Almost always/always 5 
 
3. Over the past 4 weeks when you attempted sexual intercourse, how often 
were you able to penetrate (enter) your partner?   
Did not attempt intercourse 0 
Almost never/never 1 
A few times (much less than half the time) 2 
Sometimes (about half the time) 3 
Most times (much more than half the time) 4 
Almost always/always 5 
 
4. Over the past 4 weeks during sexual intercourse, how often were you able 
to maintain your erection after you had penetrated (entered) your partner? 
   
Did not attempt intercourse 0 
Almost never/never 1 
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A few times (much less than half the time) 2 
Sometimes (about half the time) 3 
Most times (much more than half the time) 4 
Almost always/always 5 
 
 
 
5.  Over the past 4 weeks during sexual intercourse, how difficult was it to 
maintain your erection to completion of intercourse? 
Did not attempt intercourse 1 
Very difficult 2 
Difficult 3 
Slightly difficult 4 
Not difficult 5 
 
6.  Over the past 4 weeks how many times have you attempted sexual 
intercourse? 
No attempts 0 
One to two attempts 1 
Three to four attempts 2 
Five to six attempts 3 
Seven to ten attempts 4 
Eleven + attempts 5 
 
7. Over the past 4 weeks when you attempted sexual intercourse, how often 
was it satisfactory for you? 
Did not attempt intercourse 0 
Almost never/never 1 
A few times (much less than half the time) 2 
Sometimes (about half the time) 3 
Most times (much more than half the time) 4 
Almost always/always 5 
 
8. Over the past 4 weeks how much have you enjoyed sexual intercourse? 
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No intercourse 0 
No enjoyment 1 
Not very enjoyable 2 
Fairly enjoyable 3 
Highly enjoyable 4 
Very highly enjoyable 5 
 
9. Over the past 4 weeks when you had sexual stimulation or intercourse, 
how often did you ejaculate?   
No sexual stimulation/intercourse 0 
Almost never/never 1 
A few times (much less than half the time) 2 
Sometimes (about half the time) 3 
Most times (much more than half the time) 4 
Almost always/always 5 
 
10.  Over the past 4 weeks when you had sexual stimulation or intercourse, 
how often did you have the feeling of orgasm or climax?   
No sexual stimulation/intercourse 0 
Almost never/never 1 
A few times (much less than half the time) 2 
Sometimes (about half the time) 3 
Most times (much more than half the time) 4 
Almost always/always 5 
 
 
11. Over the past 4 weeks how often have you felt sexual desire?   
Almost never/never 1 
A few times (much less than half the time) 2 
Sometimes (about half the time) 3 
Most times (much more than half the time) 4 
Almost always/always 5 
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12. Over the past 4 weeks how would you rate your level of sexual desire?  
Very low/none at all 1 
Low 2 
Moderate 3 
High 4 
Very high 5 
 
13. Over the past 4 weeks how satisfied have you been with your overall sex 
life? 
Very dissatisfied 1 
Moderately dissatisfied 2 
About equally satisfied and dissatisfied 3 
Moderately satisfied 4 
Very satisfied 5 
 
14. Over the past 4 weeks how satisfied have you been with your sexual 
relationship with your partner?   
Very dissatisfied 1 
Moderately dissatisfied 2 
About equally satisfied and dissatisfied 3 
Moderately satisfied 4 
Very satisfied 5 
 
15. Over the past 4 weeks how do you rate your confidence that you could get 
and keep an erection?    
Very low/none at all 1 
Low 2 
Moderate 3 
High 4 
Very high 5 
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If erections were sufficient for sexual intercourse were these aided by 
any form of tablets or injections? 
 
 
Yes (tablets)   Yes (injections)                        No 
 
 
 
If yes please insert name if known 
_________________________________________ 
 
 
 
 
C. UCLA-EPIC Urinary Function Questionnaire 
 
Please answer the following questions as honestly and clearly as possible. 
Please Circle One Number 
 
1. Over the past 4 weeks, how often have you leaked urine? 
 
More than once a day 1 
About once a day 2 
More than once a week 3 
About once a week 4 
Rarely or never 5 
 
2. Over the past 4 weeks, how often have you urinated blood? 
 
More than once a day 1 
About once a day 2 
More than once a week 3 
About once a week 4 
Rarely or never 5 
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3. Over the past 4 weeks, how often have you had pain or burning with 
urination? 
 
More than once a day 1 
About once a day 2 
More than once a week 3 
About once a week 4 
Rarely or never 5 
 
4. Which of the following best describes your urinary control during the last 
4 weeks?  
 
No urinary control whatsoever 1 
Frequent dribbling 2 
Occasional dribbling 3 
Total control  4 
 
5. How many pads or adult diapers per day did you usually use to control 
leakage during the last 4 weeks?  
 
None 0 
1 pad per day 1 
2 pads per day 2 
3 or more pads per day 3 
 
 
 
6. How big a problem, if any, has each of the following been for you during 
the last 4 weeks? (Circle one number on each line)  
 
 No 
problem 
Very 
small 
problem 
Small 
problem 
Moderate 
problem 
Big 
problem 
a. Dripping or 
leaking urine 
0 1 2 3 4 
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b. Pain or 
burning on 
urination 
0 1 2 3 4 
c. Bleeding 
with urination 
0 1 2 3 4 
d. Weak urine 
stream or 
incomplete 
emptying 
0 1 2 3 4 
e. Waking up 
to urinate 
0 1 2 3 4 
f. Need to 
urinate 
frequently 
during the day 
0 1 2 3 4 
 
 
7. Overall, how big a problem has your urinary function been for you during 
the last 4 weeks? 
 
No problem 1 
Very small problem 2 
Small problem 3 
Moderate problem 4 
Big problem 5 
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D. UCLA-EPIC Bowel Function Questionnaire 
 
Please answer the following questions as honestly and clearly as possible. 
Please Circle One Number 
 
1. Over the past 4 weeks, how often have you had rectal urgency (felt like 
passing stool, but did not) 
 
More than once a day 1 
About once a day 2 
More than once a week 3 
About once a week 4 
Rarely or never 5 
 
2. Over the past 4 weeks, how often have you had uncontrolled leakage of 
stool or faeces? 
 
More than once a day 1 
About once a day 2 
More than once a week 3 
About once a week 4 
Rarely or never 5 
 
3. Over the past 4 weeks, how often have you had stools (bowel 
movements) that were loose or liquid (no form, watery, mushy)? 
 
More than once a day 1 
About once a day 2 
More than once a week 3 
About once a week 4 
Rarely or never 5 
 
4. Over the past 4 weeks, how often have you had bloody stools? 
 
More than once a day 1 
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About once a day 2 
More than once a week 3 
About once a week 4 
Rarely or never 5 
 
5. Over the past 4 weeks, how often have your bowel movements been 
painful? 
 
More than once a day 1 
About once a day 2 
More than once a week 3 
About once a week 4 
Rarely or never 5 
 
6. Over the past 4 weeks, how many bowel movements have you had on a 
typical day? 
 
Two or less 1 
Three to four 2 
Five or more 3 
 
 
7. How often have you had a crampy pain in your abdomen, pelvis or rectum 
during the last 4 weeks?  
 
More than once a day 1 
About once a day 2 
More than once a week 3 
About once a week 4 
Rarely or never 5 
 
 
 
8. How big a problem, if any, has each of the following been for you during 
the last 4 weeks? (Circle one number on each line)  
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 No 
problem 
Very 
small 
problem 
Small 
problem 
Moderate 
problem 
Big 
problem 
a. Urgency to 
have a bowel 
movement 
0 1 2 3 4 
b. Increased 
frequency of 
bowel 
movements 
0 1 2 3 4 
c. Watery bowel 
movements 
0 1 2 3 4 
d. Losing control 
of your stools 
0 1 2 3 4 
e. Bloody stools 0 1 2 3 4 
f. 
Abdominal/pelvic 
/rectal pain 
0 1 2 3 4 
 
 
7. Overall, how big a problem has your bowel habits been for you during the 
last 4 weeks? 
 
No problem 1 
Very small problem 2 
Small problem 3 
Moderate problem 4 
Big problem 5 
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End of Questionnaire 
 
 
Please use this page for any additional comments you feel may help or 
you wish to portray. 
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10.3 Outcomes of FORECAST Trial – FS-HIFU and Cryotherapy 
 
10.3.1 Table 49 – Functional outcomes– Baseline scores of functional 
questionnaires and 12 months. Baseline scores of functional 
questionnaires and then follow up at 4 weeks, 3 months, 6 months, 9 
months and 12 months.  
 
 
 Mean Median SD 
Baseline IPSS 
(n=18) 
9.67 8.00 5.531 
Baseline IPSS 
QOL 
1.44 1.00 1.247 
Baseline IIEF-15 
(n=18) 
21.61 15.00 19.162 
Baseline IIEF -1 1.978 .50 1.50 
Baseline IIEF-2 1.33 .00 1.910 
Baseline IIEF-3 1.17 .00 1.886 
Baseline IIEF-4 1.06 .00 1.862 
Baseline IIEF – 5 
(n=16) 
1.69 1.00 1.352 
Baseline UCLA 
EPIC URINE 
(n=17) 
23.53 23.00 3.145 
Baseline UCLA 
EPIC URINE 1 
4.65 5.00 .862 
Baseline UCLA 
EPIC URINE 4 
3.76 4.00 .437 
Baseline UCLA 
EPIC URINE 5 
.00 .00 .000 
Baseline UCLA 
EPIC BOWEL 
(n=18) 
24.17 23.00 3.808 
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Baseline UCLA 
EPIC BOWEL 1 
4.72 5.00 .752 
Baseline UCLA 
EPIC BOWEL 2 
5.00 5.00 .000 
Baseline UCLA 
EPIC BOWEL 8D 
.22 .00 .428 
4 WEEK IPSS 
(n=19) 
11.47 10.00 6.670 
4WK IPSS QOL 2.32 2.00 1.293 
4 WK IIEF-15 16.79 13.00 12.331 
4 WK IIEF -1 1.05 .00 1.715 
4 WK IIEF-2 .47 .00 .964 
4 WK IIEF-3 .26 .00 .733 
4 WK IIEF-4 .26 .00 .733 
4 WK IIEF - 5 1.21 1.00 .713 
4 WK UCLA EPIC 
URINE 
24.47 24.00 3.687 
4 WK UCLA EPIC 
URINE 1 
4.28 5.00 1.018 
4 WK UCLA EPIC 
URINE 4 
3.37 3.00 .597 
4 WK UCLA EPIC 
URINE 5 
.21 .00 .419 
4 WK UCLA EPIC 
BOWEL 
25.11 25.00 5.043 
4 WK UCLA EPIC 
BOWEL 1 
4.58 5.00 .838 
4 WK UCLA EPIC 
BOWEL 2 
4.74 5.00 .733 
4 WK UCLA EPIC 
BOWEL 8D 
.26 .00 .562 
3 MTH IPSS 
(n=18) 
11.33 11.50 6.834 
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3 MTH IPSS QOL 2.00 2.00 1.138 
3 MTH IIEF-15 18.72 13.50 15.017 
3 MTH IIEF -1 .94 .00 1.474 
3 MTH IIEF-2 .78 .00 1.114 
3 MTH IIEF-3 .61 .00 1.037 
3 MTH IIEF-4 .61 .00 1.037 
3 MTH IIEF - 5 1.44 1.00 .984 
3 MTH UCLA 
EPIC URINE 
23.39 23.50 4.642 
3 MTH UCLA 
EPIC URINE 1 
4.39 5.00 .850 
3 MTH UCLA 
EPIC BOWEL 2 
(n=17) 
4.82 5.00 .529 
3 MTH UCLA 
EPIC URINE 4 
(n=17) 
3.59 4.00 .507 
3 MTH UCLA 
EPIC URINE 5 
(n=18) 
.06 .00 .236 
3 MTH UCLA 
EPIC BOWEL 
(n=17) 
25.29 24.00 6.039 
3 MTH UCLA 
EPIC BOWEL 1 
(n=17) 
4.82 5.00 .393 
3 MTH UCLA 
EPIC BOWEL 8D 
(n=16) 
.31 .00 .793 
6 MTH IPSS 
(n=19) 
9.95 9.00 5.864 
6 MTH IPSS QOL 1.95 2.00 1.129 
6 MTH IIEF-15 19.42 17.00 12.777 
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6 MTH IIEF -1 2.68 1.00 7.219 
6 MTH IIEF-2 1.00 1.00 1.374 
6 MTH IIEF-3 .79 .00 1.357 
6 MTH IIEF-4 .74 .00 1.195 
6 MTH IIEF - 5 1.37 1.00 .895 
6 MTH UCLA 
EPIC URINE 
(N=19) 
24.42 24.00 3.906 
6 MTH UCLA 
EPIC URINE 1 
(n=18) 
4.67 5.00 .594 
6 MTH UCLA 
EPIC URINE 4 
3.63 4.00 .496 
6 MTH UCLA 
EPIC URINE 5 
.00 .00 .000 
6 MTH UCLA 
EPIC BOWEL 
(N=18) 
24.00 22.00 8.863 
6 MTH UCLA 
EPIC BOWEL 1 
(n=18) 
4.83 5.00 .383 
6 MTH UCLA 
EPIC BOWEL 2 
(n=18) 
4.89 5.00 .323 
6 MTH UCLA 
EPIC BOWEL 8D 
.39 .00 .778 
12 MTH IPSS 
(N=8) 
11.88 11.50 6.379 
12 MTH IPSS 
QOL 
2.13 2.50 1.126 
12 MTH IIEF-15 15.63 13.50 7.999 
12 MTH IIEF -1 .50 .00 .756 
12 MTH IIEF-2 .38 .00 .518 
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12 MTH IIEF-3 .25 .00 .707 
12 MTH IIEF-4 .13 .00 .354 
12 MTH IIEF - 5 1.13 1.00 .354 
12 MTH UCLA 
EPIC URINE 
26.13 25.00 3.944 
12 MTH UCLA 
EPIC URINE 1 
4.63 5.00 .518 
12 MTH UCLA 
EPIC URINE 4 
3.50 3.50 .535 
12 MTH UCLA 
EPIC URINE 5 
.00 .00 .000 
12 MTH UCLA 
EPIC BOWEL 
25.63 24.50 6.501 
12 MTH UCLA 
EPIC BOWEL 1 
4.75 5.00 .463 
12 MTH UCLA 
EPIC BOWEL 2 
4.88 5.00 .354 
12 MTH UCLA 
EPIC BOWEL 8D 
.50 .00 .756 
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10.3.2 Table 50 –  Paired t –test Functional outcomes – Baseline scores of 
functional questionnaires compared with follow up at 4 weeks, 3 months, 
6 months, 9 months and 12 months.   
 
 
Paired Differences 
p-value Mean 
Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
Baseline IPSS 
- 4 WEEK 
IPSS 
-2.000 5.134 1.210 -4.553 .553 .117 
Pair 
2 
Baseline IPSS 
- 3 MTH IPSS 
-1.667 5.509 1.299 -4.406 1.073 .217 
Pair 
3 
Baseline IPSS 
- 6 MTH IPSS 
-.611 7.724 1.821 -4.452 3.230 .741 
Pair 
4 
Baseline IPSS 
- 9 MTH IPSS 
-.692 4.516 1.253 -3.422 2.037 .591 
Pair 
5 
Baseline IPSS 
- 12 MTH 
IPSS 
-.500 6.481 2.291 -5.918 4.918 .833 
Pair 
6 
Baseline IPSS 
QOL - 4WK 
IPSS QOL 
-.889 1.711 .403 -1.740 -.038 
                                   
.042 
Pair 
7 
Baseline IPSS 
QOL - 3 MTH 
IPSS QOL 
-.556 1.542 .364 -1.323 .211 .145 
Pair 
8 
Baseline IPSS 
QOL - 6 MTH 
IPSS QOL 
-.500 1.465 .345 -1.229 .229 .166 
Pair 
9 
Baseline IPSS 
QOL - 9 MTH 
IPSS QOL 
-.692 .630 .175 -1.073 -.311 .002 
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Pair 
10 
Baseline IPSS 
QOL - 12 
MTH IPSS 
QOL 
-.625 1.061 .375 -1.512 .262 .140 
Pair 
11 
Baseline IIEF-
15 - 4 WK 
IIEF-15 
5.611 14.017 3.304 -1.360 12.582 .108 
Pair 
12 
Baseline IIEF-
15 - 3 MTH 
IIEF-15 
2.889 13.239 3.121 -3.695 9.473 .368 
Pair 
13 
Baseline IIEF-
15 - 6 MTH 
IIEF-15 
1.944 21.618 5.095 -8.806 12.695 .707 
Pair 
14 
Baseline IIEF-
15 - 9 MTH 
IIEF-15 
4.833 22.478 6.489 -9.448 19.115 .472 
Pair 
15 
Baseline IIEF-
15 - 12 MTH 
IIEF-15 
6.750 17.144 6.061 -7.583 21.083 .302 
Pair 
16 
Baseline IIEF 
-1  - 4 WK 
IIEF -1 
.667 1.138 .268 .101 1.232 .024 
Pair 
17 
Baseline IIEF 
-1  - 3 MTH 
IIEF -1 
.556 1.294 .305 -.088 1.199 .086 
Pair 
18 
Baseline IIEF 
-1  - 6 MTH 
IIEF -1 
-1.278 7.940 1.871 -5.226 2.670 .504 
Pair 
19 
Baseline IIEF 
-1  - 9 MTH 
IIEF -1 
.917 1.782 .514 -.215 2.049 .102 
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Pair 
20 
Baseline IIEF 
-1  - 12 MTH 
IIEF -1 
.875 1.356 .479 -.259 2.009 .111 
Pair 
21 
Baseline IIEF-
2  - 4 WK 
IIEF-2 
.889 1.410 .332 .188 1.590 .016 
Pair 
22 
Baseline IIEF-
2  - 3 MTH 
IIEF-2 
.556 1.149 .271 -.016 1.127 .056 
Pair 
23 
Baseline IIEF-
2  - 6 MTH 
IIEF-2 
.333 2.567 .605 -.943 1.610 .589 
Pair 
24 
Baseline IIEF-
2  - 9 MTH 
IIEF-2 
.833 1.801 .520 -.311 1.977 .137 
Pair 
25 
Baseline IIEF-
2  - 12 MTH 
IIEF-2 
.875 1.642 .581 -.498 2.248 .175 
Pair 
26 
Baseline IIEF-
3  - 4 WK 
IIEF-3 
.889 1.530 .361 .128 1.650 .025 
Pair 
27 
Baseline IIEF-
3  - 3 MTH 
IIEF-3 
.556 1.199 .283 -.041 1.152 .066 
Pair 
28 
Baseline IIEF-
3  - 6 MTH 
IIEF-3 
.333 2.612 .616 -.966 1.632 .595 
Pair 
29 
Baseline IIEF-
3  - 9 MTH 
IIEF-3 
.917 1.505 .434 -.040 1.873 .059 
Pair 
30 
Baseline IIEF-
3  - 12 MTH 
IIEF-3 
.750 1.389 .491 -.411 1.911 .170 
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Pair 
31 
Baseline IIEF-
4  - 4 WK 
IIEF-4 
.778 1.517 .358 .023 1.532 .044 
Pair 
32 
Baseline IIEF-
4  - 3 MTH 
IIEF-4 
.444 1.199 .283 -.152 1.041 .134 
Pair 
33 
Baseline IIEF-
4  - 6 MTH 
IIEF-4 
.278 2.469 .582 -.950 1.505 .639 
Pair 
34 
Baseline IIEF-
4  - 9 MTH 
IIEF-4 
.667 1.435 .414 -.245 1.579 .136 
Pair 
35 
Baseline IIEF-
4  - 12 MTH 
IIEF-4 
.750 1.488 .526 -.494 1.994 .197 
Pair 
36 
Baseline IIEF 
- 5 - 4 WK 
IIEF - 5 
.500 1.265 .316 -.174 1.174 .135 
Pair 
37 
Baseline IIEF 
- 5 - 3 MTH 
IIEF - 5 
.250 .577 .144 -.058 .558 .104 
Pair 
38 
Baseline IIEF 
- 5 - 6 MTH 
IIEF - 5 
.250 1.732 .433 -.673 1.173 .572 
Pair 
39 
Baseline IIEF 
- 5 - 9 MTH 
IIEF - 5 
.700 1.703 .539 -.518 1.918 .226 
Pair 
40 
Baseline IIEF 
- 5 - 12 MTH 
IIEF - 5 
.429 .787 .297 -.299 1.156 .200 
Pair 
41 
Baseline 
UCLA EPIC 
URINE - 4 
-1.000 4.757 1.154 -3.446 1.446 .399 
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WK UCLA 
EPIC URINE 
Pair 
42 
Baseline 
UCLA EPIC 
URINE - 3 
MTH UCLA 
EPIC URINE 
.059 3.929 .953 -1.961 2.079 .952 
Pair 
43 
Baseline 
UCLA EPIC 
URINE - 6 
MTH UCLA 
EPIC URINE 
-.941 3.682 .893 -2.834 .952 .308 
Pair 
44 
Baseline 
UCLA EPIC 
URINE - 9 
MTH UCLA 
EPIC URINE 
.667 5.015 1.448 -2.520 3.853 .654 
Pair 
45 
Baseline 
UCLA EPIC 
URINE - 12 
MTH UCLA 
EPIC URINE 
-1.875 3.523 1.246 -4.820 1.070 .176 
Pair 
46 
Baseline 
UCLA EPIC 
URINE 1 - 4 
WK UCLA 
EPIC URINE 
1 
.438 1.031 .258 -.112 .987 .110 
Pair 
47 
Baseline 
UCLA EPIC 
URINE 1 - 3 
MTH UCLA 
EPIC URINE 
1 
.294 1.047 .254 -.244 .832 .264 
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Pair 
48 
Baseline 
UCLA EPIC 
URINE 1 - 6 
MTH UCLA 
EPIC URINE 
1 
-.125 1.088 .272 -.705 .455 .652 
Pair 
49 
Baseline 
UCLA EPIC 
URINE 4 - 9 
MTH UCLA 
EPIC URINE 
1 
-.583 .793 .229 -1.087 -.080 .027 
Pair 
50 
Baseline 
UCLA EPIC 
URINE 1 - 12 
MTH UCLA 
EPIC URINE 
1 
.250 .463 .164 -.137 .637 .170 
Pair 
51 
Baseline 
UCLA EPIC 
URINE 4 - 4 
WK UCLA 
EPIC URINE 
4 
.412 .712 .173 .046 .778 .030 
Pair 
52 
Baseline 
UCLA EPIC 
URINE 4 - 3 
MTH UCLA 
EPIC URINE 
4 
.250 .577 .144 -.058 .558 .104 
Pair 
53 
Baseline 
UCLA EPIC 
URINE 4 - 6 
MTH UCLA 
.118 .697 .169 -.241 .476 .496 
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EPIC URINE 
4 
Pair 
54 
Baseline 
UCLA EPIC 
URINE 4 - 9 
MTH UCLA 
EPIC URINE 
4 
.250 .622 .179 -.145 .645 .191 
Pair 
55 
Baseline 
UCLA EPIC 
URINE 4 - 12 
MTH UCLA 
EPIC URINE 
4 
.375 .744 .263 -.247 .997 .197 
Pair 
56 
Baseline 
UCLA EPIC 
URINE 5 - 4 
WK UCLA 
EPIC URINE 
5 
-.235 .437 .106 -.460 -.010 .041 
Pair 
57 
Baseline 
UCLA EPIC 
URINE 5 - 3 
MTH UCLA 
EPIC URINE 
5 
-.059 .243 .059 -.184 .066 .332 
Pair 
61 
Baseline 
UCLA EPIC 
BOWEL - 4 
WK UCLA 
EPIC BOWEL 
-.944 4.304 1.015 -3.085 1.196 .365 
Pair 
62 
Baseline 
UCLA EPIC 
BOWEL - 3 
-1.176 4.927 1.195 -3.710 1.357 .340 
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MTH UCLA 
EPIC BOWEL 
Pair 
63 
Baseline 
UCLA EPIC 
BOWEL - 6 
MTH UCLA 
EPIC BOWEL 
.889 8.288 1.954 -3.233 5.010 .655 
Pair 
64 
Baseline 
UCLA EPIC 
BOWEL - 9 
MTH UCLA 
EPIC BOWEL 
-.167 5.078 1.466 -3.393 3.060 .912 
Pair 
65 
Baseline 
UCLA EPIC 
BOWEL - 12 
MTH UCLA 
EPIC BOWEL 
-2.625 5.208 1.841 -6.979 1.729 .197 
Pair 
66 
Baseline 
UCLA EPIC 
BOWEL 1 - 4 
WK UCLA 
EPIC BOWEL 
1 
.111 1.183 .279 -.477 .699 .695 
Pair 
67 
Baseline 
UCLA EPIC 
BOWEL 1 - 3 
MTH UCLA 
EPIC BOWEL 
1 
-.118 .928 .225 -.595 .359 .608 
Pair 
68 
Baseline 
UCLA EPIC 
BOWEL 1 - 6 
MTH UCLA 
-.118 .857 .208 -.559 .323 .579 
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EPIC BOWEL 
1 
Pair 
69 
Baseline 
UCLA EPIC 
BOWEL 1 - 9 
MTH UCLA 
EPIC BOWEL 
1 
-.083 .996 .288 -.716 .550 .777 
Pair 
70 
Baseline 
UCLA EPIC 
BOWEL 1 - 
12 MTH 
UCLA EPIC 
BOWEL 1 
.250 .463 .164 -.137 .637 .170 
Pair 
71 
Baseline 
UCLA EPIC 
BOWEL 2 - 4 
WK UCLA 
EPIC BOWEL 
2 
.278 .752 .177 -.096 .652 .135 
Pair 
72 
Baseline 
UCLA EPIC 
BOWEL 2 - 3 
MTH UCLA 
EPIC BOWEL 
2 
.176 .529 .128 -.095 .448 .188 
Pair 
73 
Baseline 
UCLA EPIC 
BOWEL 2 - 6 
MTH UCLA 
EPIC BOWEL 
2 
.118 .332 .081 -.053 .288 .163 
Pair 
74 
Baseline 
UCLA EPIC 
.333 .778 .225 -.161 .828 .166 
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BOWEL 2 - 9 
MTH UCLA 
EPIC BOWEL 
2 
Pair 
75 
Baseline 
UCLA EPIC 
BOWEL 2 - 
12 MTH 
UCLA EPIC 
BOWEL 2 
.125 .354 .125 -.171 .421 .351 
Pair 
76 
Baseline 
UCLA EPIC 
BOWEL 8D - 
4 WK UCLA 
EPIC BOWEL 
8D 
-.056 .639 .151 -.373 .262 .717 
Pair 
77 
Baseline 
UCLA EPIC 
BOWEL 8D - 
3 MTH UCLA 
EPIC BOWEL 
8D 
-.063 .929 .232 -.557 .432 .791 
Pair 
78 
Baseline 
UCLA EPIC 
BOWEL 8D - 
6 MTH UCLA 
EPIC BOWEL 
8D 
-.176 .883 .214 -.630 .277 .422 
Pair 
79 
Baseline 
UCLA EPIC 
BOWEL 8D - 
9 MTH UCLA 
EPIC BOWEL 
8D 
-.083 .289 .083 -.267 .100 .339 
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Pair 
80 
Baseline 
UCLA EPIC 
BOWEL 8D - 
12 MTH 
UCLA EPIC 
BOWEL 8D 
-.500 .756 .267 -1.132 .132 .104 
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Chapter 11 Publications and Abstracts 
 
11.1 Role of focal salvage ablative therapy in localised radiorecurrent 
prostate cancer 
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11.2 Biopsy Strategies for selecting patients for focal therapy for prostate 
cancer 
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11.3 Transperineal Magnetic Resonance Imarge Targeted Biopsy versus 
Transperineal Template Prostate Mapping Biopsy in the Detection of 
Localised radiorecurrent Prostate Cancer
 
 
327 
  
 
328 
  
329 
 
330 
  
331 
 
332 
 
333 
  
 
334 
 
  
335 
11.4 Focal Salvage high intensity focused ultrasound in radiorecurrent prostate 
cancer
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11.6 Presentation at European Association of Urology 2015 Targeted 
transperineal prostate biopsy versus transperineal prostate mapping 
biopsy in the detection of radiorecurrent prostate cancer 
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11.7 Presentation at British Association of Urological Surgeons 2015 
Targeted transperineal prostate biopsy versus transperineal prostate 
mapping biopsy in the detection of radiorecurrent prostate cancer 
 
 
 
 
